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ABSTRACT
The objective of this work was to develop and evaluate paclitaxel-loaded liposomal
formulations for targeted drug delivery to breast cancer. The liposomal formulation was
optimized to maximize drug loading and physical stability. Cholesterol and saturated
lipid content showed a negative influence on paclitaxel loading. Short-term stability
studies showed that optimum drug-lipid ratio is necessary for adequate physical stability.
Biodistribution studies in mouse xenografts bearing MDA-MB-231 breast cancer using
near infrared fluorescence imaging showed that the accumulation of tumor vasculature
targeted long-circulating liposomes (LCL) in the tumor was significantly less than nontargeted LCL at 48 h. The accumulation of these liposomes in the peritoneal cavity was
higher suggesting that they were cleared rapidly by the reticuloendothelial system. The
antitumor efficacy of paclitaxel-loaded tumor vasculature targeted LCL was compared
with paclitaxel-loaded tumor cell targeted LCL. The antitumor efficacy was comparable
for tumor vasculature targeted LCL, non-targeted LCL, and paclitaxel solution
formulation with tumor volumes of ~ 60-70% of the control treatment on 39 days post
tumor inoculation. In contrast, tumor cell targeted LCL showed a significantly higher
antitumor efficacy compared to all other treatments with tumor volumes of ~ 30% of the
control treatment. To improve the long-term stability, these liposomes were lyophilized.
The leakage and vesicle size increase during lyophilization was minimized by using
lyoprotectant sucrose in the formulation. Feasibility of developing gas-filled liposomes
for ultrasound mediated drug delivery was evaluated using freeze drying gas entrapment
method for the preparation. The in vitro measurements of echogenicity showed that these
paclitaxel-loaded tumor vasculature targeted gas-filled liposomes were acoustically active
and can be disintegrated by high intensity ultrasound pulses.

iv

TABLE OF CONTENTS
CHAPTER 1. INTRODUCTION ........................................................................................1
1.1. STATEMENT OF THE PROBLEM ............................................................................1
1.1.1. Breast Cancer and Treatment Choices ............................................................1
1.1.2. Chemotherapy .................................................................................................1
1.1.3. Paclitaxel: Mechanisms of Action ..................................................................2
1.1.4. Drawbacks of Paclitaxel Therapy ...................................................................2
1.1.5. Barriers in Drug Delivery to Solid Tumors ....................................................2
1.1.6. Strategies for Effective Delivery of Paclitaxel to Solid Tumors ....................3
1.1.7. Liposomes for Paclitaxel Delivery to Solid Tumors.......................................3
1.1.8. Stability of Liposomes ....................................................................................4
1.1.9. Echogenic Liposomes .....................................................................................4
1.2. REVIEW OF LITERATURE: FORMULATION DEVELOPMENT, AND
DELIVERY ASPECTS OF LIPOSOMES IN CANCER CHEMOTHERAPY ..........5
1.2.1. Composition of Liposomes .............................................................................6
1.2.2. Size of Liposomes ...........................................................................................9
1.2.3. Surface Modification of Liposomes..............................................................10
1.2.4. Drug Loading in Liposomes .........................................................................12
1.2.5. Targeted Drug Delivery with Liposomes .....................................................15
1.2.6. Controlling Drug Release/Uptake from Liposomes .....................................25
1.2.7. Lyophilization to Improve the Stability of Liposomes .................................29
1.3. HYPOTHESIS AND SPECIFIC AIMS .....................................................................33
CHAPTER 2. DEVELOPMENT OF PROTOTYPE FORMULATION OF GASFILLED TARGETED LIPOSOMES ................................................................................37
2.1. MATERIALS AND METHODS................................................................................38
2.1.1. Materials .......................................................................................................38
2.1.2. Preparation of Long-Circulating Liposomes (LCL) .....................................38
2.1.3. Verification of Conjugation Reaction between cRGD and Maleimide
DSPE-PEG2000...............................................................................................39
2.1.4. Preparation of cRGD Conjugated Targeted Long-Circulating
Liposomes (RGD-TLCL)..............................................................................39
2.1.5. Determination of Conjugation Efficiency .....................................................39
2.1.6. Determination of Particle Size and Zeta Potential ........................................40
2.1.7. Preparation of Gas-Filled LCL (GFLCL) and Gas-Filled RGD-TLCL
(RGD-GFTLCL) ...........................................................................................40
2.1.8. Thermal Analysis by DSC ............................................................................42
2.1.9. Determination of Moisture Content ..............................................................42
2.1.10. Determination of Echogenicity .....................................................................42
2.1.11. Characterization of Morphology of Liposomes ............................................42

v

2.2. RESULTS AND DISCUSSION .................................................................................44
2.2.1. Effect of Liposomal Bilayer Composition ....................................................44
2.2.2. Effect of Lyoprotectant and Surfactant .........................................................44
2.2.3. Effect of Sucrose Concentration on Echogenicity ........................................46
2.2.4. Determination of Conjugation Efficiency .....................................................51
2.2.5. Characteristics of GFLCL and RGD-GFTLCL ............................................51
2.3. SUMMARY AND CONCLUSIONS .........................................................................56
CHAPTER 3. OPTIMIZATION OF PACLITAXEL LOADING AND
PHYSICAL STABILITY IN THE DEVELOPMENT OF LONGCIRCULATING LIPOSOMES .........................................................................................57
3.1. MATERIALS AND METHODS................................................................................58
3.1.1. Materials .......................................................................................................58
3.1.2. Preparation of Paclitaxel-Loaded Long-Circulating Liposomes (PacLCL) ..............................................................................................................59
3.1.3. Determination of Paclitaxel Loading Efficiency ..........................................59
3.1.4. Quantification of Paclitaxel from Liposomes ...............................................59
3.1.5. Determination of Particle Size and Zeta Potential ........................................60
3.1.6. Stability Evaluation of Pac-LCL ...................................................................60
3.1.7. Characterization of Morphology of Pac-LCL ...............................................60
3.2. RESULTS AND DISCUSSION .................................................................................60
3.2.1. Optimization of Paclitaxel Loading ..............................................................60
3.2.2. Optimization of Physical Stability ................................................................65
3.2.3. Optimization of the Extrusion Process .........................................................69
3.2.4. Stability Evaluation of Pac-LCL Dispersion ................................................69
3.3. SUMMARY AND CONCLUSIONS .........................................................................69
CHAPTER 4. DEVELOPMENT OF PACLITAXEL-LOADED RGD
CONJUGATED GAS-FILLED LIPOSOMES ..................................................................75
4.1. MATERIALS AND METHODS................................................................................76
4.1.1. Materials .......................................................................................................76
4.1.2. Preparation of Paclitaxel-Loaded Long-Circulating Liposomes (PacLCL) ..............................................................................................................77
4.1.3. Preparation of Paclitaxel-Loaded cRGD Conjugated Targeted LongCirculating Liposomes (Pac-RGD-TLCL) ...................................................77
4.1.4. Determination of Conjugation Efficiency .....................................................77
4.1.5. Preparation of Gas-Filled Pac-LCL (Pac-GFLCL) and Gas-Filled PacRGD-TLCL (Pac-RGD-GFTLCL) ...............................................................78
4.1.6. Thermal Analysis by DSC ............................................................................78
4.1.7. Characterization of Pac-LCL, Pac-RGD-TLCL, Pac-GFLCL, PacRGD-GFTLCL..............................................................................................79
4.1.8. Determination of Echogenicity .....................................................................80

vi

4.1.9. In vitro Drug Leakage Study.........................................................................80
4.1.10. Stability Evaluation of Pac-RGD-GFTLCL .................................................82
4.2. RESULTS AND DISCUSSION .................................................................................82
4.2.1. Effect of Lyoprotectant and the Manufacturing Process on PSD of PacGFLCL ..........................................................................................................82
4.2.2. Effect of Mannitol Concentration .................................................................89
4.2.3. In vitro Leakage Study with Pac-GFTLCL ..................................................93
4.2.4. Conjugation Efficiency of cRGD to Maleimide-Pac-LCL ...........................93
4.2.5. Characteristics of Pac-RGD-GFTLCL .........................................................96
4.2.6. Visualization and Disintegration of Pac-RGD-GFTLCL with
Ultrasound .....................................................................................................96
4.2.7. Stability of Pac-RGD-GFTLCL ....................................................................99
4.3. SUMMARY AND CONCLUSIONS .........................................................................99
CHAPTER 5. IN VIVO EVALUATION OF BIODISTRIBUTION AND
EFFICACY OF TUMOR VASCULATURE TARGETED LIPOSOMES AND
COMPARISON OF EFFICACY WITH TUMOR CELL TARGETED
LIPOSMES ......................................................................................................................102
5.1. MATERIALS AND METHODS..............................................................................104
5.1.1. Materials .....................................................................................................104
5.1.2. Cell Culture .................................................................................................104
5.1.3. Preparation of Long-Circulating Liposomes Loaded with DiR (DiR
LCL) or Paclitaxel (Pac-LCL) ....................................................................105
5.1.4. Preparation of cRGD Conjugated Targeted Long-Circulating
Liposomes Loaded with DiR (DiR-RGD-TLCL) or Paclitaxel (PacRGD-TLCL) ...............................................................................................105
5.1.5. Preparation of Paclitaxel-Loaded Transferrin Conjugated Targeted
Long-Circulating Liposomes (Pac-Tf-TLCL) ............................................105
5.1.6. Characterization of Liposomes ...................................................................106
5.1.7. Stability Evaluation of Pac-RGD-TLCL and Pac-Tf-TLCL ......................107
5.1.8. Breast Cancer Mouse Xenograft Model .....................................................107
5.1.9. Evaluation of Biodistribution of Tumor Vasculature Targeted
Liposomes by Near Infrared Fluorescence (NIRF) Imaging ......................107
5.1.10. Evaluation of Biodistribution of Paclitaxel from Tumor Vasculature
Targeted Liposomes ....................................................................................108
5.1.11. Evaluation of Antitumor Efficacy of Paclitaxel-Loaded Tumor
Vasculature Targeted Liposomes and Tumor Cell Targeted Liposomes....109
5.1.12. Statistical Analysis ......................................................................................109
5.2. RESULTS AND DISCUSSION ...............................................................................109
5.2.1. Characterization of the Liposomal Formulations .......................................109
5.2.2. Stability of Paclitaxel-Loaded Targeted Liposomes ...................................111
5.2.3. Near Infrared Fluorescence Imaging ..........................................................111
5.2.4. Quantification of Paclitaxel from Plasma and Tumor Tissues to
Determine Biodistribution of Paclitaxel-Loaded Liposomes .....................122

vii

5.2.5.

Antitumor Efficacy of Tumor Vasculature and Tumor Cell Targeted
Liposomes ...................................................................................................122
5.3. SUMMARY AND CONCLUSIONS .......................................................................125
CHAPTER 6. LYOPHILIZATION OF PACLITAXEL-LOADED LIPOSOMES
TO IMPROVE LONG TERM STABILITY ...................................................................127
6.1. MATERIALS AND METHODS..............................................................................128
6.1.1. Materials .....................................................................................................128
6.1.2. Preparation of Paclitaxel-Loaded Long-Circulating Liposomes (PacLCL) ............................................................................................................128
6.1.3. Determination of Tgʹ ...................................................................................129
6.1.4. Lyophilization of Pac-LCL .........................................................................129
6.1.5. Characterization of Liposomal Formulations .............................................129
6.1.6. Preparation and Lyophilization of Paclitaxel-Loaded cRGD
Conjugated Targeted Long-Circulating Liposomes (Pac-RGD-TLCL) .....130
6.1.7. Preparation and Lyophilization of Paclitaxel-Loaded Transferrin
Conjugated Targeted Long-Circulating Liposomes (Pac-Tf-TLCL) ..........131
6.1.8. Stability Evaluation of Lyophilized Formulations of Pac-LCL, PacRGD-TLCL, and Pac-Tf-TLCL ..................................................................131
6.2. RESULTS AND DISCUSSION ...............................................................................131
6.2.1. Effect of Sucrose on Paclitaxel Retention and PSD ...................................131
6.2.2. Development of Lyophilized Targeted Liposomes.....................................137
6.2.3. Stability of Lyophilized Pac-LCL, Pac-RGD-TLCL, and Pac-Tf-TLCL ...140
6.3. SUMMARY AND CONCLUSIONS .......................................................................140
CHAPTER 7. SUMMARY AND CONCLUSIONS .......................................................145
LIST OF REFERENCES .................................................................................................149
VITA ................................................................................................................................167

viii

LIST OF FIGURES
Figure 2-1.
Figure 2-2.
Figure 2-3.
Figure 2-4.
Figure 2-5.
Figure 2-6.
Figure 2-7.
Figure 2-8.
Figure 2-9.
Figure 2-10.
Figure 2-11.
Figure 3-1.
Figure 3-2.
Figure 3-3.
Figure 3-4.
Figure 3-5.
Figure 3-6.
Figure 3-7.
Figure 3-8.
Figure 3-9.
Figure 3-10.
Figure 4-1.
Figure 4-2.
Figure 4-3.
Figure 4-4.
Figure 4-5.
Figure 4-6.

Cartoon representing the method of preparation of RGDGFTLCL ..............................................................................................41
Schematic representation of the in vitro technique used for the
measurement of echogenicity ..............................................................43
Effect of liposome composition on PSD of liposomes after freeze
drying ...................................................................................................45
DSC thermograms showing the effect of sucrose and poloxamer
on crystallization of mannitol ..............................................................47
Effect of mannitol-sucrose ratio on PSD of liposomes after
lyophilization .......................................................................................48
Effect of poloxamer on PSD of liposomes after lyophilization ...........49
Effect of mannitol-sucrose ratio on echogenicity of GFLCL ..............50
Conjugation reaction between maleimide-DSPE-PEG2000 and
cRGD ...................................................................................................52
HPLC chromatogram of the dialyzate obtained from equilibrium
dialysis in comparison to standard solution of cRGD. ........................53
PSD of GFLCL and RGD-GFTLCL before and after
lyophilization .......................................................................................54
TEM images of GFLCL (A) and RGD-GFTLCL (B) .........................55
Effect of total phospholipids on paclitaxel loading .............................62
Effect of cholesterol concentration on paclitaxel loading....................63
Effect of saturated-unsaturated lipid ratio on paclitaxel loading .........64
Effect of drug-lipid ratio on paclitaxel loading....................................66
Effect of drug-lipid ratio on physical stability of Pac-LCL .................67
Effect of drug-lipid ratio on physical stability of improved PacLCL ......................................................................................................68
Effect of number of extrusion cycles on PSD and paclitaxel
loading..................................................................................................70
Effect of extrusion pressure on PSD and paclitaxel loading................71
TEM image depicting morphology of Pac-LCL ..................................72
Stability of Pac-LCL dispersion at 5 ± 3ºC..........................................73
The in vitro model used for demonstrating disintegration of gasfilled liposomes ....................................................................................81
DSC thermograms showing the effect of lipid-sucrose ratio on
Tg′ ........................................................................................................83
Effect of lipid-sugar ratio on PSD after lyophilization of PacLCL ......................................................................................................84
Effect of inravesicular-extravesicular ratio of sucrose on PSD of
Pac-LCL ...............................................................................................86
Effect of number of extrusion cycles on the PSD and PDI after
lyophilization .......................................................................................87
Effect of primary drying temperature on PDI after lyophilization
of Pac-LCL...........................................................................................88

ix

Figure 4-7.
Figure 4-8.
Figure 4-9.
Figure 4-10.
Figure 4-11.
Figure 4-12.
Figure 4-13.
Figure 4-14.
Figure 5-1.
Figure 5-2.
Figure 5-3.
Figure 5-4.
Figure 5-5.
Figure 5-6.
Figure 5-7.
Figure 5-8.
Figure 5-9.
Figure 5-10.
Figure 6-1.
Figure 6-2.
Figure 6-3.
Figure 6-4.
Figure 6-5.
Figure 6-6.
Figure 6-7.
Figure 6-8.

Effect of mannitol concentration on Tg′ ..............................................90
Effect of mannitol concentration on the PSD and PDI after
lyophilization .......................................................................................91
Effect of mannitol concentration on echogenicity of Pac-GFLCL ......92
In vitro drug leakage study of Pac-GFLCL .........................................94
Verification of conjugation efficiency of cRGD .................................95
TEM images of Pac-GFLCL (A) and Pac-RGD-GFTLCL (B) ...........97
Disintegration of Pac-RGD-GFTLCL with ultrasound pulses ............98
Stability of Pac-RGD-GFTLCL .........................................................100
Stability data for Pac-RGD-TLCL dispersion ...................................112
Stability data for Pac-Tf-TLCL dispersion ........................................113
Representative NIRF images of localization of DiR formulations
in mice bearing MDA-MB-231 breast cancer ...................................114
NIRF images of tissues isolated 72 h post injection showing the
accumulation of DiR in tumor, liver, and spleen ...............................116
Localization of DiR-loaded liposomal formulations in tumor
tissue calculated from NIRF imaging ................................................117
Localization of DiR formulations in the flank region to represent
the concentration in the circulation ....................................................118
Localization of DiR formulations in peritoneal cavity to
represent uptake in liver and spleen ...................................................120
Tumor/normal tissue ratio of DiR formulations calculated from
NIRF imaging ....................................................................................121
Biodistribution of paclitaxel formulations in plasma (A), and
tumor (B) of mouse xenografts bearing MDA-MB-231 breast
cancer. ................................................................................................123
Antitumor efficacy of paclitaxel formulations in mouse
xenografts bearing MDA-MB-231 breast cancer ..............................124
Effect of sucrose concentration on Tgʹ ..............................................133
Effect of sucrose concentration on the effect of paclitaxel
retention in the liposomes during lyophilization ...............................135
Effect of sucrose concentration on Tm of the lipids in the bilayer .....136
Effect of sucrose concentration on PSD of paclitaxel-loaded
liposomes during lyophilization .........................................................138
Effect of internal-external ratio of sucrose on PSD during
lyophilization .....................................................................................139
Stability of lyophilized Pac-LCL formulation ...................................141
Stability of lyophilized Pac-RGD-TLCL ...........................................142
Stability of lyophilized Pac-Tf-TLCL ...............................................143

x

LIST OF ABBREVIATIONS
∆pH
∆ψ
ANOVA
BBB
Biotinyl DSPE-PEG2000
BNCT
BSH
cRGD
DiR
DiR-LCL
DiR-RGD-TLCL
D-MEM
DOPE
DPPC
DPPG
DSC
DSPE
DSPE-PEG2000
EDTA
EFGR
EPC
EPR
ESR
FTIR
GFLCL
GM1
HEPES
HER2
HPLC
HSPC
IL-2
LCL
LUV
Maleimide DSPE-PEG2000
MDSC
MGSV
MLV
MWCO

Transmembrane pH gradient
Transmembrane potential gradient
Analysis of variance
Blood brain barrier
1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N(biotinyl poly(ethylene glycol)2000)
Boron neutron capture therapy
Mercaptoundecahydrododecaborate
Cyclo (Arg-Gly-Asp-D-Phe-Cys) peptide
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine
iodide
DiR-loaded long-circulating liposomes
DiR-loaded cRGD conjugated targeted long-circulating
liposomes
Dulbecco’s modified eagle medium
Dioleyl phosphatidylethanolamine
Dipalmitoyl phosphatidylcholine
Dipalmitoyl phosphatidylglycerin
Differential scanning calorimetry
Distearoyl phosphatidylethanolamine
1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N(poly(ethylene glycol)2000)
Ethylenediaminetetraacetic acid
Epidermal growth factor receptor
Egg phosphatidylcholine
Enhanced permeability and retention
Electron spin resonance
Fourier transform infra red
Gas-filled long-circulating liposomes
Monosialoganglioside
N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid
Human epidermal growth factor receptor 2
High performance liquid chromatography
Hydrogenated soy phosphatidylcholine
Interleukin 2
Long-circulating liposomes
Large unilamellar vesicles
1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N(maleimide poly(ethylene glycol)2000)
Modulated differential scanning calorimetry
Mean gray scale value
Multilamellar vesicles
Molecular weight cut-off

xi

NGPE
NGR
NIRF
NMR
NS
Pac-GFLCL
Pac-LCL
Pac-RGD-GFTLCL
Pac-RGD-TLCL
Pac-Tf-TLCL
PDI
PE
PEG
P-gp
PS
PSD
PVA
RES
RGD
RGD-GFTLCL
RGD-TLCL
ROI
RPHPLC
SALCL
SUV
T
TAT
TEM
Tf
TfR1
Tgʹ
Tm
To
VEGF
Z-Avg or Z-Average

N-glutaryl-phosphatidylethanolamine
Asn-Gly-Arg peptide
Near infrared fluorescence
Nuclear magnetic resonance
Normal saline
Paclitaxel-loaded gas-filled long-circulating liposomes
Paclitaxel-loaded long-circulating liposomes
Paclitaxel-loaded cRGD conjugated gas-filled targeted
long-circulating liposomes
Paclitaxel-loaded cRGD conjugated targeted longcirculating liposomes
Paclitaxel-loaded transferrin conjugated targeted longcirculating liposomes
Polydispersity index
Phosphatidylethanolamine
Polyethylene glycol
P-glycoprotein
Phosphatidylserine
Particle size distribution
Polyvinyl alcohol
Reticuloendothelial system
Arg-Gly-Asp peptide
cRGD conjugated gas-filled targeted long-circulating
liposomes
cRGD conjugated targeted long-circulating liposomes
Region of interest
Reversed phase high performance liquid chromatography
Streptavidin conjugated long-circulating liposomes
Small unilamellar vesicles
Temperature
trans-activating transcriptional activator
Transmission electron microscopy
Transferrin
Transferrin receptor 1
Glass transition temperature of maximally freeze
concentrated amorphous phase
Gel to liquid crystalline transition temperature
Transition temperature of the fully hydrated lipid
Vascular endothelial growth factor
Average diameter

xii

CHAPTER 1. INTRODUCTION
1.1. STATEMENT OF THE PROBLEM
1.1.1.

Breast Cancer and Treatment Choices

Cancer is the disease characterized by a rapid and abnormal proliferation of cells.
Cancer cells originate from normal cells through a series of genetic changes leading to
progressive conversion to cancer cells [1]. Cancer is a dreadful disease and is the second
leading cause of death in United States [2, 3]. About 1.5 million new cases of cancer and
more than half-a-million deaths have been estimated in the United States for the year
2009 [4]. Solid tumors account for more than 85 percent of all the cases reported with
cancer [5, 6]. Breast cancer is the most commonly diagnosed form of solid tumors and is
the second leading cause of death in western women. About 20-30% women with breast
cancers develop metastatic breast cancers. Breast cancer research has increased
dramatically during the last 2 decades, resulting in an extraordinary progress in our
understanding of the disease, and in more efficient, and less toxic treatment options. The
treatment choices for breast cancer can be categorized into local or systemic therapy.
Surgery, radiation therapy, hyperthermia, and photodynamic therapy are examples of
localized therapy. Surgery is the treatment of choice for breast cancer which involves
lumpectomy, partial mastectomy or quadrantectomy, and mastectomy. Radiation therapy
is an adjuvant therapy in which high energy radiation is used to kill cancer cells
remaining in the breast, chest wall, underarm area after the surgery. Local therapy is
beneficial for non-metastatic forms of breast cancers whereas systemic therapy is
required for metastatic forms of breast cancers. Systemic therapy by means of
chemotherapy, hormonal therapy, immunotherapy or targeted therapy, and gene therapy
involves administration of the respective therapeutic agent by the oral or parenteral route.
1.1.2.

Chemotherapy

Chemotherapy is the use of drugs to kill cancer cells. It can be used as adjuvant
therapy after surgery for patients with no evidence of metastasis. Adjuvant chemotherapy
reduces the risk of recurrence of cancer. Chemotherapy can also be used as a neoadjuvant
therapy to surgery wherein the drugs are administered before surgery to shrink the tumor
so that it can be removed easily by surgery. Chemotherapy is the first line therapy for
advanced breast cancer in which the cancer has already spread beyond the breast and
underarm area at the time of diagnosis. In chemotherapy, the drug distributes throughout
the body via blood stream to reach the cancer cells. This form of systemic therapy is very
useful to kill breast cancer cells which have metastasized to distant organs. Apart from
killing cancer cells, these drugs also kill normal cells and result in toxic effects. For
chemotherapy to be effective, the drug should be delivered at the tumor sites at adequate
concentrations [7]. Inadequate concentrations of the drug at the tumor microenvironment
could result in regrowth of the tumor cells and development of resistance [5].
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1.1.3.

Paclitaxel: Mechanisms of Action

Paclitaxel, one of the most effective drugs used in chemotherapy of breast cancer, is a
natural product isolated from bark of the Pacific Yew tree, Taxus brevifolia [8, 9]. It
exhibits cytotoxic activity by promoting the assembly of microtubules from tubulin
dimers and stabilizes microtubules by preventing depolymerization. The stability results
in inhibition of the normal dynamic reorganization of the microtubule network that is
essential for vital interphase and mitotic cellular functions [9]. Paclitaxel, like other
antimicrotubule agents, activates the intrinsic mitochondrial apoptotic pathway. Loss of
the mitochondrial membrane potential by opening of the permeability transition pore
results in the release of proapoptotic factor cytochrome c, caspase cascade activation, and
DNA fragmentation [10-12]. These effects are modulated by the members of Bcl-2
family composed of proapoptotic proteins (Bax-like proteins and BH3-only proteins) and
antiapoptotic proteins (Bcl-2-like proteins). Paclitaxel turns the balance of proapoptotic
and antiapoptotic proteins towards apoptosis by translocation of Bax from cytosol to
mitochondria and/or by phosphorylation mediated inhibition of Bcl-2 [13, 14].
1.1.4.

Drawbacks of Paclitaxel Therapy

Paclitaxel is marketed as Taxol® and AbraxaneTM as an adjuvant in the treatment of
node-positive breast cancer or second line treatment of breast cancer after failure of
combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant
chemotherapy. Due to poor solubility of paclitaxel, Taxol® was formulated with ethanol
and Cremophor®EL. Although the product is diluted before use, the concentration of
Cremophor®EL is high enough to cause serious hypersensitivity reactions on
administration requiring pre-medication with corticosteroids and antihistamines [15].
AbraxaneTM, albumin-bound nanoparticle formulation of paclitaxel, addressed solvent
related adverse effects of Taxol® and eliminated the need for premedication with
corticosteroids. But, phase III clinical trials in metastatic breast cancer patients showed
higher rates of sensory neuropathy compared to Taxol® treatment [16]. Apart from the
toxicity associated with the formulation components, administration of free paclitaxel is
also associated with systemic toxicities such as myelosuppression, and peripheral
neuropathy [17]. So, it is imperative to deliver paclitaxel locally to the tumor sites to
minimize systemic toxicity. Hence, there is a need for an effective drug delivery system
for chemotherapy with paclitaxel to produce cytotoxic concentrations of the drug at the
tumor sites without affecting normal tissues.
1.1.5.

Barriers in Drug Delivery to Solid Tumors

Since cancer cells require nutrition to grow and metastasize in to other organs, they
form new vessels, from existing vessels, which are structurally and functionally
abnormal. These newly formed vessels are leaky, tortuous, dilated, and saccular and have
abnormal interconnections [6]. The variations in distribution of blood vessels in a solid
tumor can range from well perfused periphery to seminecrotic to avascular or necrotic

2

regions at the core of the tumor. In addition, hydrostatic pressure generated by
proliferating cancer cells within the tumor can compress the blood vessels and lymphatic
vessels leading to impaired blood flow and lymphatic drainage. The high interstitial
pressure in tumors compared to normal tissues results in a net convection flow in the
tumor interstitium outwards from the core of the tumor. Conventional and modern
therapeutic agents for solid tumors include molecules, particles, and cells. To reach
cancer cells in a solid tumor, these agents must make their way to the blood vessels of a
tumor, cross the vessel wall into the interstitium, and then transport through the
interstitial matrix [5, 7]. The mechanisms of transport involve diffusion and/or
convection depending upon the size, charge, and configuration of the agent [7].
Transport of small molecules in the interstitial space is mainly by diffusion which is
governed by diffusivity and the concentration gradient. The transport of larger molecules
is by convection which depends on hydraulic conductivity and pressure difference [5,
18]. The unique nature of solid tumors with high interstitial pressure, and heterogeneity
in vasculature pose a formidable barrier to delivery of therapeutic agents [19].
1.1.6.

Strategies for Effective Delivery of Paclitaxel to Solid Tumors

An ideal drug delivery system should improve the therapeutic efficacy of paclitaxel
overcoming the barriers to drug delivery and also minimize toxicity, and lower the total
dose required for the therapy. Targeted drug delivery fulfils many of these desirable
attributes, improving efficacy of many existing drugs by altering pharmacokinetics and
biodistribution [20]. Drug targeting can be broadly classified into passive targeting and
active targeting. Passive targeting is the accumulation of therapeutic agent at the target
site due physicochemical nature of the carrier or due to pathological factors of the target
site. In contrast, active targeting involves the attachment of specific active ligands to the
surface of the carrier so that it can recognize target receptors expressed on the surface of
specific cell, tissue, or an organ. Tumor cells express many molecules on their surface
which is not expressed by normal cells. Some receptors show higher expression in the
tumor cells as compared to normal cells. So, solid tumors stands out as one disease that
will get most of the benefits of targeted drug delivery [21]. Nanoscaled delivery systems
are of particular interest in targeted drug delivery to solid tumors because of their ability
to escape clearance by reticuloendothelial system (RES). The clearance of
nanoparticulate systems by the RES increases with an increase in size. Nanoscaled
systems approved or under clinical trial for use in drug delivery include liposomes,
albumin based particles, PEGylated proteins, biodegradable polymer-drug composites,
polymeric micelles, polymer-drug-conjugate based particles, dendrimers, and inorganic
or solid particles [22].
1.1.7.

Liposomes for Paclitaxel Delivery to Solid Tumors

Liposomes are biocompatible carriers with ability to incorporate both lipophilic and
hydrophilic drugs [23]. The entrapped drug is protected from inactivation, and free drug
is not available in the circulation which, in turn, minimizes systemic toxicity of the drug.
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Therefore, preparation of liposomes of paclitaxel can alter the pharmacokinetic and
pharmacodynamic properties of the free drug and result in reduced toxicity and enhanced
efficacy of the treatment. In addition, flexibility in design of liposomes allows selective
localization of these carriers by passive targeting due to enhanced penetration and
retention (EPR) effect at the tumor sites, or by active targeting due to targeting ligands
conjugated to the surface of the liposomes [24-27]. An ideal carrier for drug delivery
must have a longer circulation time which can be achieved by reducing the size of
liposomes and/or modifying the surface with poly(ethylene glycol) derivatives [28].
Targeting capability can be achieved by attaching specific ligands onto the surface of the
liposomes. Thus, incorporation of paclitaxel in the bilayer of targeted long-circulating
liposomes not only deliver the drug specifically to the tumor cells but also minimize
systemic toxicity associated with free drug, by minimizing the exposure to normal
tissues. The release of drug from these liposomes, at the target site, is determined by one
or more of the following natural cytosolic mechanisms [23].






1.1.8.

Specific or non-specific adsorption on to the cell surface
Fusion with the cell membranes and subsequent release of the drug into the
cytoplasm
Adsorption onto the cell surface resulting in destabilization of cell membrane
components so that the released drug can enter via micropinocytosis
Direct or transfer protein mediated exchange of lipid components with cell
membrane
Specific or non-specific endocytosis in which the endosomes deliver the drug
into the lysosome or the endosomes undergo destabilization and release the
drug in cytoplasm
Stability of Liposomes

The liposomal encapsulated drug tends to leak from the liposomes on storage of these
vesicles in aqueous dispersions. In addition, the liposomes can fuse together and form
larger liposomes and result in an increase in vesicle size distribution. The stability of
liposomes can be improved by freezing, lyophilization, spray drying, and supercritical
fluid technology [29-31]. Lyophilization stands out as a preferred method to improve
long-term shelf life of liposomes especially those containing thermosensitive drugs [32].
By removing water from the liposomal dispersion by lyophilization, the structural and
permeability properties can be retained [33]. However, the lyophilization process itself
can induce physical changes such as loss of the encapsulated agent, and an increase in
vesicle size [34]. Careful selection and optimization of the formulation and process is
necessary to improve the shelf life of paclitaxel-loaded liposomes.
1.1.9.

Echogenic Liposomes

Apart from targeting and controlled release, it may be an additional advantage to
improve permeability at the tumor vasculature. Incorporation of gases in the bilayer of
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liposomes makes them ultrasound active [35]. These echogenic liposomes have the
potential for stress on activation by ultrasound and eventually release the contents at the
target site. These liposomes can be visualized at the target site, and by changing the
intensity of ultrasound, they can be disintegrated providing a means for controlling the
drug release. Interestingly, the disintegration of gas-filled species by contrast enhanced
ultrasound produces liquid jets that can produce small gaps in the vasculature and
improve the permeability [36]. This phenomenon exhibited by microbubbles can be
explored for targeted delivery using echogenic liposomes wherein the targeted liposomes
maintain basal levels of the drug by virtue of cytosolic transport, and by altering intensity
of ultrasound, high cytotoxic concentrations of the drug can be achieved at the target site.
Thus, cavitation effect of ultrasound on the echogenic liposomes provides a control over
drug release, and also enhances drug permeability by producing small gaps in the
endothelial walls of vasculature [36-39].
1.2. REVIEW OF LITERATURE: FORMULATION DEVELOPMENT, AND
DELIVERY ASPECTS OF LIPOSOMES IN CANCER CHEMOTHERAPY
Liposomes are bilayered vesicles made of phospholipids. In 1964, Bangham and
Horne described that lecithin dispersions contained ‘spherulites’ composed of concentric
lamellae by negative staining technique using electron microscope [40]. This liquid
crystal phase structure of phospholipids in water or salt solutions was referred as ‘smectic
mesophase’. These lipid systems were tested for the permeability of anions and cations
through the membrane to describe their analogy to certain biological membranes [41, 42].
These artificial structures were colloquially referred as ‘Liposomes’ or ‘Bangasomes’
[43, 44]. Later, the term liposomes, derived from greek words ‘lipos’ meaning fat and
‘somas’ meaning body, gained popularity in literature and was generally accepted.
Liposomes were used initially as model membranes to characterize the behavior of cell
membrane. Gregordias and coworkers explored the therapeutic potential of liposomes by
developing Aspergillus niger aminoglucosidase entrapped liposomes as enzyme carriers
in enzyme replacement therapy of glycogen storage diseases [45, 46]. These radio labeled
liposomes were removed rapidly from plasma following intravenous administration to
rats. About 56% of the total radioactivity was recovered in liver within 15 min of
administration. These results showed that liposomes can be used as effective carriers for
delivery of enzymes to liver and spleen. Further, they developed liposomes containing
invertase (β-D-fructofuranosidase) to follow the fate of enzyme activity rather than
following radioactivity of labeled liposomes. These liposomes accumulated in liver and
spleen within 6 hours of intravenous injection in rats. The invertase activity was
maximum in the mitochondrial-lysosomal fraction of the liver suggesting that the
liposomes can be used as potential carriers for delivering enzymes and drugs to liver and
spleen [47, 48]. Then, they tested the applicability of liposomes in drug delivery by
developing liposomes loaded with actinomycin D in the lipid bilayer or penicillin in the
aqueous core of the liposomes [49]. The distribution of liposome entrapped, and nonentrapped drug was studied by intravenous injection to rats. Though the elimination of
liposomal entrapped drugs was slower than the free drugs, a considerable amount of the
liposomal drug accumulated in lysosomes of liver and spleen. On reaching lysosomes, the
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drug action requires disruption of liposomes by lysosomal lipases to release the drug. As
a further development, they evaluated the uptake of liposome entrapped agents in the
tumor cells using radio labeled albumin entrapped liposomes [50]. The study involving
three metastatic cancer patients showed that the radioactivity in the tumors was slightly
higher to much higher than that of the corresponding normal tissues. The improved
localization was attributed to extensive vascularization in tumor and enhanced
endocytotic activity of the tumor cells.
From the time liposomes found their way in drug delivery, extensive research in the
area lead to numerous advances to improve the formulation and to improve their
efficiency as a carrier in drug delivery [28, 51-54]. The following sub-sections will
briefly outline basic properties, and some of the advances in formulation development of
liposomes with special emphasis in their application in chemotherapy of solid tumors.
1.2.1.

Composition of Liposomes

Liposomes are composed of natural or synthetic phospholipids. Phospholipids have a
head group and a tail group with two fatty acyl chains of varying lengths. The phosphate
head group is attached to different functional groups which can determine the degree of
hydration and charge of the liposomes [28]. The choline functional group offers some
degree of hydration and confers a neutral charge. Ethanolamine contributes to a minimum
degree of surface hydration while it is also a neutral in charge. On the other hand, serine
and glycerin functional groups confer a negative charge with some surface hydration.
Polyethyleneglycol (PEG) ethanolamine provides high degree of hydration and a steric
effect with a negative charge. The properties of tail group fatty acyl chains determine
fluidity, thickness, and order of membrane packing of the bilayer. The chain length can
range from C14-C18. An increase in chain length increases the thickness, and gel to liquid
crystalline transition temperature (Tm) of the bilayer. An increase in the level of
saturation increases the rigidity and Tm, and reduces fluidity of the bilayer. Varying the
degree of saturation and chain length of the two tail acyl chains can result in a decrease in
the order of membrane packing and a lower Tm compared to lipids with two identical acyl
chains [55].
1.2.1.1.

Effect of Fluidity of the Bilayer

The lipid bilayers of liposome membranes exist in the well ordered gel phase at
temperatures below their gel to liquid crystalline transition temperature (Tm). The Tm
involves partial melting of acyl chains while the spherical liposomes remain intact. At
temperatures above Tm, the lipids exist in a disordered fluid phase or liquid crystalline
phase wherein the acyl chains become mobile within the hydrophobic region of the
liposome while the anchoring of polar head groups prevent complete freedom of
movement [28, 56]. At the temperatures corresponding to Tm of the phospholipids,
maximum permeability or leakage is observed [57]. The phase behavior of liposomes
determines their permeability, aggregation, ability to bind to serum proteins, and fusion
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[28]. The phase behavior on the other hand, depends on the composition of the bilayer.
By careful selection of chain length, saturation/unsaturation of fatty acyl chains of the
lipids, the fluidity of the bilayer can be altered.
Introduction of double bonds and shortening the chain length of phospholipids can
increase the fluidity of the bilayer and thereby increase the permeability across the
bilayer [55]. The permeability of glycerol and erythritol was evaluated in liposomes made
of different phospholipids. The swelling rates of liposomes composed of
(distearoyl)lecithin or (1-stearoyl-2-oleyl)lecithin or (dioleyl)lecithin or
(dilinoleyl)lecithin showed that the permeability increased with an increase in number of
double bonds. Similarly, liposomes made of (disteroyl)lecithin or (dipalimitoyl)lecithin
or (dimyristoyl)lecithin showed a decrease in permeability with an increase in chain
length as glycerol could not to penetrate the bilayer with increasing chain length.
Thermal motion of fatty acyl chains result in molecular cavities. When cholesterol is
added along with phospholipids, it occupies these cavities and therefore, does not
increase area per molecule in mixed monolayers. This observation was proved by the
measurement of surface potential for palmitoyl lecithin-cholesterol mixtures which did
not show a change in surface potential [58]. At high surface pressures cholesterol
liquefied solid monolayers indicating that cholesterol imparts fluidity to the phospholipid
monolayers. Ladbrooke et al showed that cholesterol controls fluidity of the hydrocarbon
chains of phospholipids by disrupting the crystalline chain lattice of the gel phase, and by
inhibiting the flexibility of chains in the dispersed liquid crystalline phase [59]. For lipids
which would normally be above their Tm (T > Tm), there will be a limitation in flexibility
and for those lipids which remain at gel state (T < Tm) have greater fluidity.
Liposomes containing mixtures of phospholipids and cholesterol demonstrated a
decrease in permeability with an increase in concentration of cholesterol [55]. Cholesterol
reduced the permeability of glycerol in liposome structures made of egg-yolk lecithin or
(1-palmitoyl-2-oleyl)-lecithin or (dioleyl) lecithin in a concentration dependant manner.
The effect of cholesterol permeability was not limited to glycerol. A decreased chloride
permeability, from liposomes made of egg-yolk lecithin and cholesterol compared to that
pure lecithin, has been reported [60]. Valinomycin induced permeability of 86Rb+ was
also reduced by inclusion of cholesterol in the liposome composition [61]. Demel et al
explained that the permeability reducing property of cholesterol is related to planar sterol
nucleus, an intact side chain, and a 3β-hydroxyl group based on their study with several
natural and synthetic sterols on the permeability of glucose, glycerol, and 86Rb+ using
egg lecithin liposomes [62]. The reduced permeability is due to increased packing and
decreased mobility of the hydrocarbon chains [63].
Kirby et al demonstrated that the inclusion of cholesterol in the liposomes improves
in vitro and in vivo stability of the liposomes using a fluorescent tracer
carboxyfluorescein [64]. The liposomes rich in cholesterol (1:1 ratio of egg
phosphatidylcholine (EPC) and cholesterol) were more stable following intravenous
injection to mice compared to liposomes containing less or no cholesterol. A similar
stability trend was observed in mouse whole blood, plasma or serum. The stabilizing

7

effect was similar in neutral, negative, and positive charged liposomes. The liposomes
containing cholesterol were resistant to exchange of phospholipids with high density
lipoproteins and thereby exhibited better in vivo stability.
1.2.1.2.

Effect of Surface Charge of the Liposomes

The liposomes have a charge based on the composition of head group of the
phospholipids. These phospholipids can have neutral, positive, or negative charge. The
surface charge of the liposomes determines their stability in dispersion, in vivo circulation
time, ability to interact with target cells, and recognition by plasma proteins or opsonins.
Neutral liposomes have lower tendency to be cleared by the RES but have poor stability
in dispersion due to aggregation. Negative surface charge provides better colloidal
stability, but these liposomes have higher non-specific uptake in vivo, and are easily
recognized by macrophages. With permeability of the bilayer remaining constant
between neutral and negatively charged liposomal formulations, negatively charged
liposomes were cleared faster than the liposomes with neutral charge [65]. Liposomes
with different surface charge were removed from circulation at different rates even
though the total body clearance of encapsulated compound is similar [66]. Hepatic uptake
of positive and negatively charged liposomes was greater than the liposomes of neutral
charge [67]. Neutral liposomes gain negative charge in presence of blood plasma due to
adsorption or binding plasma components whereas negatively charged liposomes remain
unchanged [68]. Wilkins and myers suggested that surface charge of the particle could
affect the steric arrangement of the adsorbed protein in a manner that is recognizable by
the fixed macrophages of the RES [69].
Phagocytosis of complement opsonized liposomes was strongly dependent on the
charge of the liposomal lipids. The presence of acidic negatively charged lipids
phosphatidylserine, phosphatidylinositol and dicetyl phosphate profoundly suppressed the
uptake of the liposomes [70]. The drug penetration through the skin was greater from a
gel formulation containing negatively charged liposomes compared to positively charged
liposomes [71]. Histological studies showed that negatively charged liposomes diffused
to the dermis and lower portions of hair follicles through the stratum corneum and the
follicles much faster than the positively charged vesicles. Electrostatic interactions are
one of the main forces affecting the association of liposomes with the charged cell
surface. An increase in the concentration of negatively charged lipid phosphatidylserine
(PS) in the lipid bilayer resulted in increased association of liposomes with human colon
CX-1.1 cancer cells [72]. Heath and coworkers demonstrated that the uptake of
methotrexate-γ-aspartate from negatively charged liposomes was more efficient in five
different cancer cell lines as compared to neutral liposomes [73].
Positively charged liposomes, frequently used for condensation of DNA on the
surface for gene delivery, also have shown higher clearance by the RES. The degree of
interaction of liposomes with macrophages can be modulated by the positive charge on
the liposomes [74]. The 99mTc marker entrapped in positively charged liposomes was
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cleared five times faster than the lipid integral membrane marker, showing that the
presence of positive charge affects in vivo stability of liposomes [75].
In vitro cellular binding and uptake study using human ovarian carcinoma HeLa cell
lines showed that endocytosis of positively charged liposomes was greater than
negatively charged liposomes, and neutral liposomes [76]. Cationic liposomes have
shown the tendency to preferentially accumulate the A-Mel-3 melanoma of the hamster
in comparison to normal surrounding tissue [77]. Intravital microscopy revealed that the
uptake of cationic liposomes in the solid tumor was due to their accumulation in
angiogenic tumor vessels but neutral, and negatively charged liposomes showed nonspecific extravasation into parenchyma. Positively charged paclitaxel-loaded liposomes
showed a significant regression of tumor and delayed metastasis due to antivascular
targeting by virtue of positive charge [77, 78].
1.2.2.

Size of Liposomes

The size of the liposomes is one of the major factors determining their fate after
intravenous injection [79]. Larger liposomes are cleared rapidly from the circulation
following intravenous administration. These liposomes are taken up into Kupffer cells of
liver and fixed macrophages of spleen [80]. Smaller liposomes of size less than 100 nm
have the ability to pass through fenestrated endothelium, or regions of increased capillary
permeability, and gain access to liver parenchymal cells. Liver and spleen are the major
sites of localization for liposomes irrespective of their size. Harashima and Kiwada
compiled the data from literature for pharmacokinetics of liposomes of different sizes and
calculated the total body clearance [79]. Their analysis indicated that the clearance was
proportional to the size of the liposomes. AmBisomeTM (Gilead Sciences, Inc., Foster
City, CA), the marketed liposomal formulation of amphotericin B is formulated to the
size specification of 45-80 nm to reduce RES uptake [28].
Liposomes of different size were treated with serum and their uptake was determined
in perfused liver [81]. The results showed that opsonins bind to the liposomes depending
upon the size, and they were taken up by the liver phagocytosis based on the extent of
opsonization. The hepatic extraction of liposomes increased with an increase in liposome
size (200, 400 and 800 nm). Allen and Everest studied the effect of liposome size and
composition on pharmacokinetics of encapsulated [14C] labeled sucrose [82]. They used
two liposomal compositions egg phosphatidylcholine-cholesterol, and sphingomyelinphosphatidylcholine with in vitro serum stability of 2.5 and 35 h respectively. Liposome
entrapment increased the circulation time of sucrose in vivo with a higher circulation time
for small unilamellar vesicles compared to multilamellar vesicles. The same trend of in
vitro stability was observed in vivo. Senior et al showed with liposomes of similar
composition, the trend is that increase in size results in rapid clearance [65]. The effect of
size was prominent in determining the circulation half life of liposomes than the
membrane permeability.
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The kinetics of differential uptake of various types of liposomes by the liver Kupffer
cells and parenchymal cells were evaluated by Rahman and coworkers [83]. Liposomes
of different size were loaded with 59Fe-Desferal. The uptake in two cell types of liver was
monitored at specific time points following intravenous injection to mice. Fractionation
of the liver into parenchymal and non-parenchymal cell fractions revealed that liposomes
of size 60-80 nm were taken up by the parenchymal cells, while the larger multilamellar
liposomes of size 500 nm were taken up by Kupffer cells. These results suggested that the
size plays an important role in sorting liposomes to Kupffer cells or hepatocytes.
The activation of complement system can also induce complement mediated
clearance of liposomes [81]. When inactivated serum was used to omit the activity of
opsonins, size dependant degradation in serum was observed which was consistent with
size dependant complement activation. The uptake of these liposomes in inactivated
serum by the liver was primarily due to complement activation. Abra et al quantified the
relationship between in vivo disposition and dose size for liposomes of three different
diameters (460, 160, 58 nm) in mice [84]. Saturation in liver with increasing lipid dose
was seen with all three sizes together with increase in blood levels.
1.2.3.

Surface Modification of Liposomes

The clearance of liposomes by RES depends on non-specific hydrophobic interactions
of liposomes with RES cells, and specific opsonization reaction involving blood
components. The liposomes cleared by RES accumulate into Kupffer cells of liver or
fixed macrophages of spleen. This will be an advantage if the liposomes are targeted to
the organs of RES. But, delivering the liposomes to non RES organs and tissues require
approaches to overcome the short circulation time due to clearance by RES. In addition,
repeated administration followed by accumulation of liposomes in the RES organs can
impair the RES and result in consequences of altering the host defense mechanism.
The rate of clearance of intravenously administered liposomes depends on several
factors including surface charge. Even though, liposomal membranes are similar to cell
membranes they are cleared rapidly by several mechanisms. But, analysis of composition
of cell membranes revealed that the presence of large amounts of sialic acid residues on
the cell membranes can impart negative charge to the surface and thereby improved
stability. Allen et al. developed liposomes with lipid composition which mimics surface
characteristics of erythrocytes by including ganglioside GM1 in the formulation [80, 85].
Biodistribution studies in mice showed that the liposomes containing ganglioside GM1
have longer circulation time compared to conventional liposomes, and other negatively
charged liposomes containing dipalmitoylphosphatidylglycerin (DPPG), and sulfatides.
The blood/RES ratio for the ganglioside GM 1 containing liposomes increased in the
presence of bilayer rigidifying lipid, sphingomyelin. The data demonstrated that surface
sialic acid and bilayer viscosity worked synergistically increasing circulation time of
liposomes. The authors also evaluated the effect of size on biodistribution of liposomes of
various compositions in the presence and absence of ganglioside GM1. Circulation halflives increased with decreasing size down to liposomes extruded through 80 nm filters.
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Further decrease in size resulted in an increased accumulation in liver possibly due to the
ability of the smaller liposomes to penetrate liver sinusoids and gain access to
hepatocytes. Gabizon and Papahadjopoulos [86] confirmed the improved circulation
time, and reduced clearance of GM1 containing liposomes. Further, they demonstrated a
25-fold increase in tumor uptake of the liposomal tracer in a J6456 lymphoma muscular
tumor model in mice as compared to the free tracer. In another study, they showed that
physicochemical features contributing to optimal retardation of liposome clearance
include a hydrophilic carbohydrate moiety and a sterically hindered negatively-charged
group [87]. Asialoganglioside (AGM1) was less effective in retarding clearance of
liposomes than monosialoganglioside (GM1) indicating that there is a need for negative
charge in addition to the carbohydrate group. The negatively charged lipids
phosphatidylinositol phosphate (PIP) and trisialoganglioside (GT1) were less effective
than phosphatidylinositol (PI) and GM1 in retarding clearance of liposomes. Increasing
the molar fraction of negatively charged lipid resulted in an increased uptake in the liver.
Blume and Cevc [88] demonstrated that the steric surface protection offered by PEG
chains slows down the adsorption of macromolecules from blood on to the vesicles, and
thereby, suppresses the clearance of the liposomes by RES. In vivo evaluation in mice
showed that the steric barriers prolonged the vesicle circulation time for up to 24 h. The
authors claimed that the polymeric coating with PEG is non-immunogenic, and non-toxic
as against the inclusion of natural glycolipids. Although glycolipids are nonimmunogenic, their use in artificial membranes at higher concentrations, not encountered
in normal membranes, can trigger immunogenic reaction. In a similar direction, Klibanov
et al demonstrated that coating the surface of the liposomes with PEG improves
circulation time of the liposomes in blood minimizing the uptake by the RES [89]. In a
biodistribution study in mice, the authors showed that the circulation half-life of PEG
coated liposomes were 10-fold greater than conventional liposomes of same size. Coating
the liposomes with PEG increases the hydrophilicity of the liposome surface and
minimizes the hydrophobic interaction with RES. It also sterically prevents the binding of
opsonins to the liposomes to overcome specific interaction with RES. Doxil®(Alza
Corporation, now part of Johnson & Johnson, Inc., New Brunswick, NJ), the marketed
liposomal formulation of doxorubicin is a PEGylated formulation to overcome clearance
by the RES.
Liposome grafted PEG can neutralize the surface charge of the liposomes and provide
shielding from interaction with various opsonins. The effect of PEG in minimizing the
clearance is dependent upon the charge of the liposomes and the chain length of the
surface grafted PEG polymer [90]. The clearance of positively charged liposomes was
minimized by incorporation of either phosphatidylethanolamine (PE) conjugated to
PEG750 or PEG5000 whereas the clearance of negatively charged liposomes was
minimized only by PE-PEG5000 but not PE-PEG750. The presence of negatively charged
lipid phosphatidylserine (PS) on the membrane surface can form transient nucleation sites
for binding plasma proteins which in turn increases the clearance. These nucleation sites
may not be accessible when PEG-lipids are present at elevated levels where they adopt a
highly compressed brush conformation. An increase in the concentration of
distearoylphosphatidylethanolamine-PEG2000 (DSPE-PEG2000) showed a decrease in
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clearance of these negatively charged liposomes with 15% providing almost complete
shielding effect [91]. The combined effects of densely packed PEG and extension of the
polymer barrier from the membrane surface provided steric inhibition of high affinity
protein-membrane interactions.
The presence of modified polyvinyl alcohol (PVA) on the surface of liposomes can
affect the interaction of liposomes with serum proteins inhibiting the protein adsorption
[92]. Flow cytometry and confocal laser scanning microscopy evaluation of interaction of
liposomes containing DiI (1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocianin
perchlorate) with J774 cells revealed that there is a steric hindrance effect on the
interaction [93]. The introduction of a PVA layer on the liposomal surface inhibited the
interaction of the liposomal core and J774 cells in a similar fashion as with PEG-coated
liposomes. The use of a mixture of PEG and PVA in the surface modification has been
shown to prolong the residence time of the liposomes compared to those with PEG alone
[94]. A decrease in the adsorbed amount of several opsonins and an increase in the
adsorbed amount of dysopsonins were responsible for lower affinity of these liposomes to
the liver and longer residence in the systemic circulation.
1.2.4.

Drug Loading in Liposomes

The unique nature of the liposomes is that their ability to incorporate lipophilic drugs
in the bilayer, and hydrophilic drugs in the aqueous core. The flexibility in the
composition of bilayer allows modification of bilayer integrity and fluidity to prepare
stable drug-loaded liposomes. It is also possible to load both lipophilic and hydrophilic
drugs in the liposomes. Drug loading in the liposomes can be accomplished by passive
loading and active loading and is reviewed by Mayer and coworkers [95]. Drug loading
efficiency can vary with the nature of the drug, lipid composition, type of liposomes, size,
drug-lipid ratio, and method of preparation.
1.2.4.1.

Passive Loading

For hydrophilic drugs, passive loading refers to the ability of the liposomes to capture
certain aqueous volume along with dissolved drug in the core of liposomes during vesicle
formation. The loading efficiency will vary with the type of liposomes as small
unilamellar vesicles (SUV) have a lower trapped volume as compared to large
unilamellar vesicles (LUV) and multilamellar vesicles (MLV).
Methotrexate was loaded in the aqueous core of liposomes by passive loading to
encapsulate the drug for delivery to liver cancer [96]. Due to small trapped volume, about
18% of the drug was entrapped in liposomes. Large unilamellar liposomes prepared by
extrusion procedure with 33% loading efficiency for methotrexate and cytosine
arabinoside have been reported [97]. Szoka and Papahadjopoulos developed large
unilamellar and oligolamellar liposomes with high trapped volumes by reversed phase
evaporation technique to encapsulate up to 65% of aqueous phase [98]. They improved
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the loading of cytosine arabinoside by inverted micelle formation within organic solvent
followed by solvent removal to improve encapsulation.
1.2.4.2.

Active Loading

Active loading refers to entrapment of lipid soluble or water soluble drugs in the
bilayer or aqueous core of liposomes respectively due to nature of the drug and lipids.
Lipid soluble drugs are dissolved along with phospholipids during film formation step in
the preparation of liposomes. The entrapment of these drugs is dependent on packing
restrictions of the bilayer and can vary with lipid composition. On the other hand,
amphiphilic drugs are often difficult to entrap in the liposomes because they easily
permeate through the bilayer. The interaction between the drug and charged head group
of the lipid components has been explored to improve loading efficiency. Electrostatic
interaction and/or intercalation of doxorubicin with negatively charged PS or cardiolipin
in the bilayer improved the drug loading efficiency as compared to neutral liposomes [99101].
Amphiphilic cations can be effectively loaded into the aqueous core liposomes
through an ion gradient across the membrane. Cationic anticancer drugs doxorubicin, and
vinblastine were actively loaded into the liposomes when a membrane potential (∆ψ,
negative inside) is generated across the vesicle membrane [97]. Membrane potentials
were generated by forming liposomes in potassium glutamate buffer followed by
exchange of unentrapped buffer with sodium chloride buffer using Sephadex G-50
desalting columns. Addition of K+ ionophore, valinomycin, induced K+ diffusion
potential and improved the drug loading into the aqueous core of the vesicles when the
drug was added. In this active loading technique, the retention time of doxorubicin was
improved by an order of magnitude compared to liposomes loaded with passive trapping
technique. Another strategy of active loading involves the use of transmembrane pH
gradients (∆pH, acidic inside). In this case, the liposomes were hydrated in presence of
an acidic buffer (pH 4.6), unentrapped acidic buffer was exchanged with a buffer of
higher pH (pH 7.5) to generate a transmembrane pH gradient. Addition of doxorubicin
results in active loading due to the pH gradient. The loading and retention of doxorubicin
was several folds higher than the liposomes with passive loading [102]. Although both
techniques employing ∆ψ, and ∆pH improve drug loading efficiency, the use of ∆pH will
be of practical significance because the techniques with ∆ψ require the presence of
external ionophore but the techniques with ∆pH does not require any additives [95].
Since the drugs are loaded in to preformed liposomes in these remote loading techniques,
harsh conditions of processing is avoided which is beneficial for labile drugs.
Another remote loading approach uses ammonium sulfate gradient where the
concentration of ammonium sulfate in the aqueous core is greater than the medium in
which liposomes are suspended. The gradient of liposomal ammonium sulfate
concentration to the concentration in the medium acts as a driving force and works by
base exchange of ammonium ions for loading amphipathic weak bases [103].
Doxorubicin was loaded by ammonium sulfate gradient method into liposomes such that
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the concentration of doxorubicin in the aqueous core was more than 100-fold than the
medium. In addition to pH gradient and ammonium ion diffusion potential, low
permeability coefficient of sulfate ions through the bilayers is also crucial in stable
accumulation. The low solubility of anthracycline sulfate salt formed in the aqueous core
is further lowered by the presence of ammonium sulfate. Salting out effect of ammonium
sulfate accelerates the flocculation and gelation of doxorubicin and improves the
encapsulation and stability.
1.2.4.3.

Coencapsulation

Almost all chemotherapeutic regimens for the treatment of cancer include
combination of drugs. Administration of combination drugs loaded in liposomes will be
less prone to development of drug resistance compared to therapies with single drug or
drugs administered sequentially. Combining liposomal formulations of two drugs will
have adverse effects associated with high lipids and hence coencapsulation of the
combination drugs is sought. However, there are difficulties associated with efficient and
stable encapsulation of two chemically different drugs. Methotrexate or cytosine
arabinoside were loaded passively into the aqueous core of liposomes followed by active
loading of doxorubicin through valinomycin induced K+ membrane potential [97]. Tardi
et al showed that it is also necessary to maintain a constant ratio between two drugs to
benefit from synergy of the treatment [104]. They developed liposomes containing
irinotecan and floxuridine in the aqueous core of the liposomes. These drugs were loaded
into the liposomes by simultaneous drug loading wherein floxuridine was passively
loaded, and irinotecan was actively loaded in to the liposomes in presence of copper
gluconate/triethylamine buffer. Biodistribution study in mice showed that the optimized
formulation maintained irinotecan-floxuridine ratio of 1:1.
Doxorubicin and combretastatin A4 were coencapsulated in Arg-Gly-Asp (RGD)
peptide conjugated liposomes for targeted delivery to melanoma [105]. Combretastatin
was loaded in the bilayer during the film formation step and doxorubicin was remote
loaded in to the aqueous core of liposomes by ammonium sulfate gradient method. RGD
conjugated formulation showed greater efficacy in regressing tumor volume in B16F10
flank tumor melanoma xenograft model in C57BL/6 mice. The authors proposed that
combretastatin disrupts the vascular matrix leaving the encapsulated gel like doxorubicin
in the tumor site, and doxorubicin is released subsequently to exert cytotoxic effect
The use of modulators to overcome drug resistance is a topic of interest in
coencapsulation of liposomes. Calcium (Ca2+) channel blockers inhibit the tumor
proliferation by inhibiting Ca2+ influx and evoke passive depletion of internal Ca2+ stores.
Amlodipine was coencapsulated as a modulator for topotecan to overcome multi drug
resistance in leukemia [106]. Both drugs were loaded in the aqueous core by ammonium
sulfate gradient method. The results from in vitro apoptosis study in non resistant K562
and resistant MDR HL-60 cell lines showed that amlodipine induces apoptosis by
activation of caspase 3/7 and 8 activities. Depletion of internal Ca2+ stores by amlodipine
lead to activation of caspase 8, then in the cascade, activation of other effector caspases 3
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and 7. In vivo evaluation in female nude mice xenografts bearing MDR HL-60 tumor
showed that the stealth liposomes containing topotecan and amlodipine showed a
significantly lower change ratio for the tumor size compared to free topotecan, and stealth
liposomal topotecan. The combination therapy worked by potentiating the apoptotic
effect and reversing the resistance.
1.2.5.

Targeted Drug Delivery with Liposomes

The drugs used in cancer chemotherapy often have severe adverse effects because
they not only kill cancer cells but also kill normal cells. Encapsulation of these drugs in
the liposomes can minimize systemic exposure of the drug, and therefore, minimize
undesired systemic toxicity. Further, selective localization of the drug at the tumor sites
would reduce the total amount of drug required for the therapy. Thus, an ideal liposomal
drug delivery system for cancer chemotherapy should improve localization of the drug at
the tumor sites and minimize exposure to normal tissues. Targeted drug delivery
approaches with liposomes by means of active targeting and passive targeting will help
accomplish these goals of an ideal delivery system.
1.2.5.1.

Passive Targeting

Passive targeting refers to the accumulation of the therapeutic agent or carrier at the
target site due to physicochemical and physiological factors [107]. An understanding of
the pathophysiology of the tumor is necessary to design a successful targeted delivery
system. The ability to target drugs passively to the tumors using liposomes originated
from the findings that the tumor blood vessels are more permeable to macromolecules
than normal blood vessels [108, 109]. Tumor vessels have wide interendothelial
junctions, large number of fenestrae and transendothelial channels formed by vesicles,
and discontinuous or absent basement membrane [110]. Due to this leaky nature of the
vasculature in the tumors, macromolecules can extravasate and accumulate in the tumors.
In addition, the recovery of these macromolecules from tumors via blood or lymphatic
drainage is impaired which results in high accumulation in the interstitial fluid
compartment of the tumors [25, 111, 112]. This phenomenon of selective accumulation
of macromolecules in the tumor is referred as enhanced permeability and retention (EPR)
effect [113].
Passive accumulation of liposomes in the tumors occurs by transvascular transport
across the blood vessels. The transport is determined by size of the liposomes, and
diameter of the pores in the vasculature. The cutoff size for the vasculature in several
tumors has been studied [114, 115]. The cutoff size varies between tumors depending
upon the stage of the tumor, size and location of the tumor. Tumors grown
subcutaneously exhibited pore cutoff sizes between 200 to 1200 nm. The cutoff was
reduced in intracranial tumors and tumors undergoing regression. Nevertheless, the
majority of tumors exhibited a vascular pore cutoff size between 380 and 780 nm. So, the
permeability of macromolecules will be independent of the pore size as long as the size
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of the molecule is less than the pore diameter. Liposomes used in cancer chemotherapy
are typically between 100 and 300 nm in size which means that they can extravasate and
selectively accumulate in most of the tumors.
The passive accumulation of liposomes in the tumors by EPR is a progressive
phenomenon which requires several passages of the liposomes through the tumor blood
vessels [51]. The liposomes should remain in circulation for a longer time to take
advantage of selective accumulation in the tumors by EPR. However, the liposomes are
considered foreign agents and are cleared by the reticuloendothelial system (RES)
comprised of Kupffer cells of the liver and fixed macrophages of the spleen. Surface
modifications of the liposomes with hydrophilic polymers such as PEG provides
shielding effect and prevent the binding of opsonins to the liposomes which in turn
minimize the recognition of these liposomes by RES [89]. If the liposomes remain in the
circulation for a prolonged period of time, the chances of their accumulation by EPR in
the tumor can be improved. Another important consideration for a longer circulation of
liposomes is their size. The clearance of liposomes by RES increases with size [79]. The
binding of opsonins and complement activation are dependent on size of the liposomes
[81]. Even with the inclusion of PEG on the surface of the liposomes to minimize the
clearance of the liposomes by RES, the cutoff size for the liposomes for long circulation
remain between 150 and 200 nm [28].
1.2.5.2.

Active Targeting

Passive accumulation of liposomes at the tumors does not necessarily elicit an
improved therapeutic response which is dependent on the cellular uptake of the
liposomes. Cellular uptake of the liposomes can be improved by active targeting
approach. Active targeting refers to the attachment of specific ligands to the therapeutic
agent or carrier system to recognize and interact with the target receptors or proteins at
the cellular or tissue components [20, 107, 116]. Although similar biodistribution and
tumor accumulation is observed with liposomes by passive targeting and active targeting,
an enhanced therapeutic response is accomplished with active targeting of liposomes
directed against specific receptors due to improved cellular uptake [117, 118].
The primary role of targeting ligands is to enhance the cellular uptake into cancer
cells and minimize the accumulation in normal tissue [22]. Thus, colloidal properties of
liposomes will determine their biodistribution, and targeting ligands will ensure cellular
uptake in the tumor. The number of ligands attached to the liposomes, distribution of
target receptors in the tumors, and selectivity of the targeting ligands to those receptors
will determine the intracellular uptake in the tumors. Under ideal conditions, the number
of ligands bound to the tumors equals the number of available receptors [21]. The binding
of targeting ligand is likely to have high nanomolar to low micromolar dissociation
constants. So, more ligands are necessary than that may be accommodated to drive the
equilibrium towards binding and receptor saturation. Once the receptors of the ligand are
saturated, the specificity of the targeting ligand declines [119]. Excess of the targeted
liposomes will be handled by the body as any non targeted liposomes.
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Tumor cells or endothelial cells of tumor vasculature over express a number of
receptors which makes cancer a disease that will be largely benefitted by targeted drug
delivery. In addition, unique expression of certain receptors by these cells can improve
the specificity of targeting. To specifically target these receptors, ligands can be attached
to the liposomes which on intravenous administration recognize these receptors. Binding
of liposomes through these ligands to the target receptors results in an improved cellular
uptake by receptor mediated endocytosis. The overall therapeutic effectiveness of the
encapsulated drug can be improved while minimizing the exposure to normal cells.
1.2.5.2.1. Targeting Receptors Expressed by Tumor Cells
Several proteins are over expressed or uniquely expressed by tumor cells. Targeting
ligands attached to the surface of liposomes should improve the cellular uptake by
receptor mediated endocytosis. However, the accumulation of liposomes in the tumor
microenvironment depends on passive targeting due to leakiness of the vasculature,
longer circulation time, and nature of the liposomes. While passive targeting results in
accumulation of the liposomes in tumor, receptor mediated endocytosis improves the
cellular internalization.
1.2.5.2.1.1. Antibodies as targeting ligands to target tumor cells
Several antibodies can be used as targeting ligands for liposomes to specifically target
proteins or receptors expressed on cancer cell surfaces. The antibodies can be covalently
coupled with the reactive phospholipids in the membrane [120] or simply by hydrophobic
bonding wherein the hydrophobic Fc portion of the antibody penetrates the lipid bilayer
and immunologically active Fab portions extend into the aqueous phase and become
available for interaction with receptors on the cell surface [121, 122]. The liposomes
with antibodies attached to the surface of the liposomes are cleared rapidly by the RES.
Coating of the liposome surface with hydrophilic polymers can help overcome the
problems with clearance and improve circulation time. PEG coating of such liposomes
with long PEG chains not only prevent the liposomes being recognized by the opsonins
from plasma, but also hamper the interaction of the surface attached ligand with the target
receptors. An interesting strategy was reported to overcome this issue by attaching the
targeting ligand to the distal end of the PEG chains [123, 124]. The binding of these
immunoliposomes containing entrapped doxorubicin resulted in an increased cytotoxicity
to murine squamous lung carcinoma cells as compared to liposomes without antibody
[124].
The surface modification of liposomes with antibodies results in an enhanced uptake
by the RES. Targeting ability with antibody depends on density of the antibody on the
surface of the liposomes. Use of only Fabʹ fragment instead of whole antibody would
minimize the RES uptake by avoiding Fc receptor mediated clearance mechanism. To
improve targeting ability without compromising circulation time, Fabʹ fragments of
monoclonal antibody 21B2 specific for human carcinoembryonic antigen was coupled to
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the distal end of the PEG lipid with maleimide functional group [125]. These liposomes
showed longer circulation time and lower RES uptake compared to the immunoliposomes
prepared with the whole antibody. These liposomes also showed a two-fold higher
accumulation in the tumor tissue, as demonstrated in a xenograft model in BALB/c nu/nu
mice bearing MKN-45 human gastric cancer cell lines. Similarly, Fabʹ fragment was used
in the preparation of Anti- human epidermal growth factor receptor 2 (HER2)
immunoliposomes for targeting breast cancer [24]. Phage antibody selection strategy has
been used to identify antibody fragments to optimize cellular internalization. Small chain
Fv (ScFv) fragments of anti-HER2 antibody, ScFv F5 was found to specifically recognize
the extracellular domain of HER2 and showed more internalization in a panel of HER2
over expressing cells [126]. Doxorubicin-loaded immunoliposomes containing Fabʹ or
ScFv fragments have shown significant cure rates in HER2 over expressing mouse
xenograft models [127].
Conjugation of antibodies to preformed liposomes containing coupling lipids,
incorporated during liposomes formation, can leave reactive functional groups on the
inner leaflet of bilayer and can potentially interfere with the encapsulated material [128,
129]. In addition, some of the coupling agents may be incompatible with the processing
conditions of liposomes. Uster et al demonstrated that 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-(methoxy(polyethylene glycol)-1900) (MPEG1900-DSPE) from
micellar phase can be transferred in a time, and temperature dependant manner into
preformed liposomes [130]. Post insertion of the micelles into preformed liposomes for
the insertion of targeting ligands on to the external leaflet of liposomes was first
demonstrated for oligopeptide and oligosaccharide ligands [129]. Ishida and coworkers
designed doxorubicin-loaded immunoliposomes by post insertion method using sheep
IgG or anti-CD19 monoclonal antibody coupled to micelles containing 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-(methoxy(polyethylene glycol)-2000) (MPEG2000DSPE) and the coupling lipid malemide-PEG2000-DSPE [131]. A very little (4%)
doxorubicin was released in the transfer process, and anti-CD19 conjugated liposomes
showed a three-fold increase in the association with human B lymphoma cell lines
suggesting that the integrity and binding affinity of the these liposomes was not altered
during the transfer process. The authors envisioned a combinatorial approach for making
many different formulations of targeted liposomes with a simple procedure of selecting a
vial of ligand-PEG-micelles for one-step incubation with the appropriate liposomal drug
formulation.
1.2.5.2.1.2. Folic acid
Folic acid is a vitamin required for one-carbon transfer reaction in several metabolic
pathways. Since folic acid is essential for the biosynthesis of nucleotide bases, its uptake
is elevated in proliferating cells [132]. Of the two types of folate receptors, the folate
receptor responsible for the internalization of oxidized folate by receptor mediated
endocytosis is over expressed in cancer cells to compete for the vitamin available in
limited quantity [133, 134]. In normal cells, folate receptors are selectively expressed on
the apical membrane surface. On malignant transformation, the polarity is reversed and
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the receptors are available for folate binding and internalization which makes them
suitable for selective targeting.
The length of the spacer used in coupling procedure has been shown to play a crucial
role in the ability of folic acid to interact with KB cells expressing folate receptors [135].
The liposomes with longer PEG spacer chains showed better internalization in the cells
compared to the ones with smaller or no spacer chains. Pretreatment of the cells with
excess free folate or antiserum against folate receptors competitively inhibited the uptake
of liposomes indicating that the targeting was mediated through receptor mediated
endocytosis. The use of folic acid conjugated PEG coated liposomes in targeted drug
delivery was demonstrated in another study using doxorubicin-loaded liposomes [136].
The uptake of doxorubicin from these liposomes by KB cells was 45 and 1.6 times
greater than non targeted liposomes or free drug respectively. The formulation also
showed 86-fold higher cytotoxicity than non targeted liposomes and 2.7-fold higher
cytotoxicity than free doxorubicin. The specificity of folate receptor mediated
endocytosis was demonstrated in co-cultures containing human cervical carcinoma cell
line Hela and human lung cancer cell line W138. Folate receptor over expressing Hela
cells were killed completely following treatment with folate targeted liposomal
doxorubicin leaving only folate non-expressing W138 cells in the culture dish. These
results suggest that anticancer drugs can be targeted safely to cancer cells by folate
mediated targeting while sparing normal cells.
Goren et al showed that doxorubicin from folate targeted liposomes was rapidly
internalized, released in the cytoplasm, and detected in the nucleus within 1-2 hours
[137]. This mechanism was suggested as a strategy to overcome multi drug resistance of
drugs which are substrates for efflux transporters. The uptake of doxorubicin by
multidrug-resistant subline of M109-HiFR lung cancer cells (M109R-HiFR) was not
affected by P-glycoprotein (P-gp) mediated efflux which was in sharp contrast to the
uptake of free doxorubicin based on verapamil-blockade experiments with quantitation of
cell-associated drug, and flow cytometry analysis. The cells pretreated with folate
targeted liposomes also inhibited the tumor growth as demonstrated by in vivo adaptive
tumor growth assay in mice.
1.2.5.2.1.3. Transferrin
Iron (Fe) is required in the active sites of the enzyme ribonucleotide reductase during
DNA synthesis [138]. Due to redox activity and its potential to generate reactive oxygen
species (ROS), the amount of free Fe is kept at minimum levels [139]. To control the
amount of unbound Fe, the metal is transported bound specifically to the two high
affinity binding sites of serum glycoprotein, transferrin (Tf). The uptake of Fe by the cells
involves binding of the Fe-loaded Tf to transferrin receptor1 (TfR1) present on the cell
surface. Binding induces receptor mediated endocytosis of Fe-Tf [140]. TfR1 is a
glycoprotein expressed in all nucleated cells at low levels [141]. The expression of TfR1
is elevated in proliferating cells which makes these receptors excellent choice for targeted
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delivery to cancer [142]. Active targeting to tumor can be accomplished via Tf or
antibodies to TfR1.
The density of TfR1 on the surface of cells is correlated with the extent of cell growth
and division, and consequently, the tumor cells express more TfR1 than normal cells.
Eavarone et al demonstrated that transferrin coupled liposomes were taken up by C6
glioma cells through receptor mediated endocytosis [143]. These liposomes with Tf
coupled to the distal ends of PEG spacers have shown an increased uptake of doxorubicin
as compared to other non targeted liposomal formulations. Anabousi and coworkers
demonstrated cytotoxicity of Tf-coupled liposomal doxorubicin on lung cancer cells
[144]. In addition to TfR1 mediated endocytosis, pH dependant cytoplasmic release was
used as a strategy to improve the delivery of encapsulated materials in T-leukemia cells
[145]. Kakudo et al showed that intracellular trafficking of the liposomes after receptor
mediated endocytosis can be controlled by attaching a pH dependant fusogenic peptide
on to the surface of the liposomes [146]. When fusogenic peptide, GALA was introduced
into liposomal membranes using a cholesteryl moiety for anchoring (Chol-GALA), the
encapsulated rhodamines were efficiently released and diffused into the cytosol.
Tf-PEG liposomes exhibited prolonged in vivo circulation time and low RES uptake
in Colon 26 tumor bearing mice [147]. Longer circulation times resulted in enhanced
extravasation of these liposomes in the tumor tissue. Electron microscopic analysis of the
tumor tissues revealed that colloidal gold encapsulated Tf-PEG liposomes were
internalized by receptor mediated endocytosis. The liposomes of size 60 and 120 nm
showed higher accumulation in tumor tissue compared to 200 and 400 nm liposomes. Li
et al showed that the tumor volume of mice bearing human hepatoma HepG2 tumor was
reduced significantly by doxorubicin-loaded TfR1 targeted liposomes compared to non
targeted liposomes and free drug [148]. Biodistribution studies indicated that doxorubicin
can be efficiently targeted to tumors using liposomes while minimizing the uptake in
heart and kidney. Cisplatin was delivered successfully by Tf targeted liposomes to mice
bearing MKN45P gastric cancer with peritoneal dissemination [149]. Tf-PEG liposomes
showed significantly higher survival rate compared to PEG liposomes, bare liposomes,
and free drug. The mice in Tf-PEG liposome group maintained high liposome and
cisplatin levels in ascites and showed a prolonged residence time in the peripheral
circulation. Similarly, oxaliplatin-loaded Tf-PEG liposomes showed a reduced tumor
growth ratio in mice bearing Colon 26 tumor [150]. Maruyama et al demonstrated
improved survival rate in mice bearing Colon 26 tumor by boron neutron capture therapy
(BNCT) with Tf-PEG liposomes encapsulated with mercaptoundecahydrododecaborate
10
B (BSH) [151]. The tumor to plasma ratio of 10B was 6 after 72 hours of administration.
Neutron irradiation after 72 hours of dosing showed improved tumor suppression
compared to PEG liposomes, bare liposomes, and free BSH. Decahydrodecaborate-10B
(GB-10) have shown better therapeutic activity compared to BSH in BNCT using TfPEG liposomes in the treatment of squamous cell carcinoma in mice [152].
Specific binding, internalization, and intracellular delivery of liposomes conjugated
with anti-Tf receptor antibody was evaluated in three different cell lines for acute T cell
leukemia [153]. Anti-TFR liposomes showed effective binding and internalization in all
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three (MT-1, HUT-102, and Molt-4) cell lines. The growth inhibition of methotrexate-γaspartate in MT-1, and HUT-102 cells which express interleukin-2 (IL-2) receptors was
40 to 60 fold higher using anti-TFR liposomes compared to anti-Tac liposomes
containing antibody directed against IL-2 receptors.
Transferrin receptor mediated endocytosis has been shown to circumvent P-gp
mediated multi drug resistance. The uptake of doxorubicin was 3.5 fold higher in multi
drug resistant SBC-3/ADM human lung cancer cells from Tf targeted liposomes as
compared to free doxorubicin [154]. The liposomes made of egg phosphatidylcholine
(EPC) showed better accumulation than the liposomes made of hydrogenated egg
phosphatidylcholine (HEPC) suggesting that the fluidity of the liposomal membrane
contributes to rapid internalization and drug release which in turn minimizes P-gp
mediated efflux. Krieger et al showed that TfR1 targeted and also non targeted
PEGylated cisplatin-loaded liposomes caused increased drug levels in cisplatin resistant
A2780 ovarian carcinoma cells and resulted in higher cytotoxicities than the free drug
[155]. Verapamil, a calcium channel antagonist with P-gp inhibitory activity was
coencapsulated with doxorubicin in Tf-PEG liposomes to improve drug delivery to
doxorubicin resistant K562 leukemia cells [156]. Cytotoxicity of Tf-PEG coencapsulated
liposomes was greater than non targeted liposomes, and Tf-PEG doxorubicin-loaded
liposomes.
A Tf liposomal formulation was evaluated for the delivery of 5-florouracil to brain
[157]. The in vivo study showed selective uptake of Tf-liposomes from the brain capillary
endothelial cells. The targeted liposomes showed 17, and 10 fold greater accumulation
than free drug, and non targeted liposomes respectively [158]. Tf conjugated liposomes
was proposed as strategy to improve the uptake of drug in brain. Paclitaxel was delivered
to mice bearing C6 glioma tumors in the brain using Tf-PEG liposomes [159]. The
uptake of Tf-PEG liposomes in the brain was supported by non invasive near infrared
fluorescence (NIRF) imaging. Paclitaxel-loaded Tf-PEG liposomes showed a significant
reduction in tumor burden compared to no treatment control. However, no significant
reduction was observed with non targeted liposomes.
A major drawback with targeting tumor cells is that the drugs do not generally
penetrate farther than three to five cell diameters from the blood vessels [160]. This
leaves many cells distant from blood vessels with no drug or low levels of drug which
increases the propensity to development of resistance.
1.2.5.2.2. Targeting Receptors Expressed by Tumor Vasculature
Endothelial cells within angiogenic blood vessels of solid tumors express several
proteins which are either absent or expressed at very low levels in well developed normal
blood vessels [161-163]. These receptors include integrins, aminopeptidases, and
vascular endothelial growth factor (VEGF). Specific ligands can be attached to the
liposomes to target these receptors for drug delivery to solid tumors. An attractive
advantage of targeting tumor vasculature is that the tumor blood vessels are readily

21

available for targeting than the tumor cells and thus specific targeting can be easily
achieved.
1.2.5.2.2.1. Integrins
Peptides with Arg-Gly-Asp (RGD) or Asn-Gly-Arg (NGR) in a cyclic framework
have been shown to bind specifically to tumor vasculature and cells over expressing αvβ3
integrin receptors [163, 164]. Janssen et al demonstrated that RGD-PEG liposomes can
be targeted specifically to proliferating endothelial cells using a Lewis lung carcinoma
model in mice [165]. Intravital microscopy of skin fold chamber showed rhodamine
labeled liposomes as fluorescent clusters in the tumor blood vessels within few minutes
of administration. But PEG liposomes, and liposomes conjugated with control peptide
were seen outside the tumor blood vessels indicating that these non specific liposomes
extravasated deeper in to tumor interstitium. In another study, doxorubicin-loaded RGDPEG liposomes showed improved tumor regression in doxorubicin resistant Colon 26
tumors in mice [166]. The enhanced therapeutic efficacy in doxorubicin insensitive
model suggested that the effect is mediated through binding of RGD-PEG liposomes to
proliferating endothelial cells and not the tumor cells. Holig et al demonstrated that the
concentration of RGD lipopeptide used in the liposomes played a crucial role in the blood
circulation time [167]. The liposomes prepared with 0.1% of lipopeptide have shown
prolonged circulation time compared to those with 1% lipopeptide.
Xiong and coworkers used flow cytometry and confocal microscopy to demonstrate
integrin receptor mediated intracellular delivery of doxorubicin from RGD-PEG
liposomes in B16 or A375 melanoma cell lines [168]. The uptake of RGD-PEG
liposomes was greater than PEGylated liposomes but was less than free drug. Although
the accumulation of RGD-PEG liposomes was greater in spleen compared to PEGylated
liposomes, a better regression in tumor growth was observed in mouse melanoma model
with the administration of single, and multiple doses. Replacing RGD peptide with RGD
mimetic also provided better tumor regression compared to PEGylated liposomes and
free drug [169, 170]. Zhao et al demonstrated improved uptake and cytotoxicity of
paclitaxel-loaded RGD-PEG liposomes in SKOV-3 human ovarian carcinoma cell lines
[171]. The targeted formulation also showed significant inhibition of tumor growth in
mouse ovarian cancer xenograft model. In another study, combretastatin A4 and
doxorubicin were coencapsulated in RGD-PEG liposomes to improve the therapeutic
efficacy in mouse melanoma model [105].
Patillo et al used αvβ3 up-regulation in irradiated tumors to selectively deliver
combretastatin-loaded RGD-PEG liposomes to melanoma in mice [172]. Treatment with
RGD-PEG liposomes and tumor irradiation resulted in a significant delay in tumor
growth compared to treatment without radiation.
Dubey et al showed that spontaneous lung metastasis and angiogenesis were
prevented by RGD peptide anchored liposomes [173]. Cyclic RGD peptide anchored
sterically stabilized liposomes containing 5-fluorouracil (5-FU) showed better activity
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against B16F10 melanoma primary tumor and metastasis than the non-targeted sterically
stabilized liposomes and free drug. Murphy and coworkers evaluated the effect of
doxorubicin-loaded RGD conjugated liposomes on primary tumor growth and
spontaneous metastasis in orthotopic pancreatic and renal cell carcinoma models [174]. A
reproducible modest effect on primary tumor growth and a substantial effect on
metastasis were observed. Antitumor effect was observed with targeted liposomes at a
dose one-fifteenth of the dose of free drug required to produce a similar effect.
1.2.5.2.2.2. Aminopeptidase N (CD13)
Endothelial cells of the angiogenic vessels over express membrane spanning
molecules such as aminopeptidase N (CD13). NGR peptide has been shown to bind to
aminopeptidase N isoform specific to the neovasculature, and can be used for targeting
liposomes to angiogenic blood vessels. Pastorino et al used NGR conjugated
doxorubicin-loaded liposomes for treating neuroblastoma in mouse orthotropic xenograft
models [175]. The targeted liposomal formulation showed a complete regression of
tumors in four out of six mice, and the two others showed more than 80% reduction in
tumor mass. The blood vessel density was also suppressed to more than 90%. These
findings demonstrated that aminopeptidase N-targeted delivery of doxorubicin to blood
vessels caused tumor regression because of its ability to promote apoptosis of the
angiogenic endothelium. In addition, the mice treated with NGR liposomes did not show
visible tumor metastasis. Garde et al demonstrated specific binding of NGR peptide
conjugated liposomes in endothelial and tumor cells [176]. Doxorubicin was shown to
internalize through the endosomal pathway, and then localize in cell nuclei. These
liposomes exhibited selective cytotoxicity in CD13 expressing endothelial cells sparing
CD13 negative colon cancer cells. Antitumor activity evaluation in PC3 prostate cancer
xenograft showed significant inhibition of tumor growth and apparent reduction in
vasculature. Antitumor effect was also improved in doxorubicin resistant HCT-116 colon
carcinoma xenografts compared to free drug.
In addition to targeting aminopeptidase N of the tumor vasculature, targeting
aminopeptidase A, over expressed on the tumor perivascular cells (pericytes), has been
explored to complement tumor targeting. Sequential administration of aminopeptidase A,
and then aminopeptidase N targeted liposome formulations resulted in an enhanced
antitumor activity of doxorubicin compared to either targeting used alone in a
neuroblastoma model [177].
1.2.5.2.2.3. Vascular endothelial growth factor (VEGF)
VEGF receptor is involved in the proliferation of vascular endothelial cells. Blocking
the interaction between VEGF and VEGF receptors is a promising strategy to inhibit
angiogenesis. Janssen and coworkers demonstrated that the peptide with the sequence
ATWLPPR shows affinity for VEGF receptor. A ten-fold higher binding was observed
with ATWLPPR conjugated liposomes in human vascular endothelial cell lines
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(HUVEC) compared to PEGylated liposomes. Kuesters and Campbell used bevacizumab,
a humanized anti-VEGF-A monoclonal antibody to evaluate its targeting ability in human
pancreatic cancer cell lines using cationic liposomes [178]. Bevacizumab conjugated
liposomes showed an improved cellular uptake and tumor targeting of cationic liposomes
compared to unmodified liposomes.
1.2.5.2.3. Combination of Targeting of Tumor Vasculature, and Tumor Cells
The combination of tumor vasculature targeting with tumor cell targeting can
potentially overcome the drawbacks of both targeting approaches and improve the
efficacy of targeted therapy. Pastorino et al demonstrated this concept by sequential
administration of doxorubicin-loaded liposomes conjugated with anti-GD2 monoclonal
antibodies directed to disialoganglioside receptor (GD2), widely expressed on cancer
cells of neuronal origin. Then, NGR peptide conjugated liposomes directed to
aminopeptidase N receptors, over expressed in tumor vasculature, was administered
[179]. Evaluation of in vivo activity against two highly aggressive pseudo metastatic
neuroblastoma animal models showed that there was a significant improvement in
antitumor efficacy with the combination approach compared to either tumor cell or tumor
vasculature targeting. It was suggested that tumor cell targeting results in direct killing of
the cells, including cytotoxicity against cells at the periphery of the tumor and are
independent of the tumor vasculature. On the other hand, vasculature targeted liposomes
binds to and kills angiogenic blood vessels and consequently, kills the tumor cells
supported by these cells, mainly in the tumor core.
1.2.5.2.4. Dual Ligands to Improve Targeting
Tumor cells over express some receptors which can be explored for targeting
liposomes to tumors. It is rare that the target receptors are expressed exclusively by the
tumor cells. These receptors are also expressed by normal cells but may not be at the
same level as tumor cells which results in off-target accumulation of the targeted
liposomes and toxicities associated with such binding. Fortunately, tumor cells over
express multiple types of receptors. This property was explored by Saul et al for targeted
drug delivery of liposomes with a dual targeting approach [180]. Doxorubicin-loaded
liposomes with two targeting ligands, for folic acid receptors and epidermal growth factor
receptors (EGFR), was developed and evaluated for cytotoxicity in KB cell lines. The
liposomes with dual targeting showed significantly higher cytotoxicity in cells expressing
both receptors compared to controls in which expression of one or both of the receptors
were blocked. The results indicated that dual targeting can improve selectivity to target
tumor cells while sparing off-target cells. Similarly, dual-targeting daunorubicin
liposomes were developed by conjugating with p-aminophenyl-α-D-mannopyranoside
(MAN) and Tf for transporting drug across the blood brain barrier (BBB) and then
targeting brain glioma [181]. The median survival time of tumor bearing rats was
significantly longer with dual targeting compared to free daunorubicin, and other
controls. Chen et al showed that multi-target RGD/octreotide-PEG-liposomes enhanced
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antitumor action of dihydrotanshinone as compared to single-target RGD-PEG liposomes
and octreotide-PEG-liposomes in AGS cell gastric cancer xenograft model [182].
1.2.6.

Controlling Drug Release/Uptake from Liposomes

Intracellular delivery of the drug is one of the key problems encountered in targeted
drug delivery [183]. Targeted drug delivery of liposomes through receptor mediated
endocytosis results in their entrapment in endosomes and eventually lysosomes. Active
degradation process takes place in the lysosomes with the help of several lysosomal
enzymes. By modification of the composition of liposomes, it is possible to control
delivery of the drug. Some of the approaches used in improving intracellular delivery of
liposomes in cancer chemotherapy will be discussed in the following sub sections.
1.2.6.1.

Cell-Penetrating Peptides

Certain proteins and peptides can translocate across the plasma membrane and deliver
their payload. This property can be used to overcome the barriers of intracellular delivery
of liposomes to tumor cells. These proteins or peptides contain basic residues with
domains of less than 20 amino acids, and are known as cell-penetrating peptides.
Torchilin et al evaluated the effect of trans-activating transcriptional activator (TAT)
protein on intracellular delivery of fluorescently labeled liposomes to Lewis lung
carcinoma, BT20 human breast cancer, and H9C2 cardio myocyte cells [184]. Liposomes
attached to TAT peptide using a PEG spacer showed high intracellular fluorescence.
Liposomes with TAT attached directly to the liposome surface or to the PEG spacer
shorter than the PEG chains used for steric stabilization did not show intracellular
fluorescence indicating that free interaction between TAT and cellular surface is
necessary for effective internalization. Low temperature or metabolic inhibitors, sodium
azide or iodoacetamide did not show any effect on the translocation of TAT liposomes
into cells confirming the energy-independent nature of this process. Tseng et al showed
that the uptake of doxorubicin from TAT conjugated liposomes was increased by 12-fold
in A431 human epidermoid carcinoma cells [185]. However, there was no difference in
cytotoxicity or in vivo antitumor efficacy between liposomes with and without TAT. A
pH responsive phospholipid was included in the formulation by Sawant and coworkers to
improve TAT mediated intracellular uptake [186]. At low pH as in tumor
microenvironment, the hydrazone link of the PEG-Hydrazone-PE hydrolyzed resulting in
loss of protective PEG which in turn and improved the internalization of liposomes due to
better interaction of TAT with the cell surface. Marty et al demonstrated that
functionalized Antennapedia (Antp, aa 43-58) conjugated liposomes loaded with
cytotoxic drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine-(5'- 5')-3'-Cethinylcytidine reduced IC50 by 70% on B16F1 melanoma cells compared to unmodified
liposomes [187].
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1.2.6.2.

pH-Sensitive Liposomes

The pH-sensitive liposomes undergo selective destabilization on exposure to acidic
environment. The rationale for the development of pH-sensitive liposomes for drug
delivery to tumors is to take advantage of the acidic microenvironment of the tumor to
trigger the release of encapsulated contents. The pH of the interstitium rarely reaches a
value below 6.5 and is difficult to tailor liposomes to be stable at physiological pH and to
destabilize at this small window. But, the pH in the endosomes and lysosomes reach as
low as 5.0 which makes it possible to develop pH-sensitive liposomes that can destabilize
following endocytosis. Several mechanisms of drug release from pH-sensitive liposomes
have been described [188, 189]. These liposomes can undergo pH induced fusion with
endosomal membrane and release encapsulated contents in cytosol. They can undergo
destabilization in the endosome and cause destabilization of the endosomal membrane
resulting in release of the drug into the cytosol. They can also destabilize completely in
the endosome, and the drug diffuse out of the endosomal membrane to reach cytosol, and
other organelles.
The first class pH-sensitive liposomes are composed of polymorphic phospholipids
with acidic stabilizers to maintain integrity at neutral pH. These liposomes are of less
practical importance due to rapid clearance from the circulation. Kim et al used
cholesterylhemisuccinate (CHEMS) as a pH-sensitive lipid in the development of
gemcitabine-loaded epidermal growth factor receptor (EGFR) targeted liposomes [190].
In vivo evaluation in A549 alveolar carcinoma bearing mice showed that the rate of tumor
inhibition improved with the pH-sensitive targeted liposomes compared to other
treatments. An increased apoptotic index revealed that the tumors treated with pHsensitive targeted liposomes resulted in an increased apoptosis of tumor cells, and
consequently, increased tumor growth inhibition.
The second class of liposomes contains bonds cleavable at low pH to expose the
destabilizing components of the liposomes resulting in release of encapsulated drug.
Ishida et al developed doxorubicin dioleylphosphatidylethanolamine (DOPE) liposomes
containing cleavable lipid derivative of PEG in which PEG was linked to
distearoylphosphatidylethanolamine (DSPE) via disulfide linkage [191]. Exposure of
these liposomes to pH 5.5 resulted in release of encapsulated drug due to cleavage of the
PEG chains and concomitant destabilization of the DOPE liposomes. These pH-sensitive
liposomes, targeted to the CD19 epitope on B-lymphoma cells, showed enhanced
delivery of doxorubicin into the nuclei of the target cells and increased cytotoxicity
compared to non-pH-sensitive liposomes. Survival studies in mouse B-cell lymphoma
model showed that the pH-sensitive liposomes improved the mean survival time of the
animals compared to other controls.
Another class of pH-sensitive liposomes uses pH-sensitive peptides for
destabilization. The fusogenic peptides undergo changes in confirmation with changes in
pH resulting in liposomes destabilization. They change from random coil at neutral pH to
amphipathic helices at pH 5.0 [192]. Self association of these structures following
conformational changes results in their insertion into lipid bilayer, destabilization of
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liposomes, and release of encapsulated contents. Turk et al used a 29-amino acid peptide
to enhance the cytotoxicity of cytosine arabinoside encapsulated in folate-targeted
liposomes, and demonstrated a 30-fold increase drug potency in cultured KB cells [193].
The recent class of pH-sensitive liposomes uses pH-titratable polymers to destabilize
membranes following change of the polymer conformation at low pH. Upon acidification
of the external medium, these polymers change from coil to globule phase, introduce
curvature in the bilayer plane, induce membrane defects, and trigger release of entrapped
cargo. The use N-isopropylacrylamide (NIPAM) as a pH-sensitive polymer was
evaluated using cytosine arabinoside-loaded liposomes coupled with anti CD33
monoclonal antibody to target leukemic cells [194]. Flow cytometry and confocal
microscopy analyses showed that the pH-sensitive liposomes were efficiently internalized
by various CD33+ leukemic cell lines. Highest cytotoxicity was observed with HL-60
cells treated with pH-sensitive targeted liposomes compared to other treatments.
1.2.6.3.

Thermosensitive Liposomes

Accumulation of liposomes in the tumor area does not guarantee that the drug is
available inside the to the tumor cell to elicit therapeutic effect [195]. Use of mild
hyperthermia, which involves heating of the tumor to temperatures up to 43°C, along
with thermosensitive liposomes can improve the drug delivery and therapeutic outcome.
Hyperthermia works in two ways. It increases vascular permeability, improves the
accumulation of liposomes in the tumor, and also sensitizes the cells for chemotherapy.
Secondly, heat triggers can be used to release drugs from thermosensitive liposomes in
close proximity to the cancer cells, and thereby, improve the uptake of drug by the cells.
Yatvin et al first demonstrated that liposomes can be designed to release entrapped drug
preferentially at temperatures attainable by mild local hyperthermia [196]. They showed
that liposomes containing phospholipids that undergoes gel-liquid crystalline phase
transition temperatures around 42°C can release encapsulated neomycin in the presence
of serum with a release ratio of 100:1 at 44°C and 37°C. Gaber and coworkers used in
vivo fluorescence video microscopy to demonstrate the extravasation of liposomes, and
the release of doxorubicin from thermosensitive liposomes in rat skin flap window
chamber containing vascularized breast cancer [197]. The calculated intensity of free
doxorubicin in the interstitial space was negligible at 34°C, and increased by with heat to
38-fold at 42°C, and 76-fold at 45°C. Conventional thermosensitive liposomes required
heating to temperatures of 43-45°C. These temperatures are higher than clinically
relevant and attainable temperatures which are in the range of 39-42°C [198]. Needham
et al included a lysolipid to further improve the permeability at phase transition
temperatures of the phospholipids [199]. The lysolipid 1-palmitoyl-2-hydroxy-snglycero-3-phosphocholine (MPPC) is kinetically trapped in the solid phase. At Tm, it
melts and leaves the bilayer and enhances the permeability of the liposomes. These
thermosensitive liposomes containing doxorubicin with mild hyperthermia showed
highest tumor concentration of doxorubicin, and significant tumor regression in mouse
xenografts of human squamous cell carcinoma compared to conventional thermosensitive
liposomes, non thermosensitive liposomes and free drug [200]. These liposomes are
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under clinical development under brand name TheromDox® (Celsion Corporation, New
York, NY) for liver cancer and breast cancer.
1.2.6.4.

Target-Sensitive Liposomes

Target-sensitive immunoliposomes have the ability to bind to the target specifically
and destabilize upon target cell binding and release the entrapped drug. Ho et al
developed target-sensitive immunoliposomes to specifically target herpes simplex virus
(HSV) using phosphatidylethanolamine (PE) liposomes [201, 202]. PE cannot form
stable liposomes by itself. Acylated monoclonal anti-HSV glycoprotein D stabilizes the
bilayer phase of PE to form stable liposomes. The authors demonstrated that specific
binding of these liposomes to HSV antigen containing glycoprotein D results in
destabilization of the liposomes followed by release of encapsulated contents.
Multivalent binding of these target specific liposomes were 10-fold more sensitive than
the standard double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) for
the determination of HSV. In another study, they demonstrated the potential use of targetsensitive immunoliposomes for the delivery of cytotoxic nucleoside analogs into the
virus-infected cells to inhibit virus replication using cytosine β-D-arabinoside, and
acyclovir-loaded liposomes [203]. These liposomes have antibodies conjugated to
N‐glutaryl‐phosphatidylethanolamine (NGPE) [204]. NGPE is equally distributed in the
bilayer that stabilizes hexagonal phase forming lipids. Binding of these liposomes to the
target cells result in capping of NGPE conjugated antibody, unequal distribution within
the bilayer, and rapid destabilization. Hexagonal phase is formed releasing entrapped
contents. Alternatively, liposomes with detachable polymer coating can be prepared
[118]. These liposomes allow the flexibility of improving circulation time, and attaching
targeting ligands to the distal end of PEG on the surface of the liposomes.
1.2.6.5.

Echogenic Liposomes

Liposomes with air or other gases entrapped in the bilayer make them ultrasound
active. These liposomes can be visualized at the target site, and can be disintegrated to
release the encapsulated contents and by altering ultrasound energy. Alkan-Onyuksel et
al developed inherently echogenic liposomes by lipid film hydration-sonication-freeze
drying method [205]. The liposomes when lyophilized in the presence of mannitol
formed echogenic liposomes. Mannitol has been shown to play a crucial role in
improving echogenicity of liposomes. It crystallizes on freezing and subsequently causes
defects in the liposomal bilayers [206]. These defects in bilayers remain in the cake and
resealing takes place at the time of reconstitution entrapping air present in the
atmosphere. Due to the presence of air, the liposomes have the potential for stress on
activation by ultrasound and eventually release the contents at the target site. This
phenomenon was explained by incorporating a fluorescent dye, calcein, into air-filled
liposomes [35]. In vitro release studies showed an increase in the release of calcein with
increasing applications of ultrasound. The release of air measured by a custom designed
method was in agreement with the release of calcein. Kopechek et al compared the
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release of hydrophilic and lipophilic agents using color Doppler ultrasound in an
exposure flow model [207]. Color Doppler effectively released hydrophilic calcein but
not lipophilic papaverine. The authors explained this phenomenon by the fact that
hydrophilic agents are entrapped in the aqueous core of the liposomes, the disruption of
which by ultrasound results in the release of encapsulated contents into extraliposomal
aqueous phase. On the other hand, lipophilic agents are strongly associated with the
phospholipids in the bilayer. When the liposomes disintegrate, these agents may remain
associated with phospholipids, may get incorporated in the micelles, but are not released
into external aqueous phase.
The disintegration of microbubbles under ultrasound can also improve vascular
permeability as demonstrated by extravasation of fluorescein isothiocyante (FITC)
labeled dextran in chick embryo model [36]. Electron microscopy revealed micron-sized
focal endothelial gaps, disseminated belbs, vacuoles and filopodia extending across tens
of microns. Echogenic liposomes retain this property of microbubbles in addition to their
ability to incorporate hydrophilic and lipophilic drugs, which makes them potential
carriers for targeted drug delivery to solid tumors. These echogenic liposomes developed
for imaging applications are ~800 nm in diameter, and may be cleared rapidly by the
RES. So, careful consideration of size and surface modification is necessary in
developing echogenic liposomes for targeted drug delivery to solid tumors. Although this
approach will be applicable only to tissues accessible by ultrasound, the long-circulating
and targeting capability of these liposomes should take care of the tumors which are not
accessible to ultrasound or those metastasized to other organs or tissues.
1.2.7.

Lyophilization to Improve the Stability of Liposomes

Phospholipids from the liposomes can undergo hydrolysis and/or oxidation and result
in physical degradation when stored as aqueous dispersions. As a result, the encapsulated
drug tends to leak from the vesicles. Apart from leakage, the liposomes can aggregate or
fuse together resulting in an increase in particle size distribution. In a stability stand
point, loss of encapsulated drug or increase in vesicle size is unacceptable. Freeze drying
or lyophilization can prevent hydrolysis of phospholipids and physical degradation during
storage of the liposomes [34]. However, lyophilization process itself can cause loss of
encapsulated drug and fusion of the vesicles. Interaction of water with hydrophilic
phosphate head groups of phospholipids plays a key role in the formation of liposomes
and hence, removal of water presents more challenges. The ability of several
carbohydrates to protect liposomes during lyophilization is described by two hypotheses.
First is ‘water replacement’ hypothesis in which sugar molecules interact with
phospholipids and replace water molecules in the microenvironment during dehydration
[208-210]. In such case sugars can maintain the hydrated environment in a dried state.
The vesicles can also be stabilized in the glassy state of good glass formers such as
trehalose and sucrose. These sugars can encase the membranes in their amorphous matrix
and thereby, impart stability as described by ‘vitrification’ hypothesis [211-213].
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Organisms such as brine shrimp cysts and some species of nematodes survive
dehydration which is related to their ability to produce nonreducing disaccharide
trehalose [214, 215]. These anhydrobiotic organisms survive for several years in dry state
and return to normal metabolic activities on rehydration. Using this analogy, the ability of
trehalose and other sugars to maintain the structure, and integrity of liposomes was
evaluated by Madden and coworkers [33]. The results showed that trehalose when used at
concentrations of 125mM or higher protected the liposomes from structural changes of
dehydration. The entrapped tracers 22Na+, and [3H]inulin were retained in the vesicles in
presence of trehalose. The protection effect was greater when trehalose was present on
both sides of the membrane as compared to when it was present only on the outer part of
the membrane. To further evaluate the ability of trehalose to prevent leakage of drugs,
adriamycin encapsulated liposomes were dehydrated in presence of 250 mM of trehalose.
More than 90% of the drug was retained following drying and rehydration. The
protection effect of trehalose was attributed to its ability to replace water molecules
normally hydrogen-bonded to the polar head groups of lipids.
Crowe et al evaluated the interaction of various carbohydrates on phospholipid
monomolecular layers formed between air-water interface [216]. Trehalose and sucrose
interacted with dipalmitoylphosphatidylcholine (DPPC) monolayer producing an
increased area per molecule, and increased membrane fluidity than normally observed
with water. This effect showed a strong correlation with the ability of trehalose and
sucrose to stabilize membrane structures. They provided a more detailed explanation for
the protection by trehalose using sodium isocitrate-loaded liposomes [217]. Freeze
fracture study of fresh, dry, and rehydrated liposomes revealed that the liposomes freeze
dried in the presence of trehalose were of the same size before and after drying and after
rehydration. But the liposomes freeze dried without trehalose fused to form multilamellar
liposomes or unilamellar liposomes of size about four-fold greater than fresh liposomes.
The study on effect of trehalose on gel to liquid crystalline transition temperature using
differential scanning calorimetry (DSC) showed that trehalose reduced the transition
temperature such that the dried phospholipid remain in liquid crystalline phase at room
temperature. The rehydrated form of liposomes also contains lipids at liquid crystalline
phase, and hence there is no transition during rehydration. In contrast, the liposomes
dried without trehalose remained at gel phase in room temperature. On rehydration, the
lipids in these liposomes have undergone a transition to liquid crystalline phase. The
transition of gel phase to liquid crystalline phase during rehydration was postulated as a
mechanism for leakage of liposomal encapsulated contents. Results obtained with
infrared spectroscopy showed that trehalose and DPPC interact by hydrogen bonding
between the -OH groups of trehalose and polar head groups of DPPC [208]. It was shown
that hydrogen bonding alters the spacing of the polar head groups and thereby decreases
van der Waals interactions in the hydrocarbon chains of the DPPC.
Residual water content was measured to compare the effect of different carbohydrates
on their ability to interact with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) [218]. As the trehalose content was increased there was no significant change in
residual water content but it increased sharply when critical trehalose concentration was
reached, producing two regions. In region I, all of the trehalose interacts with
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phospholipid and is unavailable for binding with water. In region II, free trehalose is
available for binding with water at a similar rate seen with trehalose lyophilized without
lipid. The results suggested that the ability of different sugars to protect the liposomal
bilayers depends on their strength of direct interaction with phospholipids and not on the
residual water content. Maltose and trehalose showed high interaction with the lipid
followed by sucrose and glucose. Inositol showed little or no interaction with the lipid.
Fluorescence resonance energy transfer assay was used to demonstrate the protection
effect of lyoprotectants against fusion of liposomes by incorporating donor and acceptor
fluorophores into two separate liposome populations and then freeze drying with or
without trehalose. The results indicated that the fusion was inhibited by almost 90% when
trehalose is present on both inner and outer part of the membrane [219]. Maltose,
sucrose, glucose, and fructose also prevented fusion of liposomes to a lesser extent than
trehalose, but, this effect was evident only at high concentrations of these carbohydrates.
Comparatively, trehalose prevented fusion at much lower concentrations than other
carbohydrates. In contrast, raffinose, cellobiose, inositol, and glycerol showed minimal
inhibitory effect on fusion. The relative abilities of these carbohydrates to inhibit fusion
correlated with their ability to interact with phospholipids, maintain fluidity, and preserve
biological membranes.
The ability of different saccharides to act as cryoprotectants for small unilamellar
vesicles was evaluated with high resolution 1H-NMR (nuclear magnetic resonance) ,
Electron spin resonance (ESR) spin labeling and DSC [220, 221]. The study with sucrose,
trehalose, and glucose showed that the stabilization effect is not sugar specific but is a
general property of saccharides. The ability of these saccharides to replace water
molecules of hydration by forming hydrogen bond with the polar phospholipid group, at
same binding site as water, was suggested as the mechanism for cryoprotection. The
fraction of liposomes unaffected during dehydration was dependant on the sugar to lipid
molar ratio.
Molecular dynamics simulations was used to characterize interaction of trehalose,
maltose, and glucose with DPPC bilayer at atomic resolution [222]. These sugars
interacted directly with phospholipid head group by hydrogen bonding. At higher
temperature, these sugars prevented thermal disruption, and the protective effect
correlated with the number of sugar-phospholipid head group hydrogen bonds. The
ability of disaccharides to provide better protection compared to monosaccharides was
attributed to their ability to bridge three or more lipid molecules. Trehalose preserves the
integrity of biological membranes under thermal stress. But, trehalose alone does not
preserve the integrity of phospholipid bilayers under mechanical stress in the form of
lateral stretching [223].
Fourier transform infra red (FTIR) spectrometric studies to determine hydrogen
bonding of different phosphatidylcholines with cholesterol, and galactose revealed a
downfield shift for P=O asymmetric stretch when galactose was present alone or in
combination with cholesterol [224]. These results were consistent with molecular
dynamics simulations with trehalose [225], suggesting that there is a hydrogen bonding
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interaction between P=O of the phospholipid and -OH group of the carbohydrates during
lyophilization [218].
A study with increasing amounts of internal trehalose on retention of
carboxyfluorescein-loaded liposomes showed that only a small amount of trehalose is
required inside. Adding more sugar inside had no apparent effect on stability [226]. The
authors also described that retention of the marker in the liposomes depends on the mass
ratio of sugar and lipid and not the concentration of sugar in the bulk phase.
In contrast to previous reports on internal/external ratio of carbohydrates in the
liposomes for lyophilization, Ohtake et al reported that a combination of high inner/outer
trehalose concentrations showed a decrease in Tm of DPPC or DPPC-cholesterol
containing liposomes in the hydrated state [210]. The decrease in Tm was further
amplified in the dehydrated state. The extent of Tm decrease is diminished with an
increasing exterior concentration of trehalose.
During freezing process, water crystallizes to form ice crystals. In this process, the
vesicles and remaining solute are highly concentrated. Inclusion of lyoprotectant can
form an amorphous matrix around the vesicles and protect the vesicles from fusion and
prevent rupture caused by the crystallization of ice. Koster et al showed that vitrification
of sugars occurs in the intermembrane region, and the resulting glassy state mechanically
hinders conformational changes of lipid bilayers [212, 227]. These changes further result
in alteration of phase behavior of the membranes. In the absence of sugars, Tm of the
lipids increased during lyophilization. Inclusion of sugars diminished this increase of Tm.
Thermal analysis by DSC showed that sugars vitrifying around liquid crystalline phase of
lipids lowered Tm below the transition temperature of the fully hydrated lipid, To. On the
other hand, sugars vitrifying around gel phase of lipids increased Tm during the first
heating scan and, then lowered it below To in subsequent heating scans of the sample.
However, vitrification alone is not sufficient to depress the Tm of lipids in dry state, but
both vitrification, and direct interaction between phospholipid head group and
carbohydrates is required [209].
The effect of freezing rate on the integrity of liposomes was evaluated using
carboxyfluorescein-loaded liposomes in presence of sucrose, trehalose, and glucose as
lyoprotectants [228]. The results showed that quick freezing in liquid nitrogen induced a
stress vector on DPPC containing liposomes. The stress was realized only after drying
and rehydration. This stress was dependant on composition of the liposomes i.e.,
inclusion of cholesterol in the formulation minimized the leakage. The leakage was
further minimized by slower cooling rate of 0.5°C during freezing. In contrast, a change
in freezing rate did not affect retention of carboxyfluorescein in EPC containing
liposomes. The potential of modulated DSC (MDSC) to study the thermal properties of
freeze dried and frozen phospholipid and carbohydrate mixtures has been described
[229]. The MDSC measurements of slowly and quickly frozen liposomes showed that the
glass transition for quick freezing occurred at lower temperatures than slow freezing.
This effect with slow freezing was attributed to progression of freeze concentration to
completion before the freeze concentrate solidifies. This leaves a smaller amount of water
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that remains in sugar resulting in a higher glass transition. Viscoelastic properties can
also be used to determine the effect of freezing rates on storage stability [230]. Longer
shear relaxation times were observed for cationic liposomal formulations prepared by
slow freezing compared to those prepared by quick freezing. The formulation prepared
by slow freezing have a lower matrix mobility which is an indication of better storage
stability.
The lyoprotectants used in the formulation of liposomes should not only protect the
liposomal bilayer against instability to prevent fusion and leakage of the encapsulated
drug but also protect the linkers or molecules attached to the surface of the liposomes
from degradation during lyophilization. Friede et al prepared liposomes with maleimide
functional groups, and lyophilized in presence of sorbitol [231]. These liposomes served
as shelf items for the preparation immunogenic liposomes or peptide conjugates. The
results showed that the liposomes retained their maleimide functional groups on
rehydration of lyophilized liposomes. The liposomes previously conjugated to a peptide
also retained its immunogenic activity on lyophilization followed by rehydration.
Multivesicular liposomes containing cytarabine was prepared by water-oil-water
double emulsification method and the stability was evaluated for aqueous dispersions
[232]. Almost no drug leaked from the liposomes when the concentration of trehalose on
the outer part of the membrane was isotonic. Leakage was observed at higher
concentrations of trehalose and when the liposomes were suspended in deionized water.
The protection effect was explained on the basis of osmotic gradient. When the liposomes
are suspended in hypertonic solution, the vesicles are subjected to shrinkage whereas
hypotonic conditions as with deionized water results in expansion and rupture of the
vesicles. Both these conditions can result in leakage of the drug. So the outer
concentration of trehalose was kept constant at 9%, and the inner trehalose concentration
was varied from 0 to 18% during lyophilization to study the effect of inner trehalose
concentration of liposomes containing different phospholipids on leakage. Multivesicular
liposomes made of EPC showed higher retention of cytarabine than DPPC liposomes
which showed greater retention than DOPC liposomes after lyophilization. The retention
increased with increasing inner trehalose concentrations up to 9% and then leveled off,
which showed that only a small amount of trehalose is required in the inner part of the
membrane and further addition of higher amounts of sugar does not have additional
advantages.
1.3. HYPOTHESIS AND SPECIFIC AIMS
Breast cancer is the most common type of cancer and second leading cause of death
from cancer in western women. About 20-30% of women diagnosed with breast cancer
develop metastatic breast cancer. The most successful way of treating metastatic breast
cancer is systemic therapy in the form of chemotherapy or immunotherapy. Paclitaxel is
one of the most effective chemotherapeutic agents used in the treatment of metastatic
breast cancers. It is an antimicrotubule agent that promotes the assembly of microtubules
from tubulin dimers and stabilizes microtubules by preventing depolymerization.
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Systemic administration of paclitaxel is associated with serious toxic effects including
myelosuppression and peripheral neuropathy, in addition to hypersensitivity reactions due
to the formulation components. So, development of formulation to specifically deliver
paclitaxel to the tumor is necessary.
Entrapment of paclitaxel in the bilayer of liposomes can alter pharmacokinetics and
biodistribution of the drug, and thereby, minimize systemic toxicity and improve
therapeutic efficacy. The liposomal composition needs to be optimized to maximize the
loading of paclitaxel. Even though high loading can be obtained, retention of the loaded
drug in the bilayer of liposomes is important to maintain storage stability. The optimal
loading that can be retained in the liposomes during storage needs to be determined and
factors affecting the same needs to be optimized.
Conventional liposomes are cleared rapidly by the RES. The in vivo circulation time
can be improved by circumventing RES uptake by reducing the size of the liposomes
and/or by attaching hydrophilic polymers such as PEG onto the surface of the liposomes.
Liposomes of size 100-300 nm should also improve localization of paclitaxel in the
tumor by passive targeting via EPR effect due to leaky nature of the tumor vasculature,
and impaired lymphatic drainage.
Active targeting via receptor mediated endocytosis can be accomplished by
modifying the surface of the liposomes with targeting ligands specific to the receptors
expressed by the endothelial cells of tumor vasculature or tumor cells. Actively
proliferating endothelial cells of tumor vasculature over expresses αvβ3 integrin receptors.
Peptides with RGD motif in a cyclic framework (cRGD) have been shown to effectively
bind to αvβ3 integrin receptors. Surface modification of paclitaxel-loaded liposomes with
cRGD peptide attached to the distal end of PEG chains should improve the localization of
paclitaxel in the tumor. TFR1 receptors are over expressed by proliferating tumor cells.
Transferrin attached to the surface of the liposomes by means of PEG spacer and a linker
should improve the uptake of paclitaxel by the breast cancer cells through receptor
mediated endocytosis.
Long term storage stability of liposomes is a major concern due to leakage of the
encapsulated drug and fusion/aggregation on storage. Lyophilization of the liposomes can
overcome these drawbacks and improve long-term stability. The conditions used during
lyophilization itself can be damaging to the bilayer of liposomes which requires careful
selection or optimization of the formulation and process.
In addition to the localization and uptake of these liposomes by natural cytosolic
mechanisms, external triggers can be used to improve the permeability at the vasculature
to improve localization. Design of paclitaxel-loaded targeted liposomes with air/gas
incorporated in the bilayer will make these liposomes ultrasound active. Ultrasound can
be used as an external trigger to disintegrate these liposomes to improve vascular
permeability, and the uptake.
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The objective of this dissertation work is to develop targeted liposomal formulations
to improve localization of paclitaxel in tumor sites, and therefore, minimize toxicity, and
improve the efficacy of the treatment of breast cancers. To accomplish this objective the
following hypotheses are envisaged.
I. Paclitaxel-loaded gas-filled liposomes can be developed so that they can be
visualized with ultrasound, and disintegrated using high intensity ultrasound
pulses
II. Development of stable paclitaxel-loaded liposomes conjugated to either
transferrin or cRGD peptide should improve the efficacy of the treatment of
breast cancer
To test these hypotheses, my specific aims were to:
1) Develop prototype formulation of cRGD conjugated gas-filled liposomes.
In this specific aim feasibility of developing ultrasound active, RGD
conjugated targeted liposomes was evaluated. Formulation and process
parameters critical to the target profile were identified and optimized to
achieve an acceptable prototype formulation that can be utilized as a platform
for drug-loaded liposomes for targeted drug delivery.
2) Optimize paclitaxel loading in the liposomal formulation. Formulation and
process parameters that influence paclitaxel loading in the liposomes were
identified and optimized. Stability of the liposomal dispersion was evaluated
for up to 10 days to determine the optimum composition of liposomes without
the risk of leakage. Storage stability of the optimized liposomal dispersion
was evaluated for three months.
3) Develop cRGD conjugated paclitaxel-loaded gas-filled liposomes. The
formulation and process parameters were optimized to obtain paclitaxelloaded cRGD conjugated gas-filled long-circulating liposomes (Pac-RGDGFTLCL). The echogenicity, and the ability to disintegrate these liposomes
was evaluated using in vitro models with ultrasound. Stability of the
formulation was evaluated for three months.
4) Evaluate biodistribution and efficacy of the liposomes targeted to tumor
vasculature, and to compare the efficacy of liposomes targeted to tumor
vasculature and tumor cells in a mouse breast cancer model. Mouse
xenografts bearing human MDA-MB-231 breast cancer were used for the
evaluation of biodistribution and efficacy of the formulations. The localization
cRGD conjugated liposomes were compared with long-circulating liposomes,
and solution formulation using non invasive near infrared fluorescence
(NIRF) imaging. The localization of paclitaxel-loaded liposomal formulations,
and solution formulation was evaluated by measuring tumor tissue
concentrations after 24 hours of administration. The efficacy of paclitaxelloaded long-circulating liposomes (Pac-LCL), and paclitaxel-loaded cRGD
conjugated targeted long-circulating liposomes (Pac-RGD-TLCL) were
compared to normal saline control, and paclitaxel solution formulation. To
compare the effect of targeting tumor cells, paclitaxel-loaded transferrin
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conjugated targeted liposomes (Pac-Tf-TLCL) were administered to another
group of animals. The effect of these formulations on tumor volume was
monitored as a measure of efficacy.
5) Lyophilize the paclitaxel-loaded liposomes to improve long-term storage
stability. The formulation was optimized to minimize the leakage of
paclitaxel, and fusion/aggregation of the liposomes. Stability of the
lyophilized formulation was evaluated for Pac-LCL, Pac-RGD-TLCL, and
Pac-Tf-TLCL.

36

CHAPTER 2. DEVELOPMENT OF PROTOTYPE FORMULATION OF GASFILLED TARGETED LIPOSOMES
Ultrasound is the transmission of pressure waves through a medium at frequencies
above 20,000 Hz. Microbubbles are ultrasound contrast agents used in radiology for
imaging organs and tissues accessible to ultrasound. Ultrasound travels more slowly in
gas compared to aqueous medium. The difference in speed causes an acoustic impedance
mismatch between tissue or blood surrounding the microbubbles [37]. As a result,
microbubbles act as efficient reflectors of ultrasound energy, and used as contrast agents
for imaging. The microbubbles can undergo cavitation, which can be explored for drug
delivery applications. Cavitation is the formation and/or activity of microbubbles in a
medium exposed to ultrasound [233]. When a medium containing microbubbles is
exposed to ultrasound, the microbubbles expand at low pressures and contract at high
pressures. If the resulting oscillation is stable over time with continuous expansion and
contraction cycles, it is called ‘stable’ or ‘non inertial’ cavitation [38]. This oscillation
causes micro streaming around the bubble with velocities and shear rates proportional to
the amplitudes of oscillation. If the intensity of ultrasound is increased, the amplitude of
oscillation increases such that the inward moving wall of the bubble obtain sufficient
inertia that it cannot reverse the direction when the ultrasound pressure is reversed. The
microbubble is compressed continuously creating high pressures within the bubble
resulting in ‘collapse’ or ‘inertial’ cavitation. The collapse cavitation is detrimental to
cells and vesicles because of high shear stress in the region of collapse, shock waves
produced by the collapse, and free radicals generated due to high temperature. If the
collapse occurs near a solid surface, an asymmetric collapse takes place producing liquid
jets at sonic speeds which can pierce blood vessel walls. Stieger et al demonstrated that
low frequency contrast enhanced ultrasound can increase vascular permeability resulting
in convective extravasation of fluorescent labeled dextran in a chick embryo model [36].
Liposomes are biocompatible carriers with ability to incorporate both lipophilic and
hydrophilic drugs [23]. Incorporation of gas in the bilayer of liposomes makes them
acoustically active [205]. These echogenic liposomes have the potential for stress on
activation by ultrasound, and eventually release the contents at the target site [35]. This
phenomenon exhibited by echogenic liposomes can be explored for drug delivery
applications. But, the size of these echogenic liposomes used for imaging is ~ 800 nm,
and would be cleared rapidly by the RES. The freeze drying method used for the
preparation of echogenic liposomes causes an increase in the size of liposomes.
Crystallization of mannitol present in the formulation causes rupture in the bilayer during
the freeze drying process [35, 234]. In a dry cake, air passes through these gaps and fills
up the bilayer. The ruptured bilayer reseals during reconstitution, entrapping air inside the
bilayer. The extent of damage to the bilayer caused by crystallization of mannitol
determines the amount of air/gas entrapped in the bilayer, which is reflected as final size
of the liposomes. Since the use of liposomes of size greater than 150-200 nm is
unsuitable for drug delivery due to rapid clearance by the RES [28], smaller sized
liposomes are desired. By using suitable lyoprotectants and/or surfactants at adequate
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proportions, we can control the crystallization of mannitol and minimize the increase in
size of liposomes.
An ideal carrier for therapeutic targeting to solid tumors must have a longer
circulation time than those used for imaging and should possess targeting capability. In
vivo circulation time can be increased by reducing the size of liposomes and/or modifying
the surface with PEG derivatives [28]. Targeting capability can be achieved by attaching
specific ligands onto the surface of the liposomes. The αvβ3 integrin receptors are highly
expressed in actively proliferating endothelial cells of tumor vasculature and tumor cells
[163, 235]. Peptides with Arg-Gly-Asp (RGD) motif in a cyclic framework have been
shown to bind to these receptors and are effective in targeting solid tumors [172]. By
attaching RGD peptide to the surface through PEG spacers, these liposomes can be
targeted to solid tumors. The objective of this work is to identify and optimize the
formulation and process parameters, and to develop a prototype parenteral formulation
that serves as a platform for drug-loaded ultrasound active liposomes for targeted
delivery to solid tumors.
2.1. MATERIALS AND METHODS
2.1.1.

Materials

The phospholipids used in this work were all of research grade. Hydrogenated soy
phosphatidylcholine (HSPC) and 1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N(poly(ethylene glycol)2000) (DSPE-PEG2000) were obtained from Northern Lipids
(Burnbay, BC, Canada). 1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-(maleimide
poly(ethylene glycol)2000) (maleimide DSPE-PEG2000) was obtained from Avanti Polar
Lipids (Alabaster, AL). Cholesterol and sucrose were purchased from Sigma (St. Louis,
MO). Mannitol was obtained from Mallinckrodt Chemicals (Phillipsburg, NJ). Cyclo
(Arg-Gly-Asp-D-Phe-Cys) peptide (cRGD) was obtained from Peptides International
(Louisville, KY). Poloxamer 188 was obtained from BASF (Mount Olive, NJ). High
performance liquid chromatography (HPLC) grade water, acetonitrile, and methanol were
obtained from Fisher Scientific (Fair Lawn, NJ). HPLC grade chloroform was purchased
from Acros Organics (Morris Plains, NJ). N-2-hydroxyethylpiperazine-N’-2ethanesulfonic acid (HEPES) buffer, 1M was obtained from Mediatech (Manassas, VA).
All other chemicals and reagents were of analytical grade and used without further
purification or characterization.
2.1.2.

Preparation of Long-Circulating Liposomes (LCL)

Long-circulating liposomes were prepared by the lipid film hydration-extrusion
method using HSPC, DSPE-PEG2000, and cholesterol. The lipid film was prepared by
dissolving phospholipids and cholesterol in 9:1 chloroform-methanol. The solution thus
obtained was evaporated in a round bottom flask using rotary evaporator under reduced
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pressure at 45°C for 4-6 hours. The dry film was hydrated with 50 mM HEPES buffer pH
6.5 at 65°C for 45-60 minutes. The multilamellar vesicles (MLVs) thus obtained were
sized by sonication using Misonix Sonicator 3000 probe sonicator (Misonix, Inc.,
Farmingdale, NY) in the initial experiments for the evaluation of composition of
liposomes. For the rest of the experiments, the liposomes were sized by extrusion through
stacked polycarbonate membrane filters of varying pore diameters under high pressure to
obtain small unilamellar vesicles (SUVs). The SUVs were characterized for particle size
distribution, zeta potential, and morphology. The pore diameter of filters, pressure, and
number cycles used in the extrusion process were optimized to obtain an average particle
size of 110 ± 20 nm.
2.1.3.
Verification of Conjugation Reaction between cRGD and Maleimide
DSPE-PEG2000
The conjugation of RGD peptide was verified by mass spectrometry by the method
reported by Desu [236] with slight modifications using Micromass Q-tof-2TM mass
spectrometer (Micromass, Manchester, UK). The cRGD peptide and maleimide DSPEPEG2000 were dissolved separately in 50 mM HEPES buffer pH 6.5, and mixed in
equimolar ratio. The reaction mixture was incubated at 25°C for 12 hours, and the
unconjugated peptide was removed by dialysis through 2000 molecular weight cut-off
(MWCO) Slide-A-Lyzer dialysis cassette against 50 mM HEPES buffer pH 6.5 at 5 ±
3°C for 6 h. The conjugate was desalted through a Sephadex G-25 macro spin column
(Harvard Apparatus, Holliston, MA) before analysis. For analysis, 20 µL of the conjugate
was diluted with 0.3% formic acid and injected to the electrospray ionizer at a flow rate
of 0.5 µL/min. The capillary and cone voltages were 2.80 KV and 45 V respectively.
2.1.4.
Preparation of cRGD Conjugated Targeted Long-Circulating Liposomes
(RGD-TLCL)
For the preparation of RGD-TLCL, a part of DSPE-PEG2000 was replaced with
maleimide DSPE-PEG2000 and the liposomes were prepared as described in section 2.1.2
to obtain SUVs with reactive maleimide functional group. The maleimide-LCL thus
obtained was conjugated with cRGD peptide by incubation at 25°C for 12 h. The
unconjugated peptide remaining after the reaction was removed from the liposomes by
equilibrium dialysis through 10,000 MWCO Slide-A-Lyzer dialysis cassettes (Thermo
Fisher Scientific, Rockford, IL) against 50 mM HEPES buffer pH 6.5 at 5 ± 3°C
overnight. The conjugation efficiency was determined by quantifying free RGD in the
dialyzate by reversed phase high performance liquid chromatography (RPHPLC).
2.1.5.

Determination of Conjugation Efficiency

The conjugation efficiency was determined by equilibrium dialysis through 10,000
MWCO cellulose membrane using reusable dialyzers (Harvard Apparatus, Holliston,

39

MA). The amount of unreacted RGD in the dialyzate was quantified by RPHPLC as a
measure of the conjugation efficiency. The HPLC system comprised of Waters 600
Controller, Waters 717 Plus Autosampler, and Waters 2996 Photodiode Array Detector
(Waters Corporation, Milford, MA) was used. The RPHPLC analysis was done using a
Nova-Pak C18 column (3.9 x 150 mm, 4 µm) (Waters Corporation, Milford, MA). The
gradient elution was performed using 0.05% v/v trifluoroacetic acid (TFA) in water (A)
and 0.05% v/v TFA in acetonitrile (B) with a linear gradient of 10 to 60% B in 50 min at
a flow rate of 1 mL/min The retention time for RGD was between 13 and 14 min at a
detection wavelength of 220 nm.
2.1.6.

Determination of Particle Size and Zeta Potential

The average diameter (Z-avg) of the liposomes was determined using dynamic light
scattering using Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped
with 4.5 mW diode laser as a source of light operating at 670 nm. Particle scattered
photons were detected at an angle of 173°. The samples were suitably diluted with HPLC
grade water for the determination of Z-avg. Three independent measurements were
performed for each sample. Zeta potential was determined from electrophoretic mobility
using samples suitably diluted with HPLC grade water.
2.1.7.
Preparation of Gas-Filled LCL (GFLCL) and Gas-Filled RGD-TLCL
(RGD-GFTLCL)
The LCL or RGD-TLCL was mixed with equal volume of mannitol solution (017.5% w/v) containing sucrose (0-10% w/v) as a lyoprotectant, and poloxamer 188 (00.5% w/v) as a surfactant. For the initial experiments to evaluate the composition of
liposomes, the liposome-mannitol mixture was frozen at -80°C, and then freeze dried
using Labconco FreeZone Plus 6 bench top freeze drier (Labconco Corporation, Kansas
City, MO). For rest of the experiments, the lyophilization cycle was designed based on
the glass transition temperature of maximally freeze-concentrated amorphous phase (Tg′),
determined by differential scanning calorimetry (DSC). Lyophilization was carried out
using a lab scale Virtis Genesis 25ES lyophilizer (The Virtis Company, Gardiner, NY).
The primary drying temperature was selected based on Tg′ and the mixture was
lyophilized in 5cc glass lyo vials. The moisture content of the dry cake was monitored to
ensure end point of secondary drying. On completion of the drying cycle, the vials were
sealed under a partial vacuum. Perfluoropropane was filled in the headspace above the
vials at atmospheric pressure to obtain GFLCL and RGD-GFTLCL. The procedure used
in the preparation of RGD-GFTLCL is summarized in Figure 2-1. The physical
appearance of the dry cake was recorded as quality control parameter. The vesicle size,
zeta potential, and echogenicity were monitored in reconstituted samples. The vials were
stored at 5 ± 3°C until further use.
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Figure 2-1.

Cartoon representing the method of preparation of RGD-GFTLCL

Notes. The process of preparation of RGD-GFLCL is as follows: A. The liposomes
are prepared by lipid film hydration extrusion method and then conjugated with cRGD
peptide. B. The SUVs are mixed with mannitol (♦) solution. C. Lyophilization in
presence of mannitol results in rupture of the bilayer due to crystallization of mannitol. D.
The dried cake is equilibrated with perfluoropropane (●) filled in the head space of the
vials. E. Reconstitution with water results in resealing of the bilayer with
perfluoropropane entrapped in the bilayer. The diagram is not drawn to scale.
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2.1.8.

Thermal Analysis by DSC

The effect of lyoprotectant and surfactant on crystallization of mannitol was
monitored by DSC using a Q2000 differential scanning calorimeter equipped with
refrigerated cooling system (TA Instruments, New Castle, DE). About 10-20 µL of the
liposome mixture prior to lyophilization was placed in T-Zero aluminum pans and
hermetically sealed. An empty pan prepared in a similar manner was used as reference.
The samples were equilibrated at 25°C and then cooled at 5°C/min to -70°C. After
equilibration, the samples were heated at the rate of 10°C/min to 25°C. The effect of
sucrose and poloxamer 188 on crystallization peak of mannitol was evaluated. The Tg′
was also determined from these thermograms to design the lyophilization cycle.
2.1.9.

Determination of Moisture Content

The moisture content of the lyophilized cake was determined using an Orion AF8
Volumetric Karl Fischer Titrator (Orion Research Inc., Boston, MA). The titrator was
calibrated on each day of analysis with a known quantity of water. About 75 mg of the
dried sample was weighed accurately and added to the titration vessel. The titration was
started after allowing one minute for extraction.
2.1.10.

Determination of Echogenicity

Acoustic activity of GFLCL and RGD-GFTLCL was characterized using an in vitro
method utilizing Phillips ATL HDI-5000 ultrasound system and broadband L12-5
transducer (Philips Healthcare, Andover, MA). A schematic representation of the set up
used in the measurement of echogenicity is provided in Figure 2-2. It consists of a
rectangular plexiglass chamber filled with 15 mL of normal saline (NS). A small
magnetic stir bar was placed in the chamber to enable uniform mixing. The chamber was
then placed on a magnetic stirrer. The transducer was positioned such that it has direct
contact with NS filled in the tank. The images were acquired with a mechanical index
setting of 0.1. The gas-filled liposomes were reconstituted with HPLC grade water. After
acquiring the background image for 5 sec., 200 µL of the reconstituted liposomal product
was injected into the tank with a 1 cc syringe, and the images were acquired for one
minute. All image sequences were analyzed offline using a custom program using
MATLAB 7.0.4 software (The MathWorks, Inc., Natick, MA). The pixel values in the
region of interest (ROI) were compared to the pixel values in the background. The
number of folds increase in mean gray scale value (MGSV) in the ROI over the
background was calculated as the measure of acoustic activity.
2.1.11.

Characterization of Morphology of Liposomes

Morphology of the liposomes was characterized by transmission electron microscopy
(TEM) using a negative staining technique. Sequential two droplet method was used for

42

To ultrasound
instrument

Sample

L12‐5 Transducer

Rectangular
plexiglass chamber
filled with normal
saline

Stir bar

Magnetic stirrer

Figure 2-2. Schematic representation of the in vitro technique used for the
measurement of echogenicity
Notes. The apparatus used for the determination of echogenicity consists of a
rectangular plexiglass chamber filled with normal saline. A magnetic stir bar was placed
in the chamber to enable uniform mixing. The ultrasound transducer was immersed in
normal saline up to not more than 0.5 cm from the top of the plexiglass chamber. The
reconstituted echogenic liposomes were injected in to the tank using a syringe. The
diagram is not drawn to scale.
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staining liposome samples with 2% w/v uranyl acetate on 400-mesh formvar support film
on copper specimen grid (Electron Microscopy Sciences, Hartfield, PA). The TEM
images were acquired using JEOL 2000EX transmission electron microscope (JEOL
USA, Inc., Peabody, MA) equipped with high resolution digital camera.
2.2. RESULTS AND DISCUSSION
2.2.1.

Effect of Liposomal Bilayer Composition

The effect of composition of the bilayer of liposomes on the particle size distribution
(PSD) was evaluated before and after freeze drying. These liposomes were sized by
sonication using probe sonicator, and the liposome-mannitol mixture was freeze dried
using bench top freeze dryer. Figure 2-3 shows the effect of increasing the concentration
of cholesterol on the PSD after freeze drying. An increase in size was observed with all
the bilayer compositions. The trend shows that cholesterol minimizes the increase in size
of liposomes after freeze drying. Cholesterol is known to reduce the fluidity and improve
the rigidity of the liposomes [59]. The higher rigidity in turn minimizes the rupture of the
bilayer caused by the crystallization of mannitol. Since the final size of the liposomes
after freeze drying depends on the amount of gas entrapped in the liposomes which
depends on the extent of rupture to the bilayer caused by mannitol, the increase in rigidity
provides better control on the final size of GFLCL. The composition with HSPC: DSPEPEG2000: Cholesterol in a ratio 45:5:50 was selected for further studies. The sonication
process for sizing resulted in a high batch to batch variability (data not shown) even
though the conditions were optimized and strictly controlled. Hence, an extrusion process
was used for further studies. Similarly, the bench top freeze dryer did not have the
options to control product temperature. So, further studies were carried out using a more
robust lab scale lyophilizer.
2.2.2.

Effect of Lyoprotectant and Surfactant

Mannitol undergoes crystallization from the frozen aqueous solutions during the
warming phase of freeze drying [237-239]. The crystallization of mannitol has been
shown to play a critical role in the preparation of echogenic liposomes [206]. The
crystallization causes rupture in the bilayer of liposomes due to which air/gas is
entrapped in the liposomes. But these liposomes developed for ultrasound contrast
imaging were ~ 800 nm in diameter, and can be cleared rapidly by the RES. For drug
delivery applications, liposomes of size 150-200 nm is desired to escape clearance by the
RES [28]. Since the final size of these echogenic liposomes depends on the amount of gas
entrapped in the liposomes which is determined by the extent of rupture to the bilayer
caused by the crystallization of mannitol, we attempted to control the crystallization of
mannitol to develop echogenic liposomes of size < 200 nm. The crystallization of
mannitol can be controlled by altering the process parameters during freeze drying and by
additives [238, 240, 241]. In our preliminary experiments, we evaluated sucrose and
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Effect of liposome composition on PSD of liposomes after freeze drying

Notes. The liposomes were prepared by lipid film hydration sonication method. The
PSD was determined before and after freeze drying in presence of mannitol. The freeze
dried gas-filled liposome samples were reconstituted with HPLC grade water for the
measurement of PSD. The results indicate mean ± standard deviation of three
independent measurements (□ Before lyophilization; ■ After lyophilization).
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trehalose as lyoprotectants, and poloxamer 188 and Solutol HS15 as surfactants. The
combination of sucrose and poloxamer 188 provided better control on PSD (Data not
shown), and hence they were selected for further evaluation. Figure 2-4 shows DSC
heating profile of frozen liposomes in presence of mannitol and sucrose as a
lyoprotectant. When only mannitol was present, an exothermic transition characteristic of
crystallization of mannitol was observed with an onset temperature of -25.23°C and a
peak temperature of -18.52°C. The crystallization peak was suppressed by sucrose
showing that the crystallization of mannitol can be controlled by the inclusion non
crystallizing solute sucrose in the formulation for lyophilization. In contrast, the
surfactant poloxamer 188 did not show any effect on the crystallization of mannitol. The
lyophilization cycle for the preparation of GFLCL was designed based on Tg′,
determined by DSC. The Tg′ of the formulations containing mannitol and sucrose was
around -42°C and hence the primary drying temperature was set at -45°C. The influence
of sucrose was also evident on the PSD of liposomes after lyophilization. Figure 2-5
shows the effect of mannitol-sucrose ratio on the PSD before and after lyophilization.
The liposomes prepared in presence of mannitol without lyoprotectant showed more than
five-fold increase in size. This increase in size was minimized by the addition of
lyoprotectant sucrose. Increasing concentrations of sucrose in the formulation reduced the
final size of GFLCL. This effect could be attributed the control of crystallization of
mannitol by the inclusion of non crystallizing solute sucrose in the formulation. Control
in crystallization resulted in minimal rupture to the bilayer and thereby minimal
entrapment of gas in the liposomes. The effect of surfactant on the PSD of liposomes
after lyophilization is depicted in Figure 2-6. Although there was no evidence on control
of crystallization of mannitol from DSC, the addition of surfactant, poloxamer 188
showed a decrease in the final size of GFLCL. This effect could be attributed to the
formation of monolayer on the surface of liposomes which in turn minimize the
aggregation due to steric effects.
2.2.3.

Effect of Sucrose Concentration on Echogenicity

The effect of increasing concentrations of sucrose in the formulation on echogenicity
of the GFLCL was evaluated in a custom in vitro model. The data is presented in Figure
2-7. A maximum increase in gray scale intensity was observed in the ROI with GFLCL
formulation that was lyophilized without sucrose. Inclusion of sucrose reduced the
echogenicity of GFLCL. The trend was similar to that observed with the PSD. A decrease
in echogenicity was expected with the addition of sucrose because the smaller liposomes
contain less amount of gas per vesicle compared to larger liposomes. The high
echogenicity in the mannitol containing formulation serves as further proof of the role of
crystallization of mannitol on size and echogenicity. In contrast, the formulation without
mannitol also showed echogenicity similar to the formulation containing both mannitol
and sucrose suggesting that other factors are also involved in determining echogenicity of
liposomes. The mean grayscale intensity in the ROI for all the formulations decreased
with time on continuous exposure to ultrasound. The decrease in intensity could be due to
loss perfluoropropane from vesicles due to diffusion or due to disintegration induced by
ultrasound. The formulation with intermediate mannitol-sucrose ratio of 4:3, and a
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Figure 2-4. DSC thermograms showing the effect of sucrose and poloxamer on
crystallization of mannitol
Notes. The liposomes were mixed with equal volume of mannitol solution with or
without sucrose or poloxamer 188. The samples were hermetically sealed in aluminum
pans, and cooled at the rate of 5°C/min to -70°C. After equilibration at -70°C, the
samples were heated at the rate of 10°C/min to 25°C. The heating profile is shown in the
figure. Heat flow is shown on an arbitrary scale.
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Effect of mannitol-sucrose ratio on PSD of liposomes after lyophilization

Notes. The liposomes were prepared by lipid film hydration extrusion method. The
PSD was determined before and after freeze drying in presence of varying ratios of
mannitol and sucrose in presence of 0.15% w/v poloxamer 188. The freeze dried gasfilled liposome samples were reconstituted with HPLC grade water for the measurement
of PSD. The results indicate mean ± standard deviation of three independent
measurements (■ Before lyophilization; ▲After lyophilization).
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Effect of poloxamer on PSD of liposomes after lyophilization

Notes. The liposomes were prepared by lipid film hydration extrusion method. The
PSD was determined before and after freeze drying in presence of mannitol and sucrose
at varying concentrations of poloxamer 188. The freeze dried gas-filled liposome samples
were reconstituted with HPLC grade water for the measurement of PSD. The results
indicate mean ± standard deviation of three independent measurements (■ Before
lyophilization; ▲After lyophilization).
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Effect of mannitol-sucrose ratio on echogenicity of GFLCL

Notes. The echogenicity was determined in an in vitro model with Philips ATL-HDI
5000 ultrasound system and L12-5 broadband transducer. The freeze dried gas-filled
liposome samples were reconstituted with HPLC grade water for the measurement of
echogenicity. After acquiring background images for 5 sec., 200 µL of the sample was
added using a syringe, and the acquisition was continued for up to one minute. The data
was processed off-line with a custom MATLAB program. Three ROIs were randomly
selected, and the average increase in mean grayscale intensity in the ROI from the
background was calculated. The results represent mean ± standard deviation for three
samples (Mannitol-sucrose ratios were ■ 1:0; ▲ 5:2; ● 4:3; ♦ 3:4; ▼0:1).
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poloxamer concentration of 0.15% w/v was selected as optimum based on size and
echogenicity for further development of RGD conjugated echogenic liposomes.
2.2.4.

Determination of Conjugation Efficiency

One of the most stable and efficient conjugation reactions, the formation of covalent
thioether bond by the reaction between sulfhydryl group and maleimide group [172, 242244] was used for conjugation of cRGD to maleimide DSPE-PEG2000. The formation of
conjugate was verified by reacting cRGD and maleimide DSPE-PEG2000 in 1:1 ratio. The
conjugate was purified, and analyzed by quadrupole time-of-flight (Q-TOF) mass
spectrometry using electrospray ionizer in MS only positive ion mode. The analysis of
mass/charge ratio of the product ions confirmed the formation of conjugate in the
reaction (Figure 2-8). For the preparation of RGD-TLCL, maleimide DSPE-PEG2000 was
incorporated in the liposome bilayer during film formation step to form Maleimide-LCL
with reactive maleimide functional groups. The cRGD peptide was added to preformed
liposomes with maleimide functional group on the distal end of the PEG spacer chains,
and incubated at 25°C for the conjugation reaction. The amount of unreacted peptide
present in the dialyzate after equilibrium dialysis was quantified as a measure of
conjugation efficiency. Figure 2-9 shows HPLC chromatogram of dialyzate obtained
from equilibrium dialysis of the liposomes immediately after conjugation reaction. The
cRGD in free form elutes between 12-14 min as shown in the chromatogram for standard.
The peak for cRGD was not detectable in the dialyzate, indicating that the reaction was
nearly complete.
2.2.5.

Characteristics of GFLCL and RGD-GFTLCL

RGD-GFTLCL was prepared using RGD-TLCL similar to the procedure for the
preparation of GFLCL. The particle size of the RGD-GFTLCL was similar to GFLCL
with an average diameter ~ 150 nm which is favorable for longer circulation time (Figure
2-10). These liposomes can escape RES, and also benefit from passive targeting due to
EPR effect. The zeta potential of both GFLCL and RGD-GFTLCL was -36.27 ± 2.14 and
-32.60 ± 0.46 mV respectively indicating that these liposomes will have good colloidal
stability. The zeta potential measurements before and after lyophilization showed a drop
from -22.8 mV to -36.27 mV for GFLCL, and -26.4 mV to -32.60 mV for RGD-GFTLCL
after lyophilization. This phenomenon could be attributed to ionic drift across the bilayer
during lyophilization. The moisture content of the dried cake was less than 1% w/v. The
dried cake exhibited acceptable physical properties with respect to appearance, cake
integrity, cake height vs volume, and ease of reconstitution. The TEM images showed
that both GFLCL and RGD-GFTLCL were spherical in structure (Figure 2-11). Electron
transparent regions were observed in electron dense vesicles corresponding to areas of
gas localization as suggested in literature [245, 246].The liposomes appeared similar to
lipid shelled microbubbles with planar microdomains [247] separated by defects which
affect mechanical properties and gas permeability [248]. The echogenicity of RGDGFTLCL was also comparable to GFLCL (Data not shown).
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buffer were mixed and incubated for 12 h. The conjugate was purified and analyzed by
mass spectrometry. A segment of product ion mass spectrum is shown.
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Figure 2-9. HPLC chromatogram of the dialyzate obtained from equilibrium dialysis
in comparison to standard solution of cRGD
Notes. The liposomes were dialyzed by equilibrium dialysis through 10,000 MWCO
cellulose membrane. The dialyzate obtained was analyzed by HPLC (top panel). The
lower panel shows the chromatogram obtained for a standard solution of cRGD. The
HPLC conditions were as follows: Mobile phase - Solvent A (0.05% v/v TFA in water)
and Solvent B (0.05% v/v TFA in acetonitrile) with a linear gradient of 10 to 60% B in
50 min; Column- Nov-Pak C18; Detection wavelength - 220 nm.
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Figure 2-10. PSD of GFLCL and RGD-GFTLCL before and after lyophilization
Notes. The PSD was determined before and after lyophilization. The freeze dried gasfilled liposome samples were reconstituted with HPLC grade water for the measurement
of PSD. The results indicate mean ± standard deviation of three independent
measurements (□ Before lyophilization; ■ After lyophilization).
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Figure 2-11. TEM images of GFLCL (A) and RGD-GFTLCL (B)
Notes. The samples were prepared by negative staining with uranyl acetate using
sequential two drop technique on formvar coated copper grids. The results are shown at a
magnification of 250,000x.
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2.3. SUMMARY AND CONCLUSIONS
The formulation and process parameters were identified and optimized in the
preparation of GFLCL. The crystallization of mannitol was controlled by the inclusion of
lyoprotectant sucrose so that echogenic liposomes of size less than 200 nm, suitable for
drug delivery can be prepared. The formulations containing mannitol showed over twofold higher echogenicity compared to formulations containing mannitol and sucrose. An
interesting observation was that the liposomes prepared without mannitol also showed
echogenicity despite negligible increase in the average diameter. The optimum
formulation contained both mannitol and sucrose in a ratio 4:3 to meet the target
requirements for size and echogenicity. Although poloxamer 188 did not show any effect
on crystallization of mannitol, its steric effects improved the formulation with respect to
control in size of the liposomes during lyophilization. The cRGD peptide was
successfully conjugated to the PEG termini on the surface of the liposomes. The RGDGFTLCL was similar to GFLCL in size, charge, and echogenicity demonstrating that the
conjugation procedure did not affect the properties of these echogenic liposomes. These
echogenic liposomes can serve as a potential platform for the delivery of hydrophilic
and/or lipophilic drugs for targeted drug delivery to solid tumors. The ultrasound activity
can be used for visualizing these agents at the target site, and by changing the ultrasound
intensity they can be disintegrated to release the encapsulated drugs. The uptake at the
tumor sites can also be improved by enhanced vascular permeability mediated by
ultrasound disintegration.
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CHAPTER 3. OPTIMIZATION OF PACLITAXEL LOADING AND PHYSICAL
STABILITY IN THE DEVELOPMENT OF LONG-CIRCULATING LIPOSOMES
Paclitaxel is one of the most effective drugs used in chemotherapy of cancer and is a
natural product isolated from bark of the Pacific Yew tree, Taxus brevifolia [8, 9]. It
exhibits cytotoxic activity by promoting the assembly of microtubules from tubulin
dimers and stabilizes microtubules by preventing depolymerization. The stability results
in inhibition of the normal dynamic reorganization of the microtubule network that is
essential for vital interphase and mitotic cellular functions [9]. Paclitaxel is marketed as
Taxol® (Bristol-Myers Squibb Company, Princeton, NJ) for the treatment of ovarian,
breast, non-small cell lung cancers, and AIDS related Kaposi’s sarcoma [249]. Since
paclitaxel is highly insoluble in water, Taxol® was formulated with ethanol and
Cremophor®EL. Although the formulation is diluted before use, the concentration of
Cremophor®EL is high enough to cause serious hypersensitivity reactions on parenteral
administration, which require pretreatment with antihistamines and corticosteroids [15].
In addition, the use of free paclitaxel can affect normal tissues and result in systemic
toxicities such as myelosuppression, and peripheral neuropathy [17]. So, it is imperative
to deliver paclitaxel locally to the tumor sites to minimize systemic toxicity. In addition,
failure to maintain adequate concentration at the tumor microenvironment can result in
regrowth of the tumor cells and development of resistance [5].
Liposomes are biocompatible carriers with ability to incorporate both lipophilic and
hydrophilic drugs [23]. Encapsulating drugs within vesicles has the potential advantage
of higher drug carrying capacity compared to attaching them to single polymer chain
[250]. Preparation of liposomes of paclitaxel can alter the pharmacokinetic and
pharmacodynamic properties of the free drug and result in reduced toxicity and enhanced
efficacy of the treatment [251]. The maximum tolerated dose of paclitaxel has been
shown to increase with the liposomal formulation compared to the administration of
Taxol® [252]. The liposomal formulation of paclitaxel was also effective in delaying
tumor progression in paclitaxel resistant Colon 26 tumor in mice [251, 253], suggesting
that the development of liposomes opens up newer avenues to overcome drug resistance
in cancer.
Conventional liposomes are cleared rapidly by the reticuloendothelial system (RES)
comprised of Kupffer cells of the liver, and fixed macrophages of the spleen [80].
Clearance of liposomes by the RES is directly proportional to the vesicle size [79].
Liposomes of size ~100 nm can escape clearance by the RES and remain in circulation
for a prolonged period of time. In addition, coating the surface of the liposomes with
hydrophilic polymers such as PEG can provide a shielding effect to the liposomes and
prevent recognition and binding of opsonins [88]. Therefore, these liposomes can escape
clearance by the RES and remain in circulation for a longer period of time. If the
liposomes remain in circulation for a longer time, the possibility of their passive
accumulation in the tumors by enhanced permeability and retention (EPR) effect will be
improved. Even with PEG coating to minimize the clearance by the RES, the cutoff size
for the liposomes for long circulation remain between 150 and 200 nm [28].

57

Loading paclitaxel in the bilayer of the liposomes, and retaining the encapsulated
drug during storage requires special consideration in product development because the
encapsulated drug tends to precipitate at higher loading. Paclitaxel is incorporated into
the acyl chain portion of the liposome bilayer [254]. At lower concentrations, it partitions
into the upper bilayer domain towards the aqueous interface. When the concentration is
increased, it partitions into to deeper parts of the bilayer. Higher concentrations can
induce self aggregation which can act as nucleation for precipitation of paclitaxel as
needle shaped crystals. Partitioning of paclitaxel in the bilayer of liposomes induces
conformational changes which are different for saturated and unsaturated lipids [255].
Thermotropic phase behavior of phospholipids is altered inducing fluidity in the gel
phase of saturated lipids, and slight rigidity in unsaturated lipids. It also affects bilayer
spacing of planar phospholipids in lipid specific, and concentration dependant manner
[256]. Thus, drug-lipid interaction plays a major role in determining the physical stability
of the liposomes [257]. It has been suggested that a tradeoff exists between the drug
content and duration of stability in aqueous dispersion [252]. Even though high drug
loading has been reported with certain lipid compositions [249, 258, 259], the physical
stability of the liposomes varied with each composition. Apart from that, inclusion of
PEGylated lipids has been shown to reduce drug loading and physical stability of
liposomes [258]. The extent of paclitaxel loading in the liposomes, and the stability of
such liposomes is dependent on the nature and concentration of phospholipids, and druglipid interaction determined by the drug-lipid ratio. So, there is a need to optimize these
parameters to achieve adequate stability of the liposomes. The objective of this work is to
determine, and optimize the factors influencing drug loading, and physical stability of
paclitaxel-loaded long-circulating liposomes (Pac-LCL).
3.1. MATERIALS AND METHODS
3.1.1.

Materials

Paclitaxel was procured from 21CEC Pharmaceuticals (Bradenton, FL). The
phospholipids used in this work were all of research grade. Egg phosphatidylcholine
(EPC), hydrogenated soy phosphatidylcholine (HSPC) and 1,2-distearoyl-sn-glycero-3phoshoethanolamine-N-(poly(ethylene glycol)2000) (DSPE-PEG2000) were obtained from
Northern Lipids (Burnbay, BC, Canada). Cholesterol and α-tocopherol were purchased
from Sigma (St. Louis, MO). HPLC grade water, acetonitrile, and methanol were
obtained from Fisher Scientific (Fair Lawn, NJ). HPLC grade chloroform was purchased
from Acros Organics (Morris Plains, NJ). N-2-hydroxyethylpiperazine-N’-2ethanesulfonic acid (HEPES) buffer, 1 M was obtained from Mediatech (Manassas, VA).
All other chemicals and reagents were of analytical grade and used without further
purification or characterization.
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3.1.2.

Preparation of Paclitaxel-Loaded Long-Circulating Liposomes (Pac-LCL)

The Pac-LCL was be prepared by the lipid film hydration-extrusion method using
HSPC, DSPE-PEG2000, cholesterol, and/or EPC. The lipid film was prepared by
dissolving paclitaxel, phospholipids, cholesterol, and /or α-tocopherol in 9:1 chloroformmethanol. The solution thus obtained was evaporated in a round bottom flask using rotary
evaporator under reduced pressure at 45°C for 4-6 h. The dry film was hydrated with
50mM HEPES buffer pH 6.5 at 65°C for 45-60 min. The multilamellar vesicles (MLVs)
thus obtained were sized by extrusion through stacked polycarbonate membrane filters of
varying pore diameters under high pressure to obtain small unilamellar vesicles (SUVs).
The SUVs were characterized for particle size distribution, zeta potential, paclitaxel
loading and morphology. The pore diameter of filters, pressure, and number cycles used
in the extrusion process were optimized to obtain an average particle size of 100 ± 20 nm.
3.1.3.

Determination of Paclitaxel Loading Efficiency

The loading efficiency of paclitaxel in the liposomes was determined by minicolumn
centrifugation method using Sephadex G-25 macro spin columns (Harvard apparatus,
Holliston, MA) similar to the method described by Zhang et al [249] with modifications.
Briefly, the Sephadex G-25 particles in the column were suspended in 0.1% w/v TFA and
was allowed to swell for 15 minutes. The columns were centrifuged at 1500 g at 25°C for
4 min using IEC CL31R Multispeed Centrifuge (Thermo Scientific, Asheville, NC) to
remove TFA. About 100 µL of placebo LCL was added and centrifuged to saturate the
column. The column saturation with placebo liposomes was repeated for a total of three
times. The gel columns were placed in fresh collection tubes for use with drug-loaded
liposomes. The Pac-LCL samples were diluted with 50 mM HEPES buffer pH 6.5. About
100 µL of the diluted sample was added to the gel column, and centrifuged for 4 minutes.
The eluate in the collection tube, containing only entrapped paclitaxel was analyzed by
RPHPLC. The encapsulation efficiency was calculated from total paclitaxel determined
before passing through Sephadex G-25, using the formula, Entrapment efficiency =
(Entrapped paclitaxel x 100)/Total paclitaxel).
3.1.4.

Quantification of Paclitaxel from Liposomes

The total and entrapped paclitaxel in the liposomes was quantified by RPHPLC
method. The HPLC system comprised of Waters 600 Controller, Waters 717 Plus
Autosampler, and Waters 2996 Photodiode Array Detector (Waters Corporation, Milford,
MA) was used. The RPHPLC analysis was performed using a Nova-Pak C18 column (3.9
x 150 mm, 4 µm) (Waters Corporation, Milford, MA). An isocratic elution was
performed using acetonitrile-water in a ratio 55: 45 v/v at a flow rate of 1 mL/min, and
detection wavelength of 230 nm. The liposomes were digested with absolute ethanol, and
suitably diluted before injection.
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3.1.5.

Determination of Particle Size and Zeta Potential

The average diameter (Z-avg) of the Pac-LCL was determined using dynamic light
scattering using Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped
with 4.5 mW diode laser as a source of light operating at 670 nm. Particle scattered
photons were detected at an angle of 173°. The samples were suitably diluted with HPLC
grade water for the determination of Z-avg. Three independent measurements were
performed for each sample. Zeta potential was determined from electrophoretic mobility
using samples suitably diluted with HPLC grade water.
3.1.6.

Stability Evaluation of Pac-LCL

Stability of Pac-LCL was evaluated at two stages. Initially, the stability was evaluated
for 7-10 days for the optimization of the liposome composition. The Pac-LCL samples
were stored in 7 mL glass scintillation vials at 5 ± 3ºC. Aliquots were withdrawn at
specific intervals. The entrapped paclitaxel was determined by minicolumn centrifugation
method followed by analysis of the eluate by RPHPLC method. In the stability evaluation
stage, the optimized formulation was stored in 2 cc amber glass vials at 5 ± 3ºC for three
months. Samples were withdrawn at specific intervals and analyzed for total and
entrapped paclitaxel, entrapment efficiency, PSD, and zeta potential.
3.1.7.

Characterization of Morphology of Pac-LCL

Morphology of the Pac-LCL was characterized by transmission electron microscopy
(TEM) using a negative staining technique. Sequential two droplet method was used for
staining liposome samples with 2% w/v uranyl acetate on 400-mesh formvar support film
on copper specimen grid (Electron Microscopy Sciences, Hartfield, PA). The TEM
images were acquired using JEOL 2000EX transmission electron microscope (JEOL
USA, Inc., Peabody, MA) equipped with high resolution digital camera.
3.2. RESULTS AND DISCUSSION
3.2.1.

Optimization of Paclitaxel Loading

The target concentration in the paclitaxel liposome dispersion was set at 1.0 – 1.5
mg/mL with a size of 100 ± 20 nm. The initial composition for the liposomes was HSPC:
DSPE-PEG2000: cholesterol in a ratio of 45: 5: 50, and a total lipid concentration of 10
mM. The entrapment efficiency of paclitaxel was calculated by minicolumn
centrifugation method using Sepadex G-25 columns. The columns were pretreated with
placebo liposomes three times to completely saturate the column so that non-specific
adsorption and subsequent loss of paclitaxel-loaded liposomes can be minimized. The
total and entrapped paclitaxel in the liposome formulation was calculated from standard
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curve which was liner between 0.256 to 20 µg/mL with a coefficient of determination (r2)
value of 0.9999.
The effect of total phospholipids on paclitaxel loading is shown in Figure 3-1. As
expected, an increase in total phospholipids resulted in an increase in the amount of
paclitaxel per mL of liposomes. But, the entrapment efficiency was low with a total
entrapped paclitaxel concentration of ~ 4.0 µg/mL at the highest concentration tested for
phospholipids. Inclusion of cholesterol in the bilayer of liposomes has been shown to
improve the rigidity of the bilayer, and thereby, improve in vitro and in vivo stability of
the liposomes [59, 61, 64]. It also reduces leakage of encapsulated contents from the
liposomes. Cholesterol was included in the formulation to improve the rigidity, and to
minimize drug leakage. Figure 3-2 shows the effect of cholesterol on paclitaxel loading
in the LCL formulation. Reducing cholesterol content from 50 to 30 moles % did not
show any change in the paclitaxel loading. But, a sharp increase in loading was observed
at 10 moles % of cholesterol with an entrapped drug content of ~ 100 µg/mL. The
negative effect of cholesterol on paclitaxel loading was consistent with similar reports in
literature [249, 258]. It has been suggested that paclitaxel competes with cholesterol for
hydrophobic space in the bilayer of liposomes [249]. If more molecules of cholesterol are
present, there would be less space for paclitaxel to occupy. Cholesterol can restrict the
flexibility of hydrocarbon chains and prevent penetration of paclitaxel into the bilayer
[249]. In contrast, inclusion of cholesterol even at lower concentrations in PEGylated
liposomes, have shown a positive effect in improving serum stability by preventing
exchange of phospholipids with high density lipoproteins. So the lowest concentration of
cholesterol was selected for further studies.
High rigidity of HSPC, a saturated phospholipid, can restrict the loading of paclitaxel
into the bilayer of liposomes. So we evaluated the effect of EPC, an unsaturated
phospholipid, using different ratios on paclitaxel loading (Figure 3-3). With a 1: 1 ratio
of HSPC-EPC, the paclitaxel loading increased to ~ 800 µg/mL. The results were
consistent with literature reports on paclitaxel loading using unsaturated phospholipids
[171, 249, 260, 261]. Unsaturated lipids have a low gel to liquid crystalline transition
temperature (Tm), and form liposomes which are more flexible in nature to accommodate
lipophilic drugs [249]. Though inclusion of unsaturated lipids have a positive influence,
they cannot be used solely to prepare liposomes because of problems related to
aggregation of paclitaxel-loaded liposomes made of PC alone [252]. Further increases in
EPC showed only a minimal increase in drug loading. Nevertheless, paclitaxel
precipitated from all the liposome compositions within few days of storage at 5 ± 3ºC
suggesting that further refinement of the formulation is necessary. When the total lipids
content of HSPC-EPC ratio 1:3 was increased to 100 mM, the entrapped paclitaxel
content increased to ~ 1.9 mg/mL but precipitation was observed within few days of
storage. A further increase in the lipid concentration was not feasible because the
multilamellar vesicles (MLVs) formed a gel during hydration stage. High loading being
achieved, the optimum amount paclitaxel loading that result in physically stable
formulation needs to be determined.
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Figure 3-1.

Effect of total phospholipids on paclitaxel loading

Notes. The liposome composition was HSPC: DSPE-PEG2000: cholesterol in a ratio of
45: 5: 50. The liposomes were subjected to minicolumn centrifugation in Sephadex G-25
macro spin columns to separate free paclitaxel from total paclitaxel. The eluate
containing entrapped paclitaxel was digested with ethanol, and quantified by RPHPLC
method. Two injections were made for each sample, and the average was calculated.
Three Sephadex columns were prepared for each composition and the results indicate the
mean ± standard deviation for three gel filtration columns.
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Figure 3-2.

Effect of cholesterol concentration on paclitaxel loading

Notes. The liposome composition was HSPC: DSPE-PEG2000: cholesterol in a ratio of
x: 5: x moles % with a total lipid concentration of 50 mM. The liposomes were subjected
to minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested
with ethanol, and quantified by RPHPLC method. Two injections were made for each
sample, and the average was calculated. Three Sephadex columns were prepared for each
composition and the results indicate the mean ± standard deviation for three gel filtration
columns.

63

Paclitaxel Concentration (µg/mL)

Figure 3-3.
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Effect of saturated-unsaturated lipid ratio on paclitaxel loading

Notes. The liposome composition was HSPC: EPC: DSPE-PEG2000: cholesterol with
a total lipid concentration of 50 mM. The moles % of DSPE-PEG2000 and cholesterol
were maintained constant at 5% and 10% respectively. The liposomes were subjected to
minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested
with ethanol, and quantified by RPHPLC method. Two injections were made for each
sample, and the average was calculated. Three Sephadex columns were prepared for each
composition and the results indicate the mean ± standard deviation for three gel filtration
columns.
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3.2.2.

Optimization of Physical Stability

Drug-lipid interaction is a major determining factor of physical stability of the
liposomes and is dependent on the concentration of drug and phospholipids [257]. Higher
to drug-lipid ratio can minimize the total amount of phospholipids administered and thus
reduce toxicities associated with high lipid doses. On the other hand, the ratio needs to be
optimum to attain adequate physical stability. Thus, the optimum formulation is the one
which has the highest drug-lipid ratio achievable for physically stable liposomes. A
paclitaxel-lipid ratio of 1:30 or less has been used to develop formulations with different
phospholipid compositions with good loading efficiency [249, 252, 258]. We evaluated
the effect of drug-lipid ratio on paclitaxel loading in LCL at different ratios. With
increasing drug-lipid ratio, an increase in drug loading was observed (Figure 3-4) with a
maximum loading obtained at the ratio of 1:30. Further increase in drug-lipid ratio to
1:20 resulted in a decrease in loading due to precipitation (Data not shown). This was
consistent with literature reports suggesting that the ratios above 1:30 can result in
aggregate formation that can act as nucleation for precipitation [254]. The LCL
containing three different drug-lipid ratios were stored in scintillation vials at 5 ± 3ºC to
evaluate the physical stability of these liposomes. At specific intervals, aliquots were
withdrawn from these vials after vortexing to ensure uniform mixing. The liposomes
were passed through Sephadex G-25 gel column by minicolumn centrifugation method to
separate the free drug from the dispersion. The entrapped paclitaxel in these LCL
formulations were plotted against time (Figure 3-5) to evaluate the physical stability. The
entrapped paclitaxel decreased to nearly 20% of the initial concentration in five days for
the drug-lipid ratio of 1:30. The formulation with 1:45 also showed a steady decline in
entrapped paclitaxel through the 10 days of observation. The ratio of 1:60 was stable for
up to 10 days. Even though high loading was achieved with the drug-lipid ratios 1:30,
and 1:45, they were not physically stable in this bilayer composition. This could be
attributed to over saturation of the bilayer with paclitaxel in the liposomes at higher
temperatures above the storage temperature. On returning to the storage temperature,
paclitaxel in the oversaturated liposomes started to precipitate. The precipitate acted as
nucleation and induced further precipitation of remaining paclitaxel reducing the
encapsulated paclitaxel content to a lower level even below that was seen with the ratio
1:60. The liposome bilayer composition was further modified to minimize the negative
factors that affect paclitaxel loading. HSPC-EPC ratio was changed to 1:5, and
cholesterol concentration was reduced to 5 moles %. The amount of entrapped drug for a
given drug-lipid ratio increased for these formulations. The effect of various drug-lipid
ratios on the physical stability of the improved composition was evaluated at 5 ± 3ºC for
one week, and the data is presented in Figure 3-6. Similar to the previous observations
the drug to lipid ratio of 1:30 showed a decrease in entrapped paclitaxel but at a slower
rate. Other ratios were stable for one week. The intermediate stable drug-lipid ratio of
1:60 was selected as the optimum formulation for three-month stability evaluation.
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Figure 3-4.
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Effect of drug-lipid ratio on paclitaxel loading

Notes. The liposome composition was HSPC: EPC: DSPE-PEG2000: cholesterol
(21.25: 63.75: 5: 10) with a total lipid concentration of 100 mM. The liposomes were
subjected to minicolumn centrifugation in Sephadex G-25 macro spin columns to
separate free paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel
was digested with ethanol, and quantified by RPHPLC method. Two injections were
made for each sample, and the average was calculated. Three Sephadex columns were
prepared for each composition and the results indicate the mean ± standard deviation for
three gel filtration columns.
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Effect of drug-lipid ratio on physical stability of Pac-LCL

Notes. The liposome composition was HSPC: EPC: DSPE-PEG2000: cholesterol
(21.25: 63.75: 5: 10) with a total lipid concentration of 100 mM. The liposomes were
stored at 5 ± 3ºC in scintillation vials. Aliquots were withdrawn at specific intervals and
subjected to minicolumn centrifugation in Sephadex G-25 macro spin columns to
separate free paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel
was digested with ethanol, and quantified by RPHPLC method. Two injections were
made for each sample, and the average was calculated. Three Sephadex columns were
prepared for each composition and the results indicate the mean ± standard deviation for
three gel filtration columns (Drug-lipid ratios are ■ 1:30; ▲ 1:45; ● 1:60).
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Effect of drug-lipid ratio on physical stability of improved Pac-LCL

Notes. The liposome composition was HSPC: EPC: DSPE-PEG2000: cholesterol (15:
75: 5: 5) with a total lipid concentration of 100 mM. The liposomes were stored at 5 ±
3ºC in scintillation vials. Aliquots were withdrawn at specific intervals and subjected to
minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested
with ethanol, and quantified by RPHPLC method. Two injections were made for each
sample, and the average was calculated. Three Sephadex columns were prepared for each
composition and the results indicate the mean ± standard deviation for three gel filtration
columns (Drug-lipid ratios are ■ 1:30; ▲ 1:45; ● 1:60; ♦ 1:75).
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3.2.3.

Optimization of the Extrusion Process

The extrusion process used in the preparation of LCL to reduce the vesicle size can
affect drug loading depending upon the number of extrusion cycles and the extrusion
pressure. The effect of number of extrusion cycles on PSD, and entrapment efficiency is
presented in Figure 3-7. The results are shown for the drug-lipid ratio of 1:30, and
polycarbonate membrane filter combination of 200 nm stacked over 100 nm. As
expected, the size of the liposomes decreased with increasing number of extrusion cycles.
There was no significant decrease in the entrapped paclitaxel up to five extrusion cycles.
A slight decrease in entrapment was observed with 10 extrusion cycles but it was within
the target loading desired. The effect of extrusion pressure is presented in Figure 3-8.
The particle size decreased proportionately with increase in extrusion pressure. The
entrapment efficiency did not show any significant change with increasing extrusion
pressure although there was a slight decrease in loading observed at extrusion pressure of
300 PSI. The understanding about the process helped in reaching the target size of 100 ±
20 nm with a paclitaxel loading of 1-1.3 mg/mL with changes in polycarbonate filter
combinations, extrusion pressure, and number of extrusion cycles. The TEM images of
the Pac-LCL formulation showed that these vesicles were spherical in structure with a
diameter of 100 ± 20 nm (Figure 3-9).
3.2.4.

Stability Evaluation of Pac-LCL Dispersion

The stability of the Pac-LCL dispersion was evaluated at 5 ± 3ºC in light protected
container for three months. The stability data presented in Figure 3-10 shows that the
liposomes maintained their size, charge, and integrity through the evaluation period. A
slight decrease was observed in paclitaxel retention in the first few days. This could be
attributed to partitioning of the drug form the bilayer of liposomes to the dispersion
medium to maintain equilibrium. Once the equilibrium is reached, the paclitaxel retention
remained constant.
3.3. SUMMARY AND CONCLUSIONS
The loading of paclitaxel in the liposomes can vary depending upon number of
factors including the nature and concentration of lipids in the bilayer, the amount of drug,
and the process used in the preparation of liposomes. Even though high loading can be
achieved, the physical instability of the liposomes in the dispersion is a challenging issue
and needs to be addressed to ensure long-term stability during storage. The factors
affecting drug loading have been identified and optimized to improve the loading
efficiency. A proportionate increase in loading was observed with increase in the total
phospholipid content. Cholesterol and saturated lipid content in the bilayer showed a
negative influence on paclitaxel loading. Reducing the concentration of cholesterol
showed a significant increase in paclitaxel loading. The increase in loading was further
augmented by the inclusion of EPC, an unsaturated lipid to replace a part of HSPC, a
saturated lipid. The increased flexibility of the acyl chains of the unsaturated lipids
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Effect of number of extrusion cycles on PSD and paclitaxel loading

Notes. Liposomes were sized by extrusion process and the samples were taken at
different number of cycles and evaluated for entrapped paclitaxel and PSD. For entrapped
paclitaxel determination, the eluate from gel filtration through Sephadex G-25 was
digested with ethanol, and quantified by RPHPLC method. Two injections were made for
each sample, and the average was calculated. Three Sephadex columns were prepared for
each stage of evaluation in the extrusion process. The results indicate the mean ±
standard deviation for three gel filtration columns. For PSD, the results indicate mean ±
standard deviation of three independent measurements at each stage of evaluation (■
PSD; ▲ Paclitaxel loading).
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Notes. Liposomes were sized by extrusion process using different extrusion pressures,
and evaluated for entrapped paclitaxel and PSD. For entrapped paclitaxel determination,
the eluate from gel filtration through Sephadex G-25 was digested with ethanol, and
quantified by RPHPLC method. Two injections were made for each sample, and the
average was calculated. Three Sephadex columns were prepared for each extrusion
pressure. The results indicate the mean ± standard deviation for three gel filtration
columns. For PSD, the results indicate mean ± standard deviation of three independent
measurements at extrusion pressure (■ PSD; ▲ Paclitaxel loading).
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Figure 3-9.

TEM image depicting morphology of Pac-LCL

Notes. The samples were prepared by negative staining with uranyl acetate using
sequential two drop technique on formvar coated copper grids. The results are shown at a
magnification of 300,000x.

72

100
75

1000
50
500
25
0

0

10

20

B

30

40 50 60
Time (Days)

70

80

0
90 100

-20

100

Z-Average (nm)

80
-25

60
40

-30

20
0

Percent Retention

1500

0

25

50
Time (Days)

75

Zeta Potential (mV)

Paclitaxel Retained in the Liposomes (µg/mL)

A

-35
100

Figure 3-10. Stability of Pac-LCL dispersion at 5 ± 3ºC
Notes. The liposome composition was HSPC: EPC: DSPE-PEG2000: cholesterol (15:
75: 5: 5) with a total lipid concentration of 100 mM. The liposomes were stored at 5 ±
3ºC in 2 cc amber vials. Samples were withdrawn at specific intervals. A. For the
determination of paclitaxel retention, the samples were subjected to minicolumn
centrifugation in Sephadex G-25 macro spin columns to separate free paclitaxel from
total paclitaxel. The eluate containing entrapped paclitaxel was digested with ethanol, and
quantified by RPHPLC method. The results indicate the mean ± standard deviation for
three injections (▲ Paclitaxel concentration; ■ Percent paclitaxel retained in the
liposomes). B. For PSD, and zeta potential, the results indicate mean ± standard deviation
of three independent measurements (● PSD; ♦ Zeta potential).
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allowed higher amounts of paclitaxel to be accommodated in the bilayer. Although high
loading is achieved with these compositions, the entrapped paclitaxel precipitated out of
the bilayer within few days of storage at 5 ± 3ºC. The influence of drug-lipid ratio on
drug loading showed that the loading increased with an increase in the drug-lipid ratio.
But, LCL with a drug-lipid ratio of 1:30 was physically unstable. The short-term stability
evaluation of liposomes prepared with different drug-lipid ratios demonstrated that 1:60
as the optimum drug-lipid ratio to achieve a loading of 1-1.3 mg/mL without the risk of
physical instability. The optimized formulation was stable at 5 ± 3ºC for three months.
The formulation and process parameters were optimized to achieve a physically stable
formulation of Pac-LCL that maintains the size, charge, and integrity during storage.
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CHAPTER 4. DEVELOPMENT OF PACLITAXEL-LOADED RGD
CONJUGATED GAS-FILLED LIPOSOMES
Cancer is a dangerous disease and is the second leading cause of death in United
States [2, 3]. About 1.5 million new cases of cancer and more than half-a-million deaths
have been estimated in the United States for the year 2009 [4]. Solid tumors account for
more than 85 percent of all the cases reported with cancer [5, 6]. Breast cancer is the
most commonly diagnosed form of solid tumors and is the second leading cause of death
in western women. About 20-30% women with breast cancers develop metastatic breast
cancers. Chemotherapy is a form of systemic therapy of solid tumors and is also more
useful in the treatment of metastatic cancers. The cytotoxic effect of these
chemotherapeutic agents on cancer cells is highly beneficial for the therapy, but, adverse
effects were also observed with these agents due to their effect on normal cells. Thus,
there is a need for an effective drug delivery system that produces cytotoxic
concentrations of the drug at the tumor sites without affecting normal tissues.
Paclitaxel is one of the most effective drugs used in chemotherapy of cancer and is a
natural product isolated from bark of the Pacific Yew tree, Taxus brevifolia [8, 9]. It
exhibits cytotoxic activity by promoting the assembly of microtubules from tubulin
dimers and stabilizes microtubules by preventing depolymerization. The stability results
in inhibition of the normal dynamic reorganization of the microtubule network that is
essential for vital interphase and mitotic cellular functions [9]. Paclitaxel is marketed as
Taxol® (Bristol-Myers Squibb Company, Princeton, NJ) for the treatment of ovarian,
breast, non-small cell lung cancers, and AIDS related Kaposi’s sarcoma [249]. Since
paclitaxel is highly insoluble in water, Taxol® was formulated with ethanol and
Cremophor®EL. Although the formulation is diluted before use, the concentration of
Cremophor®EL is high enough to cause serious hypersensitivity reactions on parenteral
administration, which require pretreatment with antihistamines and corticosteroids [15].
In addition, the use of free paclitaxel can affect normal tissues and result in systemic
toxicities such as myelosuppression, and peripheral neuropathy [17]. So, it is imperative
to deliver paclitaxel locally to the tumor sites to minimize systemic toxicity. In addition,
failure to maintain adequate concentration at the tumor microenvironment could result in
regrowth of the tumor cells and development of resistance [5].
Liposomes are biocompatible carriers with ability to incorporate both lipophilic and
hydrophilic drugs [23]. Encapsulating drugs within the vesicles has the potential
advantage of higher drug carrying capacity compared to attaching them to single polymer
chains [250]. Preparation of liposomes of paclitaxel can alter the pharmacokinetic and
pharmacodynamic properties of the free drug and result in reduced toxicity and enhanced
efficacy of the treatment [251]. In addition, flexibility in the design of liposomes allows
tailoring to achieve passive as well as active targeting. The release of drug from these
liposomes, at the target site, is determined by natural cytosolic mechanisms [23]. It will
be an added advantage to have a control over drug release and/or uptake at the target site
so that high cytotoxic concentrations can be achieved. Secondly, the unique nature of
solid tumors with heterogeneity in vasculature, and high interstitial pressure pose a
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formidable barrier to drug delivery [19]. Apart from targeting and controlled release, it is
also necessary to improve permeability at the tumor vasculature. Incorporation of gases
in the bilayer of liposomes makes them acoustically active [205]. These echogenic
liposomes have the potential for stress on activation by ultrasound, and eventually release
the contents at the target site [35]. The disintegration of gas-filled species by contrast
enhanced ultrasound produces liquid jets that can produce small gaps in the vasculature
and improve the permeability [36]. Thus, cavitation effect of ultrasound on the echogenic
liposomes provides a control over drug release, and also enhances drug permeability by
producing small gaps in the endothelial walls of vasculature [36-39]. This phenomenon
can be explored for targeted delivery wherein the targeted liposomes maintain basal
levels of the drug by virtue of cytosolic transport, and by altering intensity of ultrasound,
high cytotoxic concentrations of the drug can be achieved at the target site.
The size of these echogenic liposomes used for imaging is ~ 800 nm, and would be
cleared rapidly by the reticuloendothelial system (RES). So, there is a need to control the
size of these echogenic liposomes to approximately 150-200 nm to minimize clearance
by the RES. An ideal carrier for therapeutic targeting to solid tumors must have a longer
circulation time than those used for imaging and should possess targeting capability. In
vivo circulation time can be increased by reducing the size of liposomes and/or modifying
the surface with PEG derivatives [28]. Targeting capability can be achieved by attaching
specific ligands onto the surface of the liposomes. The αvβ3 integrin receptors are highly
expressed in actively proliferating endothelial cells of tumor vasculature and tumor cells
[163, 235]. Peptides with Arg-Gly-Asp (RGD) motif in a cyclic framework have been
shown to bind to these receptors and are effective in targeting solid tumors [172]. By
attaching RGD peptide to the surface through PEG spacers, these liposomes can be
targeted to solid tumors. The objective of this work is to develop parenteral echogenic
RGD conjugated liposomes containing paclitaxel for ultrasound mediated targeted drug
delivery. Owing to unique nature of the proposed parenteral dosage form, there is a
potential to overcome the barriers in cancer chemotherapy.
4.1. MATERIALS AND METHODS
4.1.1.

Materials

Paclitaxel was procured from 21CEC Pharmaceuticals (Bradenton, FL). The
phospholipids used in this work were all of research grade. Egg phosphatidylcholine
(EPC), hydrogenated soy phosphatidylcholine (HSPC) and 1,2-distearoyl-sn-glycero-3phoshoethanolamine-N-(poly(ethylene glycol)2000) (DSPE-PEG2000) were obtained from
Northern Lipids (Burnbay, BC, Canada). 1,2-distearoyl-sn-glycero-3phoshoethanolamine-N-(maleimide poly(ethylene glycol)2000) (maleimide DSPEPEG2000) was obtained from Avanti Polar Lipids (Alabaster, AL). Cholesterol, αtocopherol, and sucrose were purchased from Sigma (St. Louis, MO). Mannitol was
obtained from Mallinckrodt Chemicals (Phillipsburg, NJ). Cyclo (Arg-Gly-Asp-D-PheCys) peptide (cRGD) was obtained from Peptides International (Louisville, KY).
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Poloxamer 188 was obtained from BASF (Mount Olive, NJ). HPLC grade water,
acetonitrile, and methanol were obtained from Fisher Scientific (Fair Lawn, NJ). HPLC
grade chloroform was purchased from Acros Organics (Morris Plains, NJ). N-2hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) buffer, 1M was obtained
from Mediatech (Manassas, VA). All other chemicals and reagents were of analytical
grade and used without further purification or characterization.
4.1.2.

Preparation of Paclitaxel-Loaded Long-Circulating Liposomes (Pac-LCL)

The Pac-LCL was be prepared by the lipid film hydration-extrusion method using
EPC, HSPC, DSPE-PEG2000, and cholesterol. The lipid film was prepared by dissolving
paclitaxel, phospholipids, cholesterol, and α-tocopherol in 9:1 chloroform-methanol. The
solution obtained was evaporated in a round bottom flask using rotary evaporator under
reduced pressure at 45°C for 4-6 h. The dry film was hydrated with 50 mM HEPES
buffer pH 6.5 at 65°C for 45-60 min. The multilamellar vesicles (MLVs) thus obtained
were sized by extrusion through stacked polycarbonate membrane filters of varying pore
diameters under high pressure to obtain small unilamellar vesicles (SUVs). The SUVs
were characterized for particle size distribution, zeta potential, and total and entrapped
paclitaxel content.
4.1.3.
Preparation of Paclitaxel-Loaded cRGD Conjugated Targeted LongCirculating Liposomes (Pac-RGD-TLCL)
For the preparation of Pac-RGD-TLCL, a part of DSPE-PEG2000 was replaced with
maleimide DSPE-PEG2000 and the liposomes were prepared as described in section 4.1.2
to obtain SUVs with reactive maleimide functional groups. The maleimide-Pac-LCL thus
obtained was conjugated with cRGD peptide by incubation at 25°C for 12 h. Aliquots
were withdrawn for the determination of conjugation efficiency. The unconjugated
peptide remaining after the reaction was removed from the liposomes by equilibrium
dialysis through 10,000 MWCO Slide-A-Lyzer dialysis cassettes (Thermo Fisher
Scientific, Rockford, IL) against 50 mM HEPES buffer pH 6.5 at 5 ± 3°C overnight. The
conjugation efficiency was determined by quantifying free RGD in the liposomal
dispersion by reversed phase high performance liquid chromatography (RPHPLC).
4.1.4.

Determination of Conjugation Efficiency

Conjugation efficiency was determined by an indirect method to quantify the
unconjugated cRGD peptide. The method was validated by adding different amounts of
cRGD to the liposomes, and by quantifying unreacted peptide. An increasing amount of
cRGD was added to a constant volume of maleimide-Pac-LCL. The same amounts were
also added to Pac-LCL as a control for non-specific binding, and to HEPES buffer pH
6.5, 50 mM as a negative control. The reaction was performed in triplicates at three
different amounts of cRGD. After the incubation period for the conjugation reaction, the
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samples were digested with absolute ethanol, and the free cRGD remaining was
quantified by RPHPLC method. The gradient elution was performed using 0.05% v/v
trifluoroacetic acid (TFA) in water (A) and 0.05% v/v TFA in acetonitrile (B) with a
linear gradient of 10 to 60% B in 25 min at a flow rate of 1 mL/min. The amount of
cRGD in HEPES buffer was taken as total unbound. The amount of cRGD consumed in
Pac-LCL was taken as non-specific binding. The conjugation efficiency was calculated
from free cRGD remaining in maleimide-Pac-LCL after subtracting the loss due to nonspecific binding. For day to day analysis, a slightly excess of cRGD peptide than required
for the reaction was added to maleimide-Pac-LCL, Pac-LCL, and HEPES buffer. The
conjugation efficiency was determined as described above.
4.1.5.
Preparation of Gas-Filled Pac-LCL (Pac-GFLCL) and Gas-Filled PacRGD-TLCL (Pac-RGD-GFTLCL)
The Pac-LCL or Pac-RGD-TLCL was mixed with equal volume of sucrose solution
containing poloxamer 188 with or without mannitol. The lyophilization cycle was
designed based on the glass transition temperature of maximally freeze-concentrated
amorphous phase (Tg′), determined by differential scanning calorimetry (DSC).
Lyophilization was carried out using a lab scale Virtis Genesis 25ES lyophilizer (The
Virtis Company, Gardiner, NY). The primary drying temperature was selected based on
Tg′ and the mixture was lyophilized in 2 cc glass amber vials. The moisture content of
the dry cake was monitored to ensure end point of secondary drying. On completion of
the drying cycle, the vials were sealed under a partial vacuum. Perfluoropropane was
filled in the headspace above the vials at atmospheric pressure to obtain Pac-GFLCL and
Pac-RGD-GFTLCL. The vesicle size, zeta potential, total and entrapped paclitaxel
content, and echogenicity were monitored in samples reconstituted with HPLC grade
water. The vials were stored at 5 ± 3°C until further use.
4.1.6.

Thermal Analysis by DSC

The glass transition of maximally freeze concentrated amorphous phase (Tg′) of
mixture of liposomes and sucrose with or without mannitol was determined by
differential scanning calorimetry (DSC) using a Q2000 differential scanning calorimeter
equipped with refrigerated cooling system (TA Instruments, New Castle, DE). About 1020 µL of the liposome mixture prior to lyophilization was placed in T-Zero aluminum
pans and hermetically sealed. An empty pan prepared in a similar manner was used as
reference. The samples were equilibrated at 25°C and then cooled at 5°C/min to -70°C.
After equilibration, the samples were heated at the rate of 10°C/min to 25°C.
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4.1.7.
Characterization of Pac-LCL, Pac-RGD-TLCL, Pac-GFLCL, Pac-RGDGFTLCL
The average diameter (Z-avg) of the liposomes was determined using dynamic light
scattering using Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped
with 4.5 mW diode laser as a source of light operating at 670 nm. Particle scattered
photons were detected at an angle of 173°. The samples were suitably diluted with HPLC
grade water for the determination of Z-avg. Three independent measurements were
performed for each sample. Zeta potential was determined from electrophoretic mobility
using samples suitably diluted with HPLC grade water.
The loading efficiency of paclitaxel in the liposomes was determined by minicolumn
centrifugation method using Sephadex G-25 macro spin columns (Harvard apparatus,
Holliston, MA) similar to the method described by Zhang et al [249] with modifications.
Briefly, the Sephadex G-25 particles in the column were suspended in 0.1% w/v TFA and
was allowed to swell for 15 minutes. The columns were centrifuged at 1500 g at 25°C for
4 min using IEC CL31R Multispeed Centrifuge (Thermo Scientific, Asheville, NC) to
remove TFA. About 100 µL of placebo LCL was added and centrifuged to saturate the
column. The column saturation with placebo liposomes was repeated for a total of three
times. The gel columns were placed in fresh collection tubes for use with drug-loaded
liposomes. The Pac-LCL samples were diluted with 50 mM HEPES buffer pH 6.5. About
100 µL of the diluted sample was added to the gel column, and centrifuged for 4 minutes.
The gas-filled liposomes were reconstituted with HPLC grade water prior to dilution. The
eluate in the collection tube, containing only entrapped paclitaxel was analyzed by
RPHPLC. Paclitaxel in the liposomes before passing through Sephadex G-25 was
quantified for the total drug content. The HPLC system comprised of Waters 600
Controller, Waters 717 Plus Autosampler, and Waters 2996 Photodiode Array Detector
(Waters Corporation, Milford, MA) was used. The RPHPLC analysis was performed
using a Nova-Pak C18 column (3.9 x 150 mm, 4 µm) (Waters Corporation, Milford, MA).
An isocratic elution was performed using acetonitrile-water in a ratio 55: 45 v/v at a flow
rate of 1 mL/min, and detection wavelength of 230 nm. The liposomes were digested
with absolute ethanol, and suitably diluted before injection. The encapsulation efficiency
was calculated using the formula, Entrapment efficiency = (Entrapped paclitaxel x
100)/Total paclitaxel).
The moisture content of the lyophilized cake was determined using an Orion AF8
Volumetric Karl Fischer Titrator (Orion Research Inc., Boston, MA). The titrator was
calibrated on each day of analysis with a known quantity of water. About 75 mg of the
dried sample was weighed accurately and added to the titration vessel. The titration was
started after allowing one minute for extraction.
Morphology of the liposomes was characterized by transmission electron microscopy
(TEM) using a negative staining technique. Sequential two droplet method was used for
staining liposome samples with 2% w/v uranyl acetate on 400-mesh formvar support film
on copper specimen grid (Electron Microscopy Sciences, Hartfield, PA). The TEM
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images were acquired using JEOL 2000EX transmission electron microscope (JEOL
USA, Inc., Peabody, MA) equipped with high resolution digital camera.
4.1.8.

Determination of Echogenicity

Acoustic activity of Pac-GFLCL and Pac-RGD-GFTLCL was characterized using an
in vitro method utilizing Phillips ATL HDI-5000 ultrasound system and broadband L12-5
transducer (Philips Healthcare, Andover, MA). A rectangular plexiglass chamber was
filled with 15 mL of normal saline (NS). A small magnetic stir bar was placed in the
chamber to enable uniform mixing. The chamber was then placed on a magnetic stirrer.
The transducer was positioned such that it has direct contact with NS filled in the tank.
The images were acquired with a mechanical index setting of 0.1. The Pac-GFLCL was
reconstituted with HPLC grade water. After acquiring the background image for 5 sec.,
50 µL of the reconstituted liposomal product was injected into the tank with a 1 cc
syringe, and the images were acquired for one minute. All image sequences were
analyzed offline using a custom program using MATLAB 7.0.4 software (The
MathWorks, Inc., Natick, MA). The pixel values in the region of interest (ROI) were
compared to the pixel values in the background. The number of folds increase in mean
gray scale value (MGSV) in the ROI over the background was calculated as the measure
of acoustic activity. For demonstrating the ability to disintegrate the Pac-RGD-GFTLCL,
VisualSonicsTM Vevo® 2100 ultrasound instrument with MS 200 transducer
(Visualsonics, Inc., Toronto, Ontario, Canada) was used in contrast mode. A MTV-1
restrained tail vein infusion catheter (Braintree Scientific, Braintree, MA) was mounted
in the plexiglass tank such that a portion of the catheter is completely immersed in water
filled in the tank (Figure 4-1). The MS 200 transducer was positioned above the catheter
with water in the tank as interface. The gas-filled liposomes were reconstituted with
HPLC water, the sample was drawn into a 1 cc syringe, and the syringe was connected to
the catheter. The sample was slowly injected through the catheter and the liposomes were
visualized by ultrasound at 12.5 MHz center frequency at 10% power. The flow was
stopped during the measurement sequence to determine the ability to disintegrate gasfilled liposomes with ultrasound. A high intensity pulse was applied for a duration of one
second at 50% of the cine loop sequence. The contrast mean power at the region of
interest was calculated.
4.1.9.

In vitro Drug Leakage Study

Paclitaxel leakage from Pac-RGD-GFTLCL was determined by equilibrium dialysis
of the liposomal dispersion using 10,000 MWCO Slide-A-Lyzer dialysis cassettes
(Thermo Fisher Scientific, Rockford, IL) against pH 7.4 phosphate buffered saline (PBS)
containing 0.1 % w/v Tween 80 in a jacketed beaker maintained at 37°C. Samples of 1
mL were withdrawn at specific intervals for a period of 72 hours, and then 1 mL of fresh
medium was added to the release vessel for replacement. The samples were analyzed by
RPHPLC method. The drug released/leaked was evaluated as a function of time.

80

Figure 4-1.
liposomes

The in vitro model used for demonstrating disintegration of gas-filled

Notes. The apparatus used for demonstrating disintegration of gas-filled liposomes
consists of a rectangular plexiglass chamber filled with water. A tail vein infusion
catheter was mounted so that it is immersed in water. The MS 200 transducer was placed
above the catheter using water as the interface. The reconstituted echogenic liposomes
were injected through the catheter, viewed and disintegrated by ultrasound. The diagram
is not drawn to scale.
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4.1.10.

Stability Evaluation of Pac-RGD-GFTLCL

Stability of Pac-RGD-GFTLCL was evaluated for three months. The optimized
formulation in 2 cc amber glass vials was stored at 5 ± 3ºC for three months. Samples
were withdrawn at specific intervals and analyzed for total and entrapped paclitaxel,
entrapment efficiency, PSD, zeta potential, and moisture content.
4.2. RESULTS AND DISCUSSION
The optimized composition of paclitaxel-loaded liposomes from chapter 3 was mixed
with mannitol solutions containing 0.3 % w/v poloxamer 188 and different amounts of
sucrose, and then lyophilized. The particle size of the liposomes increased to above 400
nm irrespective of the concentration of sucrose in the formulation. This could be due to
fusion or aggregation of liposomes during lyophilization. The results were in contrast to
the optimized formulation obtained for the prototype formulation in chapter 2. The
possible reasons for the increase in PSD could be the changes in the lipid composition,
lipid concentration, and inclusion of paclitaxel in the formulation. So, attempts were
made to lyophilize the formulation with sucrose and poloxamer 188 to determine the
optimum lipid-sugar ratio for a better control in PSD. Then, mannitol was included in the
composition to determine its effects on PSD and echogenicity. The optimization of the
formulation for lyophilization was performed with Pac-LCL, and then Pac-RGD-TLCL
was used with the optimum composition to prepare Pac-RGD-GFTLCL. Comparisons
were made between Pac-GFLCL, and Pac-GFTLCL.
4.2.1.
Effect of Lyoprotectant and the Manufacturing Process on PSD of PacGFLCL
Phospholipids can undergo hydrolysis or oxidation during storage of liposomes in the
form of dispersion. As a result, the liposomes can aggregate or fuse together resulting in
an increase in particle size distribution. Freeze drying or lyophilization can prevent
hydrolysis of phospholipids and physical degradation during storage of the liposomes
[34]. However, lyophilization process itself can cause loss of encapsulated drug and
fusion of the vesicles. Interaction of water with hydrophilic phosphate head groups of
phospholipids plays a key role in the formation of liposomes and hence, removal of water
presents more challenges. Inclusion of lyoprotectants can help maintain the structure, and
integrity of liposomes during lyophilization [33]. The effect of different lipid-sugar ratios
on PSD of Pac-LCL after lyophilization was evaluated with sucrose. The heating profile
of DSC showed that the Tg′ of these liposome-sucrose mixtures was between -35 to 39ºC (Figure 4-2). The trend showed that there was a slight increase in the Tg′ with an
increase in the concentration of sucrose. Figure 4-3 shows the effect of lipid-sugar ratio
on PSD of the liposomes after lyophilization. The increase in size of liposomes after
lyophilization was minimized at lipid-sugar ratios below 1:5. Further changes in the ratio
showed a trend of decrease in size of the liposomes with increasing amounts of sucrose in
the formulation up to a ratio of 1:7. Additional increases in sucrose concentration did not
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DSC thermograms showing the effect of lipid-sucrose ratio on Tg′

Notes. The liposomes were mixed with equal volume of sucrose solution containing
0.3% w/v poloxamer 188 at different lipid-sucrose ratios. The samples were hermetically
sealed in aluminum pans, and cooled at the rate of 5°C/min to -70°C. After equilibration
at -70°C, the samples were heated at the rate of 10°C/min to 25°C. The heating profile is
shown in the figure. Heat flow is shown on an arbitrary scale.
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Effect of lipid-sugar ratio on PSD after lyophilization of Pac-LCL

Notes. The liposomes were prepared by lipid film hydration extrusion method. The
PSD was determined before and after freeze drying in presence of varying lipid-sugar
ratios with sucrose. The freeze dried paclitaxel-loaded gas-filled liposome samples were
reconstituted with HPLC grade water for the measurement of PSD. The results indicate
mean ± standard deviation of three independent measurements (■ Before lyophilization;
▲ After lyophilization).
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show any appreciable effect. The results were consistent with findings in literature on the
ability of different saccharides to act as cryoprotectants for small unilamellar vesicles
[220, 221]. The ability of these saccharides to replace water molecules of hydration by
forming hydrogen bond with the polar phospholipid group, at same binding site as water,
was suggested as the mechanism for cryoprotection. These reports also suggested that the
fraction of liposomes unaffected during dehydration was dependant on the sugar to lipid
molar ratio. The lipid-sugar ratio of 1:7 was selected as optimum for further studies. In
addition, the lyoprotectants are known to provide better protection to liposomes during
lyophilization when they are present on both sides of the membrane [33]. The total
amount of sugar was divided into internal-external ratio and the internal sucrose portion
was added to the hydration medium during the preparation of liposomes. The external
sucrose along with poloxamer 188 was mixed with preformed Pac-LCL containing
different internal amounts of sucrose. The effect of internal-external ratio of sucrose on
PSD of Pac-LCL before and after lyophilization is presented in Figure 4-4. The
liposomes prepared with internal sucrose showed minimal increase in size compared to
those prepared without internal sucrose. This could be attributed to the lyoprotectant
effect on inner portions of the bilayer. Further increase in concentration of internal
sucrose did not show any effect as reported in literature [226] suggesting only a small
fraction of lyoprotectant is required inside the aqueous core of the liposomes. Although
these gas-filled liposomes were of size 150-200 nm in size, within the target size required
for drug delivery, a closer observation of the intensity distribution of the average
diameter showed a secondary peak appearing at approximately 1 µm diameter suggesting
the process needs to be fine tuned further for a narrow size distribution.
The effect of number of extrusion cycles used in the preparation of Pac-LCL on the
PSD after lyophilization was evaluated (Figure 4-5). The vesicle size decreased with
increase in number of extrusion cycles. It was interesting to note that the size after
lyophilization was almost similar for all the liposomes prepared with different numbers of
extrusion cycles even though they were of different size before lyophilization. The
difference between the size before and after lyophilization increased with increasing
numbers of extrusion cycles. The polydispersity index (PDI), which describes variation in
the size distribution, showed a trend of increase suggesting that the distribution was
broader when the number of extrusion cycles was increased. Folds increase in PDI
increased with increase in the number of extrusion cycles though not significant. One
extrusion cycle with minimal increase in size and PDI after lyophilization was selected
for further evaluation. Further attempts were made to minimize the increase in PDI after
lyophilization. The effect of HEPES buffer, concentration of the buffer, rate of cooling
during the freezing phase of lyophilization process, and primary drying temperature on
PSD after lyophilization of Pac-LCL was evaluated. When the primary drying
temperature was set closer to the Tg′ of the frozen liposome-sucrose mixture, the increase
in PDI after lyophilization was minimized (Figure 4-6).
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Effect of inravesicular-extravesicular ratio of sucrose on PSD of Pac-LCL

Notes. The liposomes were prepared by lipid film hydration extrusion method with
different amounts of intravesicular sucrose. The PSD was determined before and after
freeze drying in presence of varying extravesicular amounts of sucrose. The freeze dried
paclitaxel-loaded gas-filled liposome samples were reconstituted with HPLC grade water
for the measurement of PSD. The results indicate mean ± standard deviation of three
independent measurements (■ Before lyophilization; ▲After lyophilization).
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Figure 4-5. Effect of number of extrusion cycles on the PSD and PDI after
lyophilization
Notes. The liposomes were prepared by lipid film hydration extrusion method with
different numbers of extrusion cycles. The PSD was determined before and after freeze
drying. The freeze dried paclitaxel-loaded gas-filled liposome samples were reconstituted
with HPLC grade water for the measurement of PSD and PDI. The results indicate mean
± standard deviation of three independent measurements (■ Particle size before
lyophilization; ▲Particle size after lyophilization; ● Folds increase in PDI after
lyophilization).
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Effect of primary drying temperature on PDI after lyophilization of Pac-

Notes. The liposomes were prepared by lipid film hydration extrusion method. The
primary drying of the frozen liposome-sucrose mixture was started at -45ºC or -40ºC. The
PSD was determined before and after freeze drying. The freeze dried paclitaxel-loaded
gas-filled liposome samples were reconstituted with HPLC grade water for the
measurement of PSD and PDI. The results indicate mean ± standard deviation of three
independent measurements (□ Before lyophilization; ■ After lyophilization).
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4.2.2.

Effect of Mannitol Concentration

Mannitol undergoes crystallization from frozen aqueous solutions during the warming
phase of freeze drying [237-239]. Crystallization of mannitol has been shown to play a
critical role in the preparation of echogenic liposomes [206]. The crystallization causes
rupture in the bilayer of liposomes due to which air/gas is entrapped in the liposomes.
Mannitol was included in the formulation to evaluate its effect on the PSD and
echogenicity of paclitaxel-loaded gas-filled liposomes. DSC thermograms showed that
there was a decrease in Tg′ with an increase in mannitol concentration in liposomesucrose mixtures containing poloxamer 188 (Figure 4-7). However, no exothermic peak,
characteristic of crystallization of mannitol was observed at the concentrations studied.
This could be due to the presence of high concentrations of non-crystallizing solute
sucrose in the formulation which minimized the crystallization of mannitol during the
heating phase. The effect of mannitol on the PSD of Pac-LCL before and after
lyophilization is presented in Figure 4-8. An increase in mannitol concentration resulted
in an increase in average diameter of Pac-GFTLCL. Although there was no evidence of
crystallization of mannitol from the DSC thermograms, inclusion of mannitol played a
role in determining the particle size after lyophilization. The particle size distribution was
broader in presence of mannitol as exemplified by an increase in PDI. The examination
of intensity distribution for PSD revealed that formulations containing mannitol have a
bimodal distribution with secondary peak appearing at size greater than 1 µm. In contrast,
a single unimodal distribution was observed in the absence of mannitol. The possible
reasons for the effect of mannitol on the PSD could be due to the crystallization of
mannitol which might have occurred at a level that is not perceivable by DSC
thermograms at the concentrations studied. The effect of crystallization of mannitol
during warming phase of lyophilization of liposomes is well known. It ruptures the
bilayer and thereby increases the entrapment of gas in the bilayer resulting in an increase
in size. Another possibility is that a decrease in the concentration of lyoprotectant sucrose
in the formulation which was adjusted to accommodate mannitol to maintain a constant
lipid-sugar ratio. Adequate concentrations of sucrose was not available to provide
lyoprotectant effect which could have resulted in rupture to the bilayer, increased
entrapment of gas in the bilayer, and an increase in size.
Ultrasound measurements showed that the formulations containing mannitol were
more echogenic than the formulations without mannitol (Figure 4-9). The formulations
prepared with different concentrations of mannitol were comparable with ~50-fold
increase in reflectivity over background. In the absence of mannitol, ~20 fold increase in
reflectivity was observed. The echogenicity of the formulation that contained only
sucrose was similar to that observed with prototype formulation described in Chapter 2
(Figure 2-7) though only a fourth of the concentration was used. This could be attributed
to changes in the lipid concentration, lipid composition, and inclusion of a hydrophobic
drug paclitaxel in the bilayer of the liposomes. Even though the presence of mannitol
contributes to improve acoustic activity of Pac-GFLCL similar to the formulations
described in Chapter 2, its presence has a negative impact on PSD and PDI. Mannitol
containing formulations were slightly larger in size with a broader PDI compared to the
formulation without mannitol. Though the echogenicity was lower with the formulation
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Notes. The liposomes were mixed with equal volume of sucrose solution containing
0.3% w/v poloxamer 188 and different concentrations of mannitol. The samples were
hermetically sealed in aluminum pans, and cooled at the rate of 5°C/min to -70°C. After
equilibration at -70°C, the samples were heated at the rate of 10°C/min to 25°C. A
segment of heating profile is shown in the figure. The heat flow is shown on an arbitrary
scale.
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Notes. The liposomes were prepared by lipid film hydration extrusion method. The
Pac-LCL was mixed with equal volume of sucrose solution containing 0.3% w/v
poloxamer 188 at different concentrations of mannitol. The PSD was determined before
and after freeze drying. The freeze dried paclitaxel-loaded gas-filled liposome samples
were reconstituted with HPLC grade water for the measurement of PSD and PDI. The
results indicate mean ± standard deviation of three independent measurements (■ Particle
size before lyophilization; ▲Particle size after lyophilization; ● Folds increase in PDI
after lyophilization).
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Effect of mannitol concentration on echogenicity of Pac-GFLCL

Notes. The echogenicity was determined in an in vitro model with Philips ATL-HDI
5000 ultrasound system and L12-5 broadband transducer. The Pac-GFLCL samples were
reconstituted with HPLC grade water for the measurement of echogenicity. After
acquiring background images for 5 sec., 50 µL of the sample was added using a syringe,
and the acquisition was continued for up to one minute. The data was processed off-line
with a custom MATLAB program. Three ROIs were randomly selected, and the average
increase in mean grayscale intensity in the ROI from the background was calculated. The
results represent mean ± standard deviation for three samples (Mannitol concentrations
were ■ 0 mM; ▲ 50 mM; ● 100 mM; ♦ 150 mM).
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prepared without mannitol, if the acoustic activity is adequate for visualization and
disintegration, this formulation is expected to have a longer in vivo circulation times due
to smaller size. On the other hand, if the acoustic activity is not adequate for visualization
and disintegration, the mannitol containing formulations can be taken forward with a
slight compromise in their circulation times due to slightly larger size than sucrose
containing formulations. Although mannitol containing formulations have the potential
for further development, we took the formulation without mannitol for further studies to
have better control over the PSD.
4.2.3.

In vitro Leakage Study with Pac-GFTLCL

The release or leakage profile of the reconstituted Pac-GFTLCL is presented in
Figure 4-10. An approximately 7% of the encapsulated paclitaxel was released or leaked
from the Pac-GFTLCL formulation over 72 h period in physiological conditions. These
results indicate that the amount of free paclitaxel available in the systemic circulation can
be minimized by loading paclitaxel in the Pac-GFTLCL and therefore, undesirable
toxicities due to systemic exposure of paclitaxel to normal tissues can be minimized.
4.2.4.

Conjugation Efficiency of cRGD to Maleimide-Pac-LCL

One of the most stable and most efficient conjugation reactions in chemistry, the
formation of covalent thioether bond by the reaction between sulfhydryl group and
maleimide group [172, 242-244] was used for conjugation of cRGD to maleimide DSPEPEG2000 present on the surface of preformed liposomes. The method used to determine
the conjugation efficiency was validated by adding different amounts of cRGD to the
reaction buffer, Pac-LCL, and maleimide-Pac-LCL. The amount of unreacted cRGD was
quantified by the RPHPLC method from the samples digested with absolute ethanol. The
cRGD recovered from the reaction buffer was taken as total unbound. The cRGD
consumed by the Pac-LCL which does not contain the reactive maleimide functional
group was taken as non-specific binding. The amount of cRGD consumed by maleimidePac-LCL after subtracting for non-specific binding was taken as the amount conjugated
to the liposomes. Figure 4-11 shows the amount of cRGD recovered from buffer, PacLCL, and maleimide-Pac-LCL. Almost all of the cRGD added to the reaction buffer was
recovered after the incubation period. There was a decrease in the amount of cRGD
recovered from Pac-LCL. This could be attributed to non-specific charge interactions of
cRGD containing residual positive charge with negatively charged liposomes. The
nonspecific binding was constant and did not change with an increase in the amount of
cRGD added to the liposomes suggesting that it can be saturated. Almost all the cRGD
was consumed in the reaction with maleimide-Pac-LCL when the amount of peptide
added was equivalent to that is needed for the reaction. The amount consumed in the
reaction slightly increased with increasing amounts of cRGD added suggesting the
conjugation efficiency can be increased by adding excess of cRGD peptide. The
unreacted peptide can be removed after the end of the reaction by equilibrium dialysis or
ultrafiltration. Further reactions for conjugation were performed at slightly excess of
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Figure 4-10. In vitro drug leakage study of Pac-GFLCL
Notes. Pac-GFTLCL was reconstituted with HPLC grade water and 3 mL of the
reconstituted sample was dialyzed through 10,000 MWCO Slide-A-Lyzer dialysis
cassettes against pH 7.4 phosphate buffered saline (PBS) containing 0.1 % w/v Tween 80
in a jacketed beaker maintained at 37°C. Samples of 1 mL were withdrawn at specific
intervals for a period 72 hours and analyzed by RPHPLC method. The results indicate
mean ± standard deviation of results from three dialysis cassettes.
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Figure 4-11. Verification of conjugation efficiency of cRGD
Notes. An increasing amount of cRGD was added to a constant volume of PacMaleimide LCL, Pac-LCL, and HEPES buffer pH 6.5, 50 mM. The reaction was
performed in triplicates at three different amounts of cRGD. After the incubation period
of 12 h. at 25ºC for the conjugation reaction, the samples were digested with absolute
ethanol, and the free cRGD remaining was quantified by RPHPLC method. The results
indicate mean ± standard deviation of three reactions (■ Maleimide-Pac-LCL; ▲ PacLCL; ● HEPES buffer pH 6.5, 50 mM).
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cRGD than required for maleimide-Pac-LCL. The Pac-LCL, and the reaction buffers
were used as controls for non-specific binding, and total unbound respectively.
4.2.5.

Characteristics of Pac-RGD-GFTLCL

The Pac-RGD-GFTLCL was prepared using Pac-RGD-TLCL similar to the
procedure for the preparation of Pac-GFLCL. The amount of entrapped paclitaxel in both
the formulations after reconstitution was similar, and was approximately 500 µg/mL with
more than 90% of paclitaxel retained in the liposomes. The particle size of the Pac-RGDGFTLCL was also similar to Pac-GFLCL with an average diameter between 150-200 nm
which is favorable for longer circulation time. These liposomes can escape RES, and also
benefit from passive targeting due to EPR effect. The zeta potential of Pac-GFLCL and
Pac-RGD-GFTLCL was -30.80 ± 6.95 and -35.07 ± 1.55 mV respectively. The zeta
potential values of approximately ~ -30 mV suggest that these vesicles have adequate
repulsive forces for better colloidal stability. The moisture content of the dried cake was
less than 1% w/v. The lyophilized cake exhibited acceptable physical properties with
respect to appearance, cake integrity, cake height vs volume, and ease of reconstitution.
The TEM images showed that both Pac-GFLCL and Pac-RGD-GFTLCL were spherical
in structure (Figure 4-12).
4.2.6.

Visualization and Disintegration of Pac-RGD-GFTLCL with Ultrasound

The ability to visualize and disintegrate the Pac-RGD-GFTLCL with ultrasound was
evaluated using MTV-1 tail vein infusion catheter mounted in a rectangular plexiglass
tank filled with water. The effect of high intensity ultrasound pulses on contrast mean
power in the ROI is shown in Figure 4-13. The Pac-RGD-GFTLCL were visualized with
ultrasound in the catheter which is about 0.2 mm internal diameter suggesting that these
gas-filled liposomes can withstand shearing forces in the blood vessels. With a
continuous flow of the liposomes through the catheter, the disintegration of the gas-filled
liposomes was not perceivable due to rapid reperfusion in the ROI. So, the flow was
stopped for the measurement sequence to determine the effect of high intensity
ultrasound pulses on the Pac-RGD-GFTLCL. The contrast mean power decreased after
application of ultrasound pulses indicating that these liposomes were disintegrated in the
ROI. The contrast mean power increased to baseline within few seconds after application
of high intensity ultrasound pulses due to reperfusion of fresh Pac-RGD-GFTLCL to the
ROI. Even when the flow was stopped, reperfusion occurred which could be attributed to
the Brownian motion of these particles of colloidal nature. We also made attempts to
demonstrate visualization and disintegration of these gas-filled liposomes using
subcutaneous breast cancer model in mice. We experienced difficulties in visualizing
these liposomes in vivo. The loss of signal in the animal model could be the result of
several factors. One reason is the presence of fewer barriers when these gas-filled
liposomes were tested by an in vitro model in which the signals were received by the
transducer with no or minimal attenuation. In contrast, the animal model presents several
barriers that can affect signal to attenuation ratio. The second reason could be the ability
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Figure 4-12. TEM images of Pac-GFLCL (A) and Pac-RGD-GFTLCL (B)
Notes. The samples were prepared by negative staining with uranyl acetate using
sequential two drop technique on formvar coated copper grids. The results are shown at a
magnification of 300,000x.
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Figure 4-13. Disintegration of Pac-RGD-GFTLCL with ultrasound pulses
Notes. The Pac-RGD-GFTLCL was reconstituted with HPLC grade water and drawn
into 1cc syringe. The syringe was connected to infusion catheter and the sample was
slowly injected to fill the catheter. A cine loop sequence was started with high intensity
pulse occurring at 50% of the loop for a duration of 1 sec. The cine loop was processed to
calculated contrast mean power in the ROI.
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of the transducer to resolve these nano-sized liposomes. Interference from the tissue can
make it even more difficult to resolve these liposomes. The third reason could be the
dilution of these liposomes in the blood stream reducing the concentration available at the
target site for visualization. The amount of gas present in each liposome, and the number
of liposomes containing certain amount of gas in a given sample of gas-filled liposomes
can also affect the average intensity received by the transducer. From the formulation
development point of view, the liposomal bilayer should have adequate rigidity to retain
gas in the bilayer in presence of shearing forces and blood pressure experienced in vivo.
The resonant frequency of nano-sized bubbles is in the range of 25-50 MHz [262].
But, the theoretical predictions of resonant frequency are based on assumption that the
bubbles exhibit linear behavior. The predictions of harmonic generation from submicron
ultrasound contrast agents by Zheng et al shows that the nanobubbles of size ~ 200 nm
exhibit non-linear behavior at frequencies relevant to clinical ultrasound instruments
[263]. The same reason also explains the high backscatter obtained in the in vitro
experiments at clinically relevant frequencies. The question of whether or not these gasfilled liposomes can be used to produce cavitation induced effect in vivo with clinical
ultrasound instruments is still debatable. The use of correlation imaging can substantiate
the data and help in demonstrating cavitation induced effects [264]. Nevertheless, these
gas filled liposomes can be used for ultrasound mediated drug delivery, because the
radiation forces can bring these liposomes closer to the cell surface and improve the
chances of uptake by the cells [265, 266].
4.2.7.

Stability of Pac-RGD-GFTLCL

The stability of the Pac-RGD-GFTLCL in 2 cc amber vials was evaluated at 5 ± 3ºC
for three months. The moisture content of the formulation was maintained below 1% w/v
through the evaluation period. The cake retained acceptable physical properties of
appearance, and ease of reconstitution. The entrapped paclitaxel content, percent
paclitaxel retained, PSD, and zeta potential were evaluated in reconstituted samples. The
stability data is presented in Figure 4-14. The Pac-RGD-GFTLCL maintained their size,
charge, and integrity through the evaluation period. Paclitaxel content and percent
paclitaxel retained in the liposomes was within ± 10% of the initial values suggesting that
the formulation has adequate stability.
4.3. SUMMARY AND CONCLUSIONS
The formulation and process parameters in the development of paclitaxel-loaded gasfilled liposomes were identified and optimized. The particle size of the paclitaxel-loaded
liposomes increased more than four-fold after lyophilization. The lipid-sugar ratio played
a key role in controlling the particle size increase during lyophilization in the preparation
of Pac-GFLCL, and the optimum lipid-sugar ratio was found to be 1:7. Inclusion of
mannitol in the formulation caused an increase in PSD, and PDI of the liposomes after
lyophilization. The mannitol containing Pac-GFLCL formulations showed higher
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Figure 4-14. Stability of Pac-RGD-GFTLCL
Notes. The Pac-RGD-GFTLCL was stored at 5 ± 3ºC in 2 cc amber vials. Samples
were withdrawn at specific intervals, and reconstituted with HPLC water and analyzed.
A. For the determination of paclitaxel retention, the samples were subjected to
minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested
with ethanol, and quantified by RPHPLC method. The results indicate the mean ±
standard deviation for three gel columns (▲ Paclitaxel concentration; ■ Percent
paclitaxel retained in the liposomes). B. For PSD, and zeta potential, the results indicate
mean ± standard deviation of three independent measurements. The zeta potential results
at 15, and 30 days indicate a single measurement (● PSD; ♦ Zeta potential).
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echogenicity than the formulation without mannitol. In spite of its positive effect on the
echogenicity, mannitol was excluded from the formulation to have a better control of the
PSD, and to avoid possible decrease in the in vivo circulation time due to slightly larger
size. Nevertheless, mannitol containing formulations also have the potential for future
development for their higher acoustic activity.
We have evaluated an indirect method for determining conjugation efficiency of
cRGD to preformed liposomes containing reactive maleimide functional groups on the
surface. The thioether bond is formed readily by covalent conjugation of sulfhydryl group
and maleimide group. The conjugation can be verified by mass, and nuclear magnetic
resonance spectroscopic methods in the pure form of the conjugate. But, it is difficult to
quantify the conjugation efficiency by these direct methods when the peptide is
conjugated to maleimide functional groups present on the surface of preformed
liposomes. The RPHPCL method can quantify free cRGD, and so we quantified
unreacted cRGD as a measure of conjugation efficiency. We have shown that there is
non-specific binding of cRGD to the liposome surface and it can be saturated. The
conjugation efficiency of cRGD to maleimide-Pac-LCL increased with an increase in the
amount of cRGD added in the reaction. Thus, a slightly excess of cRGD than needed for
the reaction is required to saturate non-specific binding, and to improve conjugation
efficiency.
The Pac-RGD-GFTLCL was similar to Pac-GFLCL in terms of size, charge,
echogenicity, and entrapped paclitaxel content. The Pac-RGD-GFTLCL was stable for
three months at 5 ± 3ºC and maintained size, charge and integrity through the evaluation
period. The in vitro experiments using mouse tail vein infusion catheter showed that PacRGD-GFTLCL can be visualized by ultrasound, and can be disintegrated with high
intensity ultrasound pulses. The paclitaxel-loaded gas-filled targeted liposomes has the
potential for improving the efficacy of the treatment of breast cancer by improving the
uptake of the liposomes due to improved vascular permeability caused by disintegration
using high intensity ultrasound pulses. While localized ultrasound pulses can be used for
improving the therapy of tumors accessible by ultrasound using Pac-RGD-GFTLCL, the
targeted nature of the liposomes can improve the therapy of tumors metastasized to other
tissues and organs not accessible by ultrasound. The unique nature of this parenteral
formulation has the potential to overcome the barriers in chemotherapy of drugs to solid
tumors.
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CHAPTER 5. IN VIVO EVALUATION OF BIODISTRIBUTION AND EFFICACY
OF TUMOR VASCULATURE TARGETED LIPOSOMES AND COMPARISON
OF EFFICACY WITH TUMOR CELL TARGETED LIPOSMES
Cancer is the second leading cause of death in United States [2, 3] with about 1.5
million new cases and more than half-a-million deaths estimated for the year 2009 [4].
Solid tumors account for more than 85 percent of all the cases reported with cancer [5, 6].
Breast cancer is the most commonly diagnosed form of solid tumors and is the second
leading cause of death in western women. About 20-30% women with breast cancers
develop metastatic breast cancers. Paclitaxel, one of the most effective drugs used in
chemotherapy of breast cancer, is a natural product isolated from bark of the Pacific Yew
tree, Taxus brevifolia [8, 9]. It exhibits cytotoxic activity by promoting the assembly of
microtubules from tubulin dimers and stabilizes microtubules by preventing
depolymerization. Paclitaxel is marketed as Taxol® and AbraxaneTM as an adjuvant in the
treatment of node-positive breast cancer or second line treatment of breast cancer after
failure of combination chemotherapy for metastatic disease or relapse within 6 months of
adjuvant chemotherapy. Due to poor aqueous solubility of paclitaxel, Taxol® was
formulated with ethanol and Cremophor®EL. Although the product is diluted before use,
the concentration of Cremophor®EL is high enough to cause serious hypersensitivity
reactions on administration requiring pre-medication with corticosteroids and
antihistamines [15]. AbraxaneTM, albumin-bound nanoparticle formulation of paclitaxel,
addressed solvent related adverse effects of Taxol® and eliminated the need for
premedication with corticosteroids. But, phase III clinical trials in metastatic breast
cancer patients showed higher rates of sensory neuropathy compared to Taxol® treatment
[16]. Apart from the toxicity associated with the formulations, administration of free
paclitaxel itself is associated with systemic toxicities such as myelosuppression, and
peripheral neuropathy [17]. It is imperative to deliver paclitaxel locally to the tumor sites
to minimize the exposure of normal tissues with free paclitaxel, and to reduce systemic
toxicities. Hence, there is a need for an effective drug delivery system for chemotherapy
with paclitaxel to produce cytotoxic concentrations of the drug at the tumor sites without
affecting normal tissues.
Liposomes are biocompatible carriers with ability to incorporate both lipophilic and
hydrophilic drugs [23]. Encapsulating drugs within vesicles has the potential advantage
of higher drug carrying capacity compared to attaching them to single polymer chain
[250]. Preparation of liposomes of paclitaxel can alter the pharmacokinetic and
pharmacodynamic properties of the free drug and result in reduced toxicity and enhanced
efficacy of the treatment [251]. The maximum tolerated dose of paclitaxel has been
shown to increase with the liposomal formulation compared to the administration of
Taxol® [252]. The liposomal formulation of paclitaxel was also effective in minimizing
the percent increase in the tumor size of paclitaxel resistant Colon 26 cancer in mice
[251, 253], suggesting that the development of liposomes can be used a strategy to
overcome drug resistance in cancer. Conventional liposomes are cleared rapidly by the
reticuloendothelial system (RES) comprised of Kupffer cells of the liver, and fixed
macrophages of the spleen [80]. Clearance of liposomes by the RES is directly

102

proportional to the vesicle size [79]. Liposomes of size ~100 nm can escape clearance by
the RES and remain in circulation for a prolonged period of time. In addition, coating the
surface of the liposomes with hydrophilic polymers such as PEG can provide a shielding
effect to the liposomes and prevent recognition and binding of opsonins [88]. Therefore,
these long-circulating liposomes can escape clearance by the RES and remain in
circulation for a longer period of time. If the liposomes remain in circulation for a longer
time, the possibility of their passive accumulation in the tumors by enhanced
permeability and retention (EPR) effect will be improved. Such passive targeting of
liposomes at the tumors does not necessarily elicit an improved therapeutic response
which is dependent on the cellular uptake of the liposomes. Cellular uptake can be
improved by an active targeting approach. Active targeting refers to the attachment of
specific targeting ligands to the therapeutic agent or carrier system to recognize and
interact with the target receptors or proteins at the cellular or tissue components [20, 107,
116]. Although similar biodistribution and tumor accumulation is observed with
liposomes by passive targeting as well as active targeting, an enhanced therapeutic
response is accomplished with active targeting of liposomes directed against specific
receptors due to improved cellular uptake [117, 118].
Endothelial cells within angiogenic blood vessels of solid tumors express several
proteins which are either absent or expressed at very low levels in well developed normal
blood vessels [161-163]. The αvβ3 integrin receptors are highly expressed in actively
proliferating endothelial cells of tumor vasculature and tumor cells [163, 235]. Peptides
with Arg-Gly-Asp (RGD) motif in a cyclic framework have been shown to bind to these
receptors and are effective in targeting solid tumors[172]. By attaching RGD peptide to
the surface of the paclitaxel-loaded liposomes through PEG spacers, paclitaxel can be
delivered specifically at the tumor site minimizing its exposure to normal tissues. An
attractive advantage of targeting tumor vasculature is that the tumor blood vessels are
readily available for targeting than the tumor cells and thus specific targeting can be
achieved.
Iron (Fe) is required in the active sites of the enzyme ribonucleotide reductase during
DNA synthesis [138]. Due to redox activity and its potential to generate reactive oxygen
species (ROS), the amount of free Fe is kept at minimum levels [139]. To control the
amount of unbound Fe, the metal is transported bound specifically to the two high
affinity binding sites of serum glycoprotein, transferrin (Tf). The uptake of Fe by the cells
involves binding of the Fe-loaded Tf to transferrin receptor1 (TfR1) present on the cell
surface. Binding induces receptor mediated endocytosis of Fe-Tf [140]. TfR1 is a
glycoprotein expressed in all nucleated cells at low levels [141]. The density of TfR1 on
the surface of cells is correlated with the extent of cell growth and division, and
consequently, the tumor cells express more TfR1 than normal cells. Thus, the expression
of TfR1 is elevated in proliferating cells which makes these receptors excellent choice for
targeted delivery to cancer [142]. By attaching Tf to the surface of the paclitaxel-loaded
liposomes through PEG spacers and linkers, paclitaxel can be delivered specifically to the
tumor cells over expressing TfR1.
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The objective of this work is to develop paclitaxel-loaded RGD conjugated targeted
long-circulating liposomes (Pac-RGD-TLCL). The biodistribution of these tumor
vasculature targeted liposomes was evaluated by non-invasive near infrared fluorescence
(NIRF) imaging using DiR-loaded RGD conjugated targeted long-circulating liposomes
(DiR-RGD-TLCL) in mouse xenografts bearing MDA-MB-231 breast cancer. The
biodistribution was also verified by quantifying paclitaxel in plasma and tumor tissues 24
hours after the administration of paclitaxel-loaded liposomes. The antitumor efficacy of
these tumor vasculature targeted liposomes were evaluated in comparison to tumor cell
targeted paclitaxel-loaded transferrin conjugated targeted long-circulating liposomes
(Pac-Tf-TLCL).
5.1. MATERIALS AND METHODS
5.1.1.

Materials

Paclitaxel was procured from 21CEC Pharmaceuticals (Bradenton, FL). 1,1′dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide (DiR) was obtained from
Molecular Probes (Eugene, OR). The phospholipids used in this work were all of
research grade. Egg phosphatidylcholine (EPC), hydrogenated soy phosphatidylcholine
(HSPC) and 1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-(poly(ethylene
glycol)2000) (DSPE-PEG2000) were obtained from Northern Lipids (Burnbay, BC,
Canada). 1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-(maleimide poly(ethylene
glycol)2000) (maleimide DSPE-PEG2000) and 1,2-distearoyl-sn-glycero-3phoshoethanolamine-N-(biotinyl poly(ethylene glycol)2000) (biotinyl DSPE-PEG2000)
were obtained from Avanti Polar Lipids (Alabaster, AL). Cyclo (Arg-Gly-Asp-D-PheCys) peptide (cRGD) was obtained from Peptides International (Louisville, KY). Biotin
labeled human transferrin (Tf), cholesterol and α-tocopherol were purchased from Sigma
(St. Louis, MO). Streptavidin was obtained from PROzyme (Hayward, CA). Dulbecco’s
Modified Eagle Medium (D-MEM) with high glucose, heat inactivated fetal bovine
serum (FBS), penicillin-streptomycin (10,000 U/mL Penicillin G, 10,000 µg/mL
streptomycin), and 0.25% Trypsin EDTA were obtained from Invitrogen (Carlsbad, CA).
BD MatrigelTM basement membrane matrix was obtained from BD Biosciences (Bedford,
MA). HPLC grade water, acetonitrile, and methanol were obtained from Fisher Scientific
(Fair Lawn, NJ). HPLC grade chloroform was purchased from Acros Organics (Morris
Plains, NJ). All other chemicals and reagents were of analytical grade and used without
further purification or characterization.
5.1.2.

Cell Culture

MDA-MB-231 human breast cancer cell lines were obtained from American Type
Culture Collection (ATCC, Manassas, VA). The cells were cultured in D-MEM
supplemented with 10% v/v FBS, and 1% v/v antibiotics (100 U/mL of penicillin G and
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100 µg/mL of streptomycin). The cells were maintained in an incubator at 37ºC in a
humidified atmosphere, and 5% carbon dioxide.
5.1.3.
Preparation of Long-Circulating Liposomes Loaded with DiR (DiR LCL)
or Paclitaxel (Pac-LCL)
The DiR LCL or Pac-LCL was be prepared by the lipid film hydration-extrusion
method using EPC, HSPC, DSPE-PEG2000, and cholesterol. The lipid film was prepared
by dissolving DiR or paclitaxel, phospholipids, cholesterol, and α-tocopherol in 9:1
chloroform-methanol. The solution obtained was evaporated in a round bottom flask
using rotary evaporator under reduced pressure at 45°C for 4-6 h. The dry film was
hydrated with 50 mM HEPES buffer pH 6.5 at 65°C for 45-60 minutes. The
multilamellar vesicles (MLVs) thus obtained were sized by extrusion through stacked
polycarbonate membrane filters of varying pore diameters under high pressure to obtain
small unilamellar vesicles (SUVs). The SUVs were characterized for particle size
distribution, zeta potential, and total and entrapped DiR or paclitaxel content. DiR was
quantified by spectrofluorimetry, and paclitaxel was quantified by reversed phase high
performance chromatography (RPHPLC). The liposomes were sterilized by filtration
through 0.22 µm membrane filter in an aseptic environment and stored in light protected
vials at 5 ± 3ºC until further use.
5.1.4.
Preparation of cRGD Conjugated Targeted Long-Circulating Liposomes
Loaded with DiR (DiR-RGD-TLCL) or Paclitaxel (Pac-RGD-TLCL)
For the preparation of DiR-RGD-TLCL or Pac-RGD-TLCL, a part (0.5 moles %) of
DSPE-PEG2000 was replaced with maleimide DSPE-PEG2000 and the liposomes were
prepared as described in section 5.1.3 to obtain SUVs with reactive maleimide functional
groups. The maleimide-DiR-LCL or maleimide-Pac-LCL thus obtained was conjugated
with cRGD peptide by incubation at 25°C for 12 h. The reaction was quenched by the
addition of 2-mercaptoethanol to block free maleimide. The unconjugated peptide and 2mercaptoethanol remaining in reaction mixture were removed from the liposomes by
equilibrium dialysis through 10,000 MWCO Slide-A-Lyzer dialysis cassettes (Thermo
Fisher Scientific, Rockford, IL) against 50 mM HEPES buffer pH 6.5 at 5 ± 3°C
overnight. The liposomes were sterilized by filtration through 0.22 µm membrane filter in
an aseptic environment and stored in light protected vials at 5 ± 3ºC until further use.
5.1.5.
Preparation of Paclitaxel-Loaded Transferrin Conjugated Targeted LongCirculating Liposomes (Pac-Tf-TLCL)
For the preparation of Pac-Tf-TLCL, a part (0.01 moles %) of DSPE-PEG2000 was
replaced with biotinylated DSPE-PEG2000 and the liposomes were prepared similar to
5.1.3 using phosphate buffered saline pH 7.2 (PBS) instead of HEPES buffer. Transferrin
was non-covalently conjugated to biotin on the distal end of the PEG spacers of the
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biotinylated SUVs using the procedure established in our laboratory [159]. Briefly,
streptavidin was dissolved in PBS to prepare a 2 nM solution. To the streptavidin solution
in a scintillation vial, biotinylated liposomes was added, and mixed. The reaction mixture
was incubated at 25ºC for 30 min, and the free streptavidin was removed by ultrafiltration
using Centricon 100 centrifugal filter device (100 KD MWCO, Millipore, Bedford, MA)
at 5000 g for 30 min to obtain purified streptavidin conjugated long-circulating liposomes
(SALCL). Biotin labeled human transferrin was dissolved in PBS (2 nM) and added to
the SALCL, incubated at 25ºC for 30 min, and the free transferrin was removed by
ultrafiltration. The liposomes were sterilized by filtration through 0.22 µm membrane
filter in an aseptic environment and stored in light protected vials at 5 ± 3ºC until further
use.
5.1.6.

Characterization of Liposomes

The average diameter (Z-avg) of the liposomes was determined using dynamic light
scattering using Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped
with 4.5 mW diode laser as a source of light operating at 670 nm. Particle scattered
photons were detected at an angle of 173°. The samples were suitably diluted with HPLC
grade water for the determination of Z-avg. Three independent measurements were
performed for each sample. Zeta potential was determined from electrophoretic mobility
using samples suitably diluted with HPLC grade water.
The loading efficiency of DiR or paclitaxel in the liposomes was determined by
minicolumn centrifugation method using Sephadex G-25 macro spin columns (Harvard
apparatus, Holliston, MA) similar to the method described by Zhang et al [249] with
modifications. Briefly, the Sephadex G-25 particles in the column were suspended in
0.1% w/v TFA and were allowed to swell for 15 minutes. The columns were centrifuged
at 1500 g at 25°C for 4 min using IEC CL31R Multispeed Centrifuge (Thermo Scientific,
Asheville, NC) to remove TFA. About 100 µL of placebo LCL was added and
centrifuged to saturate the column. The column saturation with placebo liposomes was
repeated for a total of three times. The gel columns were placed in fresh collection tubes
for use with drug-loaded liposomes. The liposome samples for analysis were diluted with
the dispersion medium of the liposomes. About 100 µL of the diluted sample was added
to the gel column, and centrifuged for 4 minutes. The eluate in the collection tube,
containing only entrapped DiR or paclitaxel was analyzed by spectrofluorimetry or
RPHPLC respectively. The total DiR or paclitaxel in the liposomes was determined form
samples before passing through Sephadex G-25 columns. For quantification of DiR, the
liposomes were digested with 70% isopropanol and the concentration of DiR was
determined in 96 well black non transparent microplates by spectrofluorimetry using
SpectraMax M2e Microplate/Cuvette Reader (Molecular Devices, Sunnyvale, CA) at the
excitation wavelength of 750 nm and the emission wavelength of 780 nm. For
quantification of paclitaxel, the liposomes were digested with absolute ethanol, and
suitably diluted before injection to the HPLC system. The HPLC system comprised of
Waters 600 Controller, Waters 717 Plus Autosampler, and Waters 2996 Photodiode
Array Detector (Waters Corporation, Milford, MA) was used. The RPHPLC analysis was
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performed using a Nova-Pak C18 column (3.9 x 150 mm, 4 µm) (Waters Corporation,
Milford, MA). An isocratic elution was performed using acetonitrile-water in a ratio 55:
45 v/v at a flow rate of 1 mL/min, and detection wavelength of 230 nm. The
encapsulation efficiency for DiR or paclitaxel was calculated using the formula,
Entrapment efficiency = (Entrapped DiR or paclitaxel x 100)/Total DiR or paclitaxel).
5.1.7.

Stability Evaluation of Pac-RGD-TLCL and Pac-Tf-TLCL

Stability of Pac-RGD-LCL and Pac-Tf-TLCL was evaluated in 2 cc amber glass vials
at 5 ± 3ºC for three months. Samples were withdrawn at specific intervals and analyzed
for total and entrapped paclitaxel, entrapment efficiency, PSD, and zeta potential.
5.1.8.

Breast Cancer Mouse Xenograft Model

The animal studies were conducted in accordance with the protocols approved by the
Institutional Animal Care and Use Committee (IACUC) of The University of Tennessee
Health Science Center, Memphis, TN. Female athymic nude mice (Harlan Laboratories,
Indianapolis, IN) of 5-6 weeks age were used for the development of human breast
cancer xenograft model. The MDA-MB-231 cells were detached from approximately
90% confluent cultures by brief exposure to 0.25% trypsin EDTA. The harvested cells
were washed, and suspended in serum free D-MEM. The cell viability was verified by
trypan blue dye exclusion method, and the viable cell count was recorded. The cell
suspension was centrifuged and the cell pellet was resuspended in serum free D-MEM to
get ~5 x 106 cells in 0.1 mL. The resulting cell suspension was mixed with equal volume
of cold MatrigelTM and mixed well. The mice were anesthetized with isoflurane prior to
tumor inoculation, and 0.2 mL of the cell suspension-MatrigelTM mixture was injected
subcutaneously into the breast tissue of each mouse in the right axillary region. The
tumor size was measured with calipers twice a week, and the tumor volume was
calculated using the formula V = 0.5ab2 (V - tumor volume; a - largest diameter; b smallest diameter).
5.1.9.
Evaluation of Biodistribution of Tumor Vasculature Targeted Liposomes
by Near Infrared Fluorescence (NIRF) Imaging
To evaluate the localization of the tumor vasculature targeted cRGD conjugated
liposomes, athymic nude mice bearing MDA-MB-231 breast cancer in the axillary region
were used. The tumors were allowed to grow up to 200 mm3 to initiate the study. The
animals were randomly divided into four groups of five mice each. The animals were
anesthetized with isoflurane, and DiR Solution formulation (Prepared by dissolving DiR
in 50: 50 Cremophor® ELP and Ethanol, and the resulting formulation was diluted to four
times with normal saline prior to administration), DiR LCL, and DiR-RGD-TLCL
containing 5 µg of DiR in ~ 50 µL of the formulation, and normal saline as control was
injected by retro-orbital injection. The animals were anesthetized with isoflurane and the
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whole body optical imaging was performed at 1, 4, 8, 24, 48, and 72 h using Xenogen
IVIS® Lumina imaging system (Caliper LifeSciences, Hopkinton, MA). The excitation
wavelength was 745 nm and the emission wavelength was 780 nm. The animals were
maintained under isoflurane anesthesia by Xenogen X91-8 Gas Anesthesia System
(Caliper LifeSciences, Hopkinton, MA) during the measurement. The fluorescence
intensity in the region of interest (ROI) was calculated in tumor, peritoneal cavity, and
flank tissue using Living Image® 3.2 Software (Caliper LifeSciences, Hopkinton, MA).
The pixel intensity of the dye in tumor was compared to the intensity in the surrounding
normal tissues as a measure of the concentration in the circulation. Tumor to normal
tissue (T/N) accumulation ratio was calculated to estimate the tumor targeting index as a
measure of localization of liposomes in the tumors. The mice were euthanized after 72
hours. The tumor, liver, and spleen were isolated and the images of the isolated organs
were acquired.
5.1.10. Evaluation of Biodistribution of Paclitaxel from Tumor Vasculature
Targeted Liposomes
To evaluate the effect of size, and tumor vasculature targeting on biodistribution of
paclitaxel from liposomes, athymic nude mice bearing MDA-MB-231 breast cancer in
the axillary region were used. The tumors were allowed to grow up to 200 mm3 to initiate
the study. The animals were randomly divided into four groups of three mice each. The
animals were anesthetized with isoflurane, and paclitaxel solution formulation (Prepared
by dissolving paclitaxel in 50: 50 Cremophor® ELP and Ethanol, and the resulting
formulation was diluted to four times with normal saline prior to administration), PacLCL (160 nm), and Pac-RGD-TLCL (160 nm), and Pac-RGD-TLCL (80 nm) containing
at a total paclitaxel dose of 7.5 mg/kg was injected by retro-orbital injection. After 24 h,
the blood samples were collected by retro-orbital bleeding under anesthesia. The animals
were euthanized and tumor tissues were collected, washed with normal saline and stored
at -20ºC until analyzed. Plasma was separated from blood by centrifugation and stored at
-20ºC until analyzed. The paclitaxel content from the plasma and tumor tissues were
quantified by the RPHPLC method similar to the method described by Yang et al [260]
with slight modifications. The paclitaxel from plasma was extracted by vortexing 50 µL
of plasma with 2 mL of ethyl acetate. The mixture was centrifuged for 5 minutes at 3000
rpm. The supernatant was collected, and the extraction was repeated with another 2 mL
of ethyl acetate. The supernatants containing paclitaxel were pooled and evaporated in a
fume hood to dryness. The residue was dissolved in absolute ethanol, centrifuged for 5
minutes at 3000 rpm and the supernatant containing paclitaxel was analyzed by the
RPHPLC method described in 5.1.6. For quantification of tissue paclitaxel, the tumor
tissues were homogenized in 2 mL of Dulbecco’s phosphate buffered saline (DPBS)
using Omni International 2000 tissue homogenizer (Omni International, Kennesaw, GA).
The homogenate was extracted twice with 2-3 mL of ethyl acetate as described for
plasma samples. The ethyl acetate fractions were combined and evaporated to dryness.
The residue was dissolved in absolute ethanol, centrifuged for 5 minutes at 3000 rpm and
the supernatant containing paclitaxel was analyzed by the RPHPLC method described in
5.1.6.
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5.1.11. Evaluation of Antitumor Efficacy of Paclitaxel-Loaded Tumor
Vasculature Targeted Liposomes and Tumor Cell Targeted Liposomes
The antitumor efficacy of tumor vasculature targeted Pac-RGD-TLCL and tumor cell
targeted Pac-Tf-TLCL was evaluated in athymic nude mice bearing MDA-MB-231 breast
cancer in the axillary region. The tumors were allowed to grow up to 100-200 mm3 to
initiate the study. The tumor bearing animals were randomly divided into five groups of
five mice each. The treatment groups were normal saline (100 µL) as a control to
evaluate the effect of no treatment, paclitaxel solution formulation (Prepared by
dissolving paclitaxel in 50: 50 Cremophor® ELP and Ethanol, and the resulting
formulation was diluted to four times with normal saline prior to administration) to
evaluate the effect of Taxol® formulation as treatment, Pac-LCL formulation to evaluate
the effect of passive targeting, Pac-RGD-TLCL to evaluate the effect of tumor
vasculature targeting, and Pac-Tf-TLCL to evaluate the effect of tumor cell targeting. The
animals were anesthetized with isoflurane and the formulations were injected by retroorbital injection at a paclitaxel dose of 7.5 mg/kg on 8. 11, and 14 days post tumor
inoculation. The effect on tumor size was monitored for six weeks. The animals were
euthanized when tumors reached 20 mm in diameter.
5.1.12.

Statistical Analysis

The statistical analysis was performed by one-way analysis of variance (ANOVA) for
paclitaxel tissue distribution study, and two-way ANOVA for NIRF imaging study and
antitumor efficacy study using GraphPad Prism 3.0 Software (GraphPad Software, La
Jolla, CA). Bonferroni post test analysis was performed to compare between the
treatment groups. The results with p < 0.05 were accepted as statistically significant.
5.2. RESULTS AND DISCUSSION
5.2.1.

Characterization of the Liposomal Formulations

The characteristics of paclitaxel-loaded liposomal formulations are presented in
Table 5-1. The paclitaxel loading in these formulations were between 1.0 to 1.2 mg/mL
with entrapment efficiency greater than 90%. The liposomal paclitaxel concentration thus
achieved allowed dosing volumes similar to paclitaxel solution formulation (Taxol®)
which is equivalent to 1.5 mg/mL when diluted with normal saline. The higher
entrapment efficiency minimizes the amount of free drug in the formulation which will
help minimize the systemic toxicities associated with the administration of free drug and
its exposure to normal tissues. The vesicle size of these liposomes was within 100 ± 20
nm indicating that they can escape clearance by the RES. The PEG coating on the surface
of these liposomes forms a hydrophilic coating on the surface which can prevent the
binding of opsonins to the surface and thereby prevent recognition by the RES. Due to
combined effect of size and PEG coating, these liposomes can remain in circulation
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Table 5-1.

Characteristics of paclitaxel-loaded liposomes

Property of liposomes
Total paclitaxela (µg/mL)
Entrapped paclitaxelb (µg/mL)
Entrapment efficiencyc
Z-Averaged (nm)
Zeta Potentiale (mV)

Pac-LCL
1249.12 ± 1.16
1153.21 ± 2.41
92.32
86.40 ± 0.77
-24.17 ± 1.00

Formulation
Pac-RGD-TLCL
1165.75 ± 1.89
1073.36 ± 0.65
92.07
91.29 ± 0.19
-27.87 ± 2.52

Pac-Tf-TLCL
1153.32 ± 1.91
1085.29 ± 4.42
94.10
108.27 ± 0.28
-11.53 ± 0.51

a

The liposomes were digested with absolute ethanol and the concentration was
determined by RPHPLC method. The results indicate mean ± standard deviation of three
injections.

b

The liposomes were subjected to minicolumn centrifugation in Sephadex G-25 macro
spin columns to separate free paclitaxel from total paclitaxel. The eluate containing
entrapped paclitaxel was digested with ethanol, and quantified by RPHPLC method. The
results indicate mean ± standard deviation of three injections.

c

The entrapment efficiency was calculated from the formula, Entrapment efficiency =
(Entrapped paclitaxel x 100)/Total paclitaxel.

d

The samples were suitably diluted with HPLC grade water and measurements were
made using dynamic light scattering method. The results indicate mean ± standard
deviation of three measurements.

e

The samples were suitably diluted with HPLC grade water and measurements were
made from electrophoretic mobility. The results indicate mean ± standard deviation of
three measurements.
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for a longer time. The leaky nature of the tumor vessels and compromised lymphatic
drainage together with long circulation property of these liposomes can improve the
passive uptake of these liposomes in the tumor by the EPR effect. The liposomes have a
slight negative charge which can improve the colloidal stability.
5.2.2.

Stability of Paclitaxel-Loaded Targeted Liposomes

The stability of the Pac-RGD-TLCL and Pac-Tf-TLCL dispersions was evaluated at 5
± 3ºC in light protected container for three months. The stability data presented in
Figures 5-1 and 5-2 shows that the liposomes maintained their size, charge, and integrity
through the evaluation period. A similar trend of slight decrease in entrapped paclitaxel
was observed with both targeted liposomes the first few days. This could be attributed to
partitioning of the drug form the bilayer of liposomes to the dispersion medium to
maintain equilibrium. Once the equilibrium is reached, the paclitaxel retention remained
constant. The conjugation with either cRGD or transferrin did not affect the stability of
the liposomes. The stability data is consistent with non targeted Pac-LCL formulation
presented in Chapter 3.
5.2.3.

Near Infrared Fluorescence Imaging

Near infrared fluorescence (NIRF) imaging is a non-invasive whole body imaging
technique that can offer valuable information on biodistribution and tumor targeting
ability [267, 268]. NIRF imaging techniques are cost effective, have high detection
sensitivity, and use non-ionizing radiation [269, 270]. Imaging performed at the NIR
region can also minimize auto fluorescent signal of tissue which increases at wavelengths
less than 600 nm. Inclusion of a fluorescent dye that can be imaged by NIRF imaging in
the bilayer of liposomes will allow direct visualization of kinetics and localization of the
liposomes in a non-invasive manner. So, DiR, a lipophilic carbocyanine dye was loaded
in the bilayer of LCL and RGD-TLCL to evaluate the biodistribution of these liposomes
in mouse xenografts bearing breast cancer. The DiR-LCL, and DiR-RGD-TLCL were of
the size 88.30 ± 1.21 nm, and 86.45 ± 0.33 nm respectively. The zeta potential of DiRLCL, and DiR-RGD-TLCL were -25.63 ± 0.57 mV, and -26.73 ± 0.76 mV respectively.
These liposomes were similar to paclitaxel-loaded liposomes in size, charge, and
composition. The in vivo circulation of these DiR-loaded liposomes are expected to
represent the fate of paclitaxel-loaded liposomes. Since NIRF imaging is non-invasive in
nature, localization of the liposomes in the tumor tissues can be determined at several
time points in the same animal without the need sacrifice the animal. The kinetic data
thus obtained can be extrapolated to determine the fate of paclitaxel-loaded liposomes
with the assumption that DiR and paclitaxel-loaded liposomes behave in a similar
manner. In this study, DiR-loaded liposomal formulations were compared with DiR
micellar solution formulation as a positive control, and normal saline as a negative
control. Representative images from each group at different time points are presented in
Figure 5-3. The DiR solution formulation showed maximum accumulation in the tumor
within 8 h of administration and the intensity decreased with time till 72 h time point.
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Stability data for Pac-RGD-TLCL dispersion

Notes. The liposomes were stored at 5 ± 3ºC in 2 cc amber vials. Samples were
withdrawn at specific intervals and analyzed for paclitaxel retention, PSD, and zeta
potential. A. For the determination of paclitaxel retention, the samples were subjected to
minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested
with ethanol, and quantified by RPHPLC method. The results indicate the mean ±
standard deviation for three injections (▲ Paclitaxel concentration; ■ Percent paclitaxel
retained in the liposome). B. PSD and zeta potential was determined in samples suitably
diluted with HPLC grade water. The results indicate mean ± standard deviation of three
independent measurements (● PSD; ♦ Zeta potential).
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Figure 5-2. Stability data for Pac-Tf-TLCL dispersion
Notes. The liposomes were stored at 5 ± 3ºC in 2 cc amber vials. Samples were
withdrawn at specific intervals and analyzed for paclitaxel retention, PSD, and zeta
potential. A. For the determination of paclitaxel retention, the samples were subjected to
minicolumn centrifugation in Sephadex G-25 macro spin columns to separate free
paclitaxel from total paclitaxel. The eluate containing entrapped paclitaxel was digested
with ethanol, and quantified by RPHPLC method. The results indicate the mean ±
standard deviation for three injections (▲ Paclitaxel concentration; ■ Percent paclitaxel
retained in the liposome). B. PSD and zeta potential was determined in samples suitably
diluted with HPLC grade water. The results indicate mean ± standard deviation of three
independent measurements (● PSD; ♦ Zeta potential).
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Figure 5-3. Representative NIRF images of localization of DiR formulations in mice
bearing MDA-MB-231 breast cancer
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in
the axillary region of female athymic nude mice. The animals received 50 µL of normal
saline (A), 5 µg of DiR in ~ 50 µL of micellar solution formulation (B), or LCL
formulation (C) or RGD-TLCL formulation (D). NIRF images were acquired at 1, 4, 8,
24, 48, and 72 hours using Xenogen IVIS® Lumina imaging system with excitation and
emission wavelengths of 745 nm and 780 nm respectively. The images from
representative animal in each treatment group are presented.
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The liposome formulations showed gradual increase in accumulation in the tumors and
reached the maximum intensity in 24-48 hours. DiR fluorescent intensity from the
liposomal formulations in the tumor tissue was observed up to 72 h and was higher
compared to DiR solution formulation. DiR fluorescence intensity was also higher in the
abdominal region of the mice which received liposomal formulations. This could be due
to clearance of the liposomal particles by the Kupffer cells of liver and fixed
macrophages of spleen. The uptake in the liver and spleen for DiR-RGD-TLCL was
higher compared to DiR-LCL or DiR solution formulation and was more clearly evident
in the images acquired with isolated tissues (Figure 5-4).
The fluorescence intensity of DiR was calculated in tumor tissue and normal tissue
selected as the region of interest. These ROI measurement results can be expressed in
terms of photon emission from the subject or radiance. The radiance unit of
photons/sec/cm2/sr is the number of photons per second that leave a square centimeter of
tissue and radiate into a solid angle of one steradian (sr). The measurement of units of
radiance takes into account measurement settings like F/stop, binning, and field of view.
The images acquired in the same session with the same animal with different camera
settings will produce same signal amplitude because the photon emission of the animal
remains the same. On the other hand, the fluorescent signal detected from the animal
depends on the amount of fluorophore present in the animal and the intensity of the
incident excitation light. But, the excitation light incident on the animal stage is not
uniform over the field of view. The amount of fluorophore being constant, the
fluorescence emission image needs to be normalized to incident excitation intensity. The
user manual for Living Image® 3.2 software (Caliper Life Sciences, Hopkinton, MA)
suggests that calculating fluorescent image data in terms of efficiency (Efficiency =
Radiance of the subject/Illumination intensity) can eliminate the variable excitation light
from the measurement and enable a more quantitative comparison of fluorescent signals.
Normalizing all the variables in the measurement is important for the kinetic
measurements because the amount of DiR remaining in the animal can vary with time
which can be quantitatively monitored even if the measurements were made at different
camera settings, and differing intensity of light.
The total efficiency data with tumor selected as the region of interest is presented in
Figure 5-5. The total efficiency for the solution formulation increased steadily up to 8 h
and then decreased until 72 h. The DiR-LCL formulation showed a biphasic distribution
with an increase in the initial 4 h of administration, a decrease from 4-8 h, and then a
steady increase to a maximum in 48 h. The total efficiency in the tumor was maintained
for 72 h. The DiR-RGD-TLCL formulation also showed similar kinetics but the total
efficiency was lower compared to DiR-LCL. Bonferroni post test analysis of two-way
ANOVA showed that all the DiR containing formulations were statistically significant (p
< 0.01) from normal saline control. At 48 h time point, the total efficiency of DiR-LCL
was significantly higher (p < 0.001) than DiR-RGD-TLCL, and DiR micellar solution
formulation. But, the total efficiency of DiR-RGD-TLCL was not significantly different
from DiR micellar solution formulation. The total efficiency in the flank region to
represent the concentration of DiR in the circulation is presented in Figure 5-6. The total
efficiency in the normal tissue decreased with time. The normal tissue accumulation
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Figure 5-4. NIRF images of tissues isolated 72 h post injection showing the
accumulation of DiR in tumor, liver, and spleen
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in
the axillary region of female athymic nude mice. The animals received 5 µg of DiR in ~
50 µL of micellar solution formulation or LCL formulation or RGD-TLCL formulation.
The animals were sacrificed after 72 hours and the tissues were isolated. NIRF images
were acquired using Xenogen IVIS® Lumina imaging system with excitation and
emission wavelengths of 745 nm and 780 nm respectively. The representative images of
tissues from the animals shown in Figure 5-3 for each of the DiR treatment group are
shown.
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Figure 5-5. Localization of DiR-loaded liposomal formulations in tumor tissue
calculated from NIRF imaging
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in
the axillary region of female athymic nude mice. The animals received 50 µL of normal
saline (■), 5 µg of DiR in ~ 50 µL of micellar solution formulation (▲), or LCL
formulation (●) or RGD-TLCL formulation (♦). NIRF images were acquired at 1, 4, 8,
24, 48, and 72 hours using Xenogen IVIS® Lumina imaging system with excitation and
emission wavelengths of 745 nm and 780 nm respectively. The total efficiency was
calculated in tumor selected as region of interest. The results indicate mean ± SEM of
ROI measurements from five animals.
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Figure 5-6. Localization of DiR formulations in the flank region to represent the
concentration in the circulation
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in
the axillary region of female athymic nude mice. The animals received 50 µL of normal
saline (■), 5 µg of DiR in ~ 50 µL of micellar solution formulation (▲), or LCL
formulation (●) or RGD-TLCL formulation (♦). NIRF images were acquired at 1, 4, 8,
24, 48, and 72 hours using Xenogen IVIS® Lumina imaging system with excitation and
emission wavelengths of 745 nm and 780 nm respectively. The total efficiency was
calculated in flank region to represent normal tissue and the concentration in circulation.
The results indicate mean ± SEM of ROI measurements from five animals.
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followed a similar trend as tumor accumulation with lower levels of DiR micellar
solution formulations from 24-48 hours. DiR-LCL showed higher normal tissue levels
than DiR-RGD-TLCL at 48 h.
The targeting with cRGD peptide is expected to improve the accumulation of the
liposomes due to receptor mediated endocytosis. But, the tumor accumulation of DiRRGD-TLCL was lower than DiR-LCL in this animal model. The size and charge of these
two liposomes were similar and should exhibit similar longer circulation properties.
Thus, the accumulation of Dir-RGD-TLCL should be at least similar to DiR-LCL
because of passive accumulation of the liposomes at the tumor due to EPR effect. In
contrast, the presence of RGD peptide on the surface of these targeted liposomes
increased opsonization and macrophage uptake as shown by their increased accumulation
in the liver and spleen. The total efficiency in the peritoneal cavity comprised of liver and
spleen which are the major organs of clearance of liposomes was higher for DiR-RGDTLCL compared to DiR-LCL and DiR solution formulation (Figure 5-7). The
accumulation of DiR-RGD-TLCL in the peritoneal cavity was significantly higher (p <
0.001) than DiR-LCL at 1, 24, 48, and 72 h imaging time points. Their accumulation was
also significantly higher (p < 0.001) than DiR solution formulation at all imaging time
points studied. The DiR-LCL formulation also showed higher accumulation than DiR
solution formulation at 8 h (p < 0.05), 24 h (p < 0.001), and 48 h (p < 0.01) imaging time
points. The higher clearance of targeted liposomes resulted in lower blood levels as
shown by the measurements from normal tissue which in turn lead to a reduced
accumulation in the tumors. The results were similar to literature report measuring the
concentration of radio labeled RGD conjugated liposomes in murine C26 colon
carcinoma model [166]. The RGD conjugated liposomes showed lower blood levels, and
an increased accumulation in spleen and liver compared to non conjugated liposomes.
The expression of αvβ3 integrin receptors by the mononuclear cells in the spleen was
suggested as a mechanism of splenic uptake of these liposomes by phagocytosis. The
lower accumulation in the tumor could also be due to the limited effect on tumors with
pre-established vasculature because integrins are not expressed in the interior parts of the
tumor.
The total efficiency of tumor tissue was compared to the total efficiency on normal
tissue calculated from the flank as the region of interest. The tumor/normal tissue (T/N)
ratio was calculated as a measure of tumor targeting index and is presented in Figure 5-8.
The T/N ratio increased for all the DiR containing formulations to more than 20 within 8
h of dosing and continued to increase for all the formulations. Even though DiR-LCL
showed higher accumulation in the tumor compared to DiR-RGD-TLCL, and DiR
solution formulation, there was no significant difference was observed in the T/N ratio of
these DiR formulations. It can be explained based on the fact the total efficiency
decreases in the normal tissue with time due to clearance. The decrease is greater for the
formulations cleared rapidly from the circulation. Since T/N ratio takes the difference in
total efficiency between tumor and normal tissue in to the calculation, the absolute
difference at the extent of accumulation is not taken in to account. Since T/N ratio is a
relative measure showing the extent of accumulation in the tumor versus normal tissue,
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Figure 5-7. Localization of DiR formulations in peritoneal cavity to represent uptake
in liver and spleen
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in
the axillary region of female athymic nude mice. The animals received 50 µL of normal
saline (■), 5 µg of DiR in ~ 50 µL of micellar solution formulation (▲), or LCL
formulation (●) or RGD-TLCL formulation (♦). NIRF images were acquired at 1, 4, 8,
24, 48, and 72 hours using Xenogen IVIS® Lumina imaging system with excitation and
emission wavelengths of 745 nm and 780 nm respectively. The total efficiency was
calculated in peritoneal cavity to represent the uptake in liver and spleen. The results
indicate mean ± SEM of ROI measurements from five animals.
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Tumor/normal tissue ratio of DiR formulations calculated from NIRF

Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in
the axillary region of female athymic nude mice. The animals received 50 µL of normal
saline (■), 5 µg of DiR in ~ 50 µL of micellar solution formulation (▲), or LCL
formulation (●) or RGD-TLCL formulation (♦). NIRF images were acquired at 1, 4, 8,
24, 48, and 72 hours using Xenogen IVIS® Lumina imaging system with excitation and
emission wavelengths of 745 nm and 780 nm respectively. The tumor/normal tissue ratio
was calculated from the ROI selected for tumor and flank tissue respectively. The results
indicate mean ± SEM of ROI measurements from five animals.
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it can only be used as a guide, and the absolute total efficiency needs to be considered for
comparison between the formulations.
5.2.4.
Quantification of Paclitaxel from Plasma and Tumor Tissues to Determine
Biodistribution of Paclitaxel-Loaded Liposomes
The biodistribution was evaluated for paclitaxel micellar solution formulation, PacLCL and Pac-RGD-TLCL in mouse xenografts bearing MDA-MB-231 breast cancer by
quantifying paclitaxel in plasma and tumor. The size of the liposomal formulation was
also varied to estimate the effect of size on plasma and tumor levels. The results are
presented in Figure 5-9. Paclitaxel levels in plasma 24 h after dosing shows that there
was no significant difference between paclitaxel solution formulation and the liposomal
formulations of size ~ 160 nm. But, the liposomes of size ~ 80 nm showed significantly
higher (p < 0.001) plasma levels compared to solution formulation and liposomes of size
~ 160 nm. The tumor accumulation of ~ 160 nm liposomes was less than solution
formulation at 24 hours post injection. But the Pac-RGD-TLCL showed significantly
higher accumulation (p < 0.001) in the tumor compared to paclitaxel solution
formulation, and Pac-LCL and Pac-RGD-TLCL of ~ 160 nm diameter. These results
indicate that the effect of conjugation with RGD was not perceivable when the liposome
size was ~ 160 nm. However, a significant effect of size was observed in plasma levels as
well as tumor accumulation levels for paclitaxel from liposomes when the size was
reduced to ~ 80 nm. The results were consistent with NIRF imaging results with similar
blood levels and tumor accumulation for non-targeted and targeted liposomes at 24 hours
post injection.
5.2.5.
Antitumor Efficacy of Tumor Vasculature and Tumor Cell Targeted
Liposomes
The antitumor efficacy of paclitaxel formulations was evaluated in mouse xenografts
bearing MDA-MB-231 breast cancer in the axillary region. Tumor vasculature targeted
RGD conjugated liposomes did not show better accumulation than non-targeted
liposomes in the biodistribution studies. So, another group of animals was included in the
antitumor efficacy study to compare the efficacy of these tumor vasculature targeted
liposomes with tumor cell targeted liposomes. Since TfR1 receptors are expressed by the
tumor cells, targeting with transferrin attached to the surface of paclitaxel-loaded
liposomes is expected to improve the efficacy of the treatment by receptor mediated
endocytosis of the tumor cells. Figure 5-10 shows the effect of different formulations on
tumor volumes measured twice weekly for six weeks. The statistical analysis was
performed using two-way ANOVA with data up to 39 days post tumor inoculation
because all the animals in normal saline control group reached euthanasia criteria of
tumor size greater than 2 cm in diameter, and were sacrificed. Bonferroni post test
comparisons between treatment groups showed that all the paclitaxel treatment groups
significantly (p < 0.001) reduced tumor volume at 39 days post tumor inoculation
compared to normal saline control group. The tumor cell targeted Pac-Tf-TLCL showed
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Figure 5-9. Biodistribution of paclitaxel formulations in plasma (A), and tumor (B) of
mouse xenografts bearing MDA-MB-231 breast cancer
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in
the axillary region of female athymic nude mice. The animals received 7.5 mg/kg of
paclitaxel in solution formulation or Pac-LCL, 160 nm or Pac-RGD-TLCL, 160 nm or
Pac-RGD-TLCL, 80 nm. Blood samples were collected after 24 hours of dosing. The
animals were sacrificed and tumor tissues were collected. The concentration of paclitaxel
in plasma and tumor tissues was determined by the RPHPLC. The results indicate mean ±
standard deviation of samples from three animals. In A, *** is p < 0.001 for Pac-RGDTLCL (~ 80 nm) versus all other formulations. In B, ** is p < 0.01 for Pac-Solution
formulation versus Pac-LCL and Pac-RGD-TLCL of size ~ 160 nm, and *** is p < 0.001
for Pac-RGD-TLCL (~ 80 nm) versus all the other formulations.
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Figure 5-10. Antitumor efficacy of paclitaxel formulations in mouse xenografts bearing
MDA-MB-231 breast cancer
Notes. MDA-MB-231 cells were inoculated subcutaneously into the breast tissue in
the axillary region of female athymic nude mice. The animals received 100 µL of normal
saline as control (■) or 7.5 mg/kg of paclitaxel in solution formulation (▲) or Pac-LCL
(●), or Pac-RGD-TLCL (♦) or Pac-Tf-TLCL (▼) on 8, 11, and 14 days post tumor
inoculation (indicated by arrows). The tumor diameters were measured twice weekly and
the tumor volume was calculated. The results indicate mean ± SEM of results calculated
from five animals.
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highest efficacy in tumor regression and was significantly (p < 0.001) higher than
paclitaxel solution formulation, Pac-LCL, and Pac-RGD-TLCL. In contrast, the tumor
vasculature targeted Pac-RGD-TLCL did not show a significant reduction in tumor
volume compared to paclitaxel solution formulation, and Pac-LCL. The observations in
the antitumor efficacy study for Pac-RGD-TLCL was similar to the observations from the
biodistribution studies with NIRF imaging and quantification of paclitaxel from cRGD
conjugated liposomes. The tumor vasculature targeting with cRGD should have increased
the localization followed by uptake of paclitaxel by receptor mediated endocytosis. But
the overall efficacy was similar to non-targeted liposomes. The possible reasons for this
could be due to higher clearance of cRGD conjugated liposomes by an additional
mechanism of phagocytosis followed by splenic uptake due to their binding to αvβ3
integrin receptors expressed by the mononuclear cells in the spleen. So the total number
of liposomes available for binding to the αvβ3 integrin receptors expressed in the tumor
vasculature is reduced. Apart from that, well established tumors express αvβ3 integrin
receptors only on the subset of vessels associated with tumor margin [174]. So, apoptosis
is induced only to those tumor cells near that margin. Even though, the αvβ3 integrin
receptors expressed on the tumor vasculature are readily accessible by the liposomes, the
expression of these receptors is limited only to neovasculature and plays a major limiting
factor in treating well established tumors. Nevertheless, Pac-RGD-TLCL would prove to
be an effective strategy for treating metastatic tumors and primary tumors at very early
stages of development. In contrast to tumor vasculature targeted liposomes, the tumor cell
targeted Pac-Tf-TLCL was very effective in minimizing the tumor growth rate of breast
cancer in mouse xenografts. The density of TfR1 on the surface of cells is correlated with
the extent of cell growth and division, and consequently, the tumor cells express more
TfR1 than normal cells. In contrast to tumor vasculature targeted liposomes, the targeting
approach with transferrin to target tumor cells takes advantage of the active process of Fe
transport to deliver paclitaxel to the tumor cells. Even though the rate limiting step is the
accumulation of these liposomes in the tumor sites by passive accumulation due to EPR
effect, the receptor mediated endocytosis by the cancer cells through transferrin is more
efficient and hence improved efficacy is observed.
5.3. SUMMARY AND CONCLUSIONS
The biodistribution of cRGD conjugated paclitaxel-loaded liposomes was evaluated
in mouse xenografts bearing MDA-MB-231 breast cancer by non-invasive NIRF imaging
method. The accumulation of DiR-RGD-TLCL in the tumor was comparable to nontargeted LCL. It was less than DiR-LCL at 48 h time point of imaging. The possible
reason is the clearance of these targeted liposomes by splenic uptake due to expression of
integrin receptors by mononuclear cells in spleen. Higher fluorescence intensity was
observed in the abdominal region of the animals in the liposomal formulation groups
suggesting the involvement of liver and spleen in clearance. The paclitaxel quantification
from liposomal formulations also showed a similar trend with paclitaxel-loaded cRGD
conjugated liposomes and non-targeted liposomes showing comparable accumulation in
the tumors. The effect of size of the liposomes was evident with smaller sized liposomes
of size ~ 80 nm showing higher blood levels, and tumor tissue levels compared to
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liposomes of approximately double the size. These smaller liposomes also showed
significantly higher blood levels and tumor tissue levels compared to paclitaxel solution
formulation. The antitumor efficacy study in breast cancer mouse xenograft model
showed that tumor cell targeted transferrin conjugated paclitaxel-loaded liposomes have
higher efficacy in minimizing the tumor growth compared to tumor vasculature targeted
cRGD conjugated paclitaxel-loaded liposomes. The Pac-Tf-TLCL showed higher
efficacy than paclitaxel solution formulation suggesting the treatment with this
formulation is superior to the currently approved therapy using Taxol®. Tumor
vasculature targeting did not produce an appreciable effect compared to non-targeted
liposomes possibly due to limited expression of integrin receptors in the core of well
established tumors and due to splenic uptake of the liposomes via integrin receptors
expressed by mononuclear cells. Even with the enhanced uptake by the spleen, the cRGD
conjugated liposomes produced comparable effect produced by non-targeted liposomes,
and paclitaxel solution formulation suggesting that these liposomes have better
therapeutic potential in cases of metastasis and primary tumors with fast developing
vasculature wherein the expression of αvβ3 integrin receptors is amplified.
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CHAPTER 6. LYOPHILIZATION OF PACLITAXEL-LOADED LIPOSOMES
TO IMPROVE LONG TERM STABILITY
Paclitaxel is one of the most effective chemotherapeutic agents used in the treatment
of solid tumors. It is a natural product obtained from the bark of Pacific Yew tree Taxus
brevifolia [8, 9]. Paclitaxel, classified under Class IV of Biopharmaceutic Classification
System (BCS) proposed by Amidon, has poor solubility and permeability [271, 272]. Due
to its poor aqueous solubility, Taxol® (Bristol-Myers Squibb Company, Princeton, NJ),
one of the marketed formulation of paclitaxel was formulated with Cremophor®EL and
ethanol. Although the formulation is diluted before use, the concentration of
Cremophor®EL is high enough to cause serious hypersensitivity reactions on parenteral
administration, and require pretreatment with antihistamines and corticosteroids [15]. In
addition, the use of free paclitaxel can affect normal tissues and result in systemic
toxicities such as myelosuppression, and peripheral neuropathy [17]. So, newer drug
delivery systems are sought so that paclitaxel can be delivered locally to the tumor sites
without affecting normal tissues. Liposomes are biocompatible carriers with ability to
incorporate both lipophilic and hydrophilic drugs [23]. Encapsulating drugs within
vesicles has the potential advantage of higher drug carrying capacity compared to
attaching them to single polymer chain [250]. Preparation of liposomes of paclitaxel can
alter the pharmacokinetic and pharmacodynamic properties of the free drug and result in
reduced toxicity and enhanced efficacy of the treatment [251].
Stability of the liposomes in dispersion during storage is a major concern in the
development of liposomal formulations. Phospholipids from the liposomes can undergo
hydrolysis and/or oxidation and result in physical degradation when stored as aqueous
dispersions. As a result, the encapsulated drug tends to leak from the vesicles. Apart from
leakage, the liposomes can aggregate or fuse together resulting in an increase in particle
size distribution. The loss of encapsulated drug, and increase in vesicle size during
storage can affect long-term stability of the product and hinder the drug development
process. The stability of liposomes can be improved by freezing, lyophilization, spray
drying, and supercritical fluid technology [29-31]. Lyophilization is one of the preferred
method to improve long-term stability of liposomes especially those containing
thermosensitive drugs [32]. It can prevent hydrolysis of phospholipids, and physical
degradation during storage of the liposomes [34]. By removing water from the liposomal
dispersion by lyophilization, the structural and permeability properties can be retained
[33]. Interaction of water with hydrophilic phosphate head groups of phospholipids plays
a key role in the formation of liposomes and hence, removal of water presents more
challenges. In addition, the lyophilization process itself can induce physical changes such
as loss of the encapsulated agent, and an increase in vesicle size [34]. Therefore, careful
selection and optimization of the formulation and process is necessary to improve the
long-term stability of paclitaxel-loaded liposomes.
The ability of several carbohydrates to protect liposomes during lyophilization is
described by ‘water replacement’ hypothesis [208-210] and ‘vitrification’ hypothesis
[211-213]. This capability to protect liposomes during dehydration originated from the
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fact that organisms such as brine shrimp cysts and some species of nematodes survive
dehydration which is related to their capacity to produce nonreducing disaccharide
trehalose [214, 215, 221]. These anhydrobiotic organisms survive for several years in dry
state and return to normal metabolic activities on rehydration. Madden et al used this
analogy to protect the integrity of liposomes with trehalose and other sugars [33]. Next to
trehalose sucrose is widely used as a lyoprotectant in the development of lyophilized
liposomal formulations [249, 260, 273]. It is a non-crystallizing solute and remains in the
amorphous state during the lyophilization process. In this research work, we evaluated
the effect of sucrose as a lyoprotectant in the development of paclitaxel-loaded longcirculating liposomes (Pac-LCL). The effect of lipid-sugar ratio, and internal-external
ratio with sucrose was evaluated for Pac-LCL. The optimized composition was used for
the lyophilization of cRGD or transferrin conjugated targeted long-circulating liposomes.
The shelf-life of these formulations was evaluated for three months.
6.1. MATERIALS AND METHODS
6.1.1.

Materials

Paclitaxel was procured from 21CEC Pharmaceuticals (Bradenton, FL). The
phospholipids used in this work were all of research grade. Egg phosphatidylcholine
(EPC), hydrogenated soy phosphatidylcholine (HSPC) and 1,2-distearoyl-sn-glycero-3phoshoethanolamine-N-(poly(ethylene glycol)2000) (DSPE-PEG2000) were obtained from
Northern Lipids (Burnbay, BC, Canada). 1,2-distearoyl-sn-glycero-3phoshoethanolamine-N-(maleimide poly(ethylene glycol)2000) (maleimide DSPEPEG2000) and 1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-(biotinyl poly(ethylene
glycol)2000) (biotinyl DSPE-PEG2000) were obtained from Avanti Polar Lipids
(Alabaster, AL). Cyclo (Arg-Gly-Asp-D-Phe-Cys) peptide (cRGD) was obtained from
Peptides International (Louisville, KY). Biotin labeled human transferrin (Tf),
cholesterol, α-tocopherol, and sucrose were purchased from Sigma (St. Louis, MO).
Streptavidin was obtained from PROzyme (Hayward, CA). HPLC grade water,
acetonitrile, and methanol were obtained from Fisher Scientific (Fair Lawn, NJ). HPLC
grade chloroform was purchased from Acros Organics (Morris Plains, NJ). All other
chemicals and reagents were of analytical grade and used without further purification or
characterization.
6.1.2.

Preparation of Paclitaxel-Loaded Long-Circulating Liposomes (Pac-LCL)

The Pac-LCL was be prepared by the lipid film hydration-extrusion method using
EPC, HSPC, DSPE-PEG2000, and cholesterol. The lipid film was prepared by dissolving
paclitaxel, phospholipids, cholesterol, and α-tocopherol in 9:1 chloroform-methanol. The
solution obtained was evaporated in a round bottom flask using rotary evaporator under
reduced pressure at 45°C for 4-6 h. The dry film was hydrated with 50 mM HEPES
buffer pH 6.5 at 65°C for 45-60 minutes. The multilamellar vesicles (MLVs) thus
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obtained were sized by extrusion through stacked polycarbonate membrane filters of
varying pore diameters under high pressure to obtain small unilamellar vesicles (SUVs).
The SUVs were characterized for particle size distribution (PSD), zeta potential, and total
and entrapped paclitaxel content. The liposomes were stored at 5 ± 3ºC until further use.
6.1.3.

Determination of Tgʹ

The glass transition of maximally freeze concentrated amorphous phase (Tg′) of
mixture of liposomes and sucrose was determined by differential scanning calorimetry
(DSC) using a Q2000 differential scanning calorimeter equipped with refrigerated
cooling system (TA Instruments, New Castle, DE). About 10-20 µL of the liposome
mixture prior to lyophilization was placed in T-Zero aluminum pans and hermetically
sealed. An empty pan prepared in a similar manner was used as reference. The samples
were equilibrated at 25°C and then cooled at 5°C/min to -70°C. After equilibration, the
samples were heated at the rate of 10°C/min to 25°C.
6.1.4.

Lyophilization of Pac-LCL

The Pac-LCL was mixed with equal volume of sucrose solution at different lipidsugar ratios. The lyophilization cycle was designed based on the glass transition
temperature of maximally freeze-concentrated amorphous phase (Tg′), determined by
DSC. Lyophilization was carried out using a lab scale Virtis Genesis 25ES lyophilizer
(The Virtis Company, Gardiner, NY). The primary drying temperature was selected
based on Tg′ and the mixture was lyophilized in 2 cc glass amber vials. The moisture
content of the dry cake was monitored to ensure end point of secondary drying. The
vesicle size, zeta potential, and total and entrapped paclitaxel content were monitored in
samples reconstituted with HPLC grade water. The vials were stored at 5 ± 3°C until
further use. The gel to liquid crystalline transition temperature (Tm) of the lipid bilayer
mixture in the lyophilized formulations was determined by DSC. About 10 mg of the
lyophilized cake was placed in the aluminum pans. The samples were equilibrated at
25°C and then heated at the rate of 10°C/min to 75°C, and thermograms were recorded.
To evaluate the effect of internal-external sucrose ratios, the liposomes were prepared
with different amounts of sucrose added at the hydration step. The resulting liposomes
were mixed with sucrose solutions containing different amounts of external sucrose and
then lyophilized.
6.1.5.

Characterization of Liposomal Formulations

The PSD (Z-avg) of the liposomes was determined using dynamic light scattering
using Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped with 4.5
mW diode laser as a source of light operating at 670 nm. Particle scattered photons were
detected at an angle of 173°. The samples were suitably diluted with HPLC grade water
for the determination of Z-avg. Three independent measurements were performed for
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each sample. Zeta potential was determined from electrophoretic mobility using samples
suitably diluted with HPLC grade water. The lyophilized formulations were reconstituted
with HPLC grade water prior to measurement of the PSD and zeta potential.
The loading efficiency of paclitaxel in the liposomes was determined by minicolumn
centrifugation method using Sephadex G-25 macro spin columns (Harvard apparatus,
Holliston, MA) similar to the method described by Zhang et al [249] with modifications.
Briefly, the Sephadex G-25 particles in the column were suspended in 0.1% w/v TFA and
were allowed to swell for 15 minutes. The columns were centrifuged at 1500 g at 25°C
for 4 min using IEC CL31R Multispeed Centrifuge (Thermo Scientific, Asheville, NC) to
remove TFA. About 100 µL of placebo LCL was added and centrifuged to saturate the
column. The column saturation with placebo liposomes was repeated for a total of three
times. The gel columns were placed in fresh collection tubes for use with drug-loaded
liposomes. The liposome samples were diluted with the dispersion medium of liposomes.
About 100 µL of the diluted sample was added to the gel column, and centrifuged for 4
minutes. The lyophilized liposomes were reconstituted with HPLC grade water prior to
dilution. The eluate in the collection tube, containing only entrapped paclitaxel was
analyzed by RPHPLC. Paclitaxel in the liposomes before passing through Sephadex G-25
was quantified for the total drug content. The HPLC system comprised of Waters 600
Controller, Waters 717 Plus Autosampler, and Waters 2996 Photodiode Array Detector
(Waters Corporation, Milford, MA) was used. The RPHPLC analysis was performed
using a Nova-Pak C18 column (3.9 x 150 mm, 4 µm) (Waters Corporation, Milford, MA).
An isocratic elution was performed using acetonitrile-water in a ratio 55: 45 v/v at a flow
rate of 1 mL/min, and detection wavelength of 230 nm. The liposomes were digested
with absolute ethanol, and suitably diluted before injection. The entrapment efficiency
was calculated using the formula, Entrapment efficiency = (Entrapped paclitaxel x
100)/Total paclitaxel).
The moisture content of the lyophilized cake was determined using an Orion AF8
Volumetric Karl Fischer Titrator (Orion Research Inc., Boston, MA). The titrator was
calibrated on each day of analysis with a known quantity of water. About 75 mg of the
dried sample was weighed accurately and added to the titration vessel. The titration was
started after allowing one minute for extraction.
6.1.6.
Preparation and Lyophilization of Paclitaxel-Loaded cRGD Conjugated
Targeted Long-Circulating Liposomes (Pac-RGD-TLCL)
For the preparation of Pac-RGD-TLCL, a part (0.5 moles %) of DSPE-PEG2000 was
replaced with maleimide DSPE-PEG2000 and the liposomes were prepared as described in
section 6.1.2 to obtain SUVs with reactive maleimide functional groups. The maleimidePac-LCL thus obtained was conjugated with cRGD peptide by incubation at 25°C for 12
h. The reaction was quenched by the addition of 2-mercaptoethanol to block free
maleimide. The unconjugated peptide and 2-mercaptoethanol remaining in the reaction
mixture were removed from the liposomes by equilibrium dialysis through 10,000
MWCO Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific, Rockford, IL)
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against 50 mM HEPES buffer pH 6.5 at 5 ± 3°C overnight. The purified liposomes were
mixed with sucrose solution and then lyophilized as described in 6.1.4. The liposomes
were stored at 5 ± 3ºC until further use.
6.1.7.
Preparation and Lyophilization of Paclitaxel-Loaded Transferrin
Conjugated Targeted Long-Circulating Liposomes (Pac-Tf-TLCL)
For the preparation of Pac-Tf-TLCL, a part (0.01 moles %) of DSPE-PEG2000 was
replaced with biotinylated DSPE-PEG2000 and the liposomes were prepared similar to
6.1.2 using phosphate buffered saline pH 7.2 (PBS) instead of HEPES buffer. Transferrin
was non-covalently conjugated to biotin on the distal end of the PEG spacers of the
biotinylated SUVs using the procedure established in our laboratory [159]. Briefly,
streptavidin was dissolved in PBS to prepare a 2 nM solution. To the streptavidin solution
in a scintillation vial, biotinylated liposomes was added, and mixed. The reaction mixture
was incubated at 25ºC for 30 min, and the free streptavidin was removed by ultrafiltration
using Centricon 100 centrifugal filter device (100 KD MWCO, Millipore, Bedford, MA)
at 5000 g for 30 min to obtain purified streptavidin conjugated long-circulating liposomes
(SALCL). Biotin labeled human transferrin was dissolved in PBS (2 nM) and added to
the SALCL, incubated at 25ºC for 30 min, and the free transferrin was removed by
ultrafiltration. The purified liposomes were mixed with sucrose solution and then
lyophilized as described in 6.1.4. The liposomes were stored at 5 ± 3ºC until further use.
6.1.8.
Stability Evaluation of Lyophilized Formulations of Pac-LCL, Pac-RGDTLCL, and Pac-Tf-TLCL
Stability of lyophilized formulations of Pac-LCL, Pac-RGD-TLCL, and Pac-TfTLCL was evaluated for three months. The formulations in 2 cc amber glass vials were
stored at 5 ± 3ºC for three months, and 25ºC for one month. Samples were withdrawn at
specific intervals and analyzed for total and entrapped paclitaxel, entrapment efficiency,
PSD, zeta potential, and moisture content.
6.2. RESULTS AND DISCUSSION
6.2.1.

Effect of Sucrose on Paclitaxel Retention and PSD

The stability of liposomes in dispersion form during storage is a major challenge in
the development of liposomal formulations. Physical instability results in leakage of
encapsulated drug, and fusion and/or aggregation with an increase in vesicle size. The
hydrolysis or oxidation of the phospholipids during storage can be prevented by
removing water from the liposomes by lyophilization. But, the interaction of water with
phospholipids plays a key role in the formation of liposomes and its removal creates more
challenges. Some carbohydrates interact by hydrogen bonding between their –OH group
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and polar head groups of phospholipids, and protect the liposomes during lyophilization
[208]. It was shown that hydrogen bonding alters the spacing of the polar head groups
and thereby decreases van der Waals interactions in the hydrocarbon chains. The net
effect is improved physical stability of the liposomes. The protection effect was also
attributed to their ability to replace water molecules normally hydrogen-bonded to the
polar head groups of lipids [33]. Developments in analytical techniques such as high
resolution 1H-NMR (nuclear magnetic resonance), Electron spin resonance (ESR) spin
labeling and DSC studies [220, 221] showed that the mechanism of lyoprotection
depends on the ability of these saccharides to replace water molecules of hydration by
forming hydrogen bond with the polar phospholipid group at the same binding sites as
water. In addition, water crystallizes during the freezing process to form ice crystals. At
this stage, the vesicles and remaining solute are in a highly concentrated state which can
induce fusion and aggregation. Inclusion of lyoprotectant can form an amorphous matrix
around the vesicles and protect the vesicles from fusion and prevent rupture of the
vesicles due to crystallization of ice. Koster et al showed that vitrification of sugars
occurs in the intermembrane region, and the resulting glassy state mechanically hinders
conformational changes of lipid bilayers [212, 227].
Trehalose is the most widely used lyoprotectant in the stabilization of liposomes [208,
217, 274]. In our preliminary evaluation of trehalose and sucrose as the lyoprotectants for
liposomes (data not shown), we observed a better control on vesicle size with sucrose
compared to trehalose. Our observations are in agreement with the results obtained by
other investigators in the development of paclitaxel-loaded liposomes [249, 273]. In
addition, Sundaramurthi and Suryanarayanan have demonstrated that trehalose has the
tendency to undergo crystallization during lyophilization [275]. They suggested that
partial crystallization occurs with annealing, and can be induced by other crystallizing
solutes in the formulation such as buffer components. Even if nucleation is induced
during lyophilization, crystal growth can occur during storage in the presence of residual
moisture. Since crystallization during lyophilization can affect the integrity of the
liposomes, we evaluated sucrose, a non-crystallizing solute as a lyoprotectant in the
development of lyophilized formulation of Pac-LCL.
The lyophilization cycle was designed based on the Tgʹ determined by DSC. The
heating profiles of mixtures of liposomes containing different concentrations of sucrose
are shown in Figure 6-1. The Tgʹ of these mixtures containing 50-450 mM of sucrose
was between -34 to -39ºC. The Tgʹ values decreased with an increase in sucrose
concentrations up to 100 mM. Further increase in sucrose caused a reverse effect with an
increase in the transition temperature. For lyophilization cycle, the liposome-sucrose
mixtures were frozen to -45ºC and held at that temperature for 5 hours. The primary
drying was started at -40ºC. The product temperature, shelf temperature, and condenser
temperature were monitored to determine the end point of primary drying. Then the
temperature was slowly ramped up 10ºC at a time to 20ºC for the secondary drying. The
end of secondary drying was monitored my measuring the moisture content of the
lyophilized cake. The physical appearance of the cake, and ease of reconstitution with
water were monitored as in-process quality control parameters.
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Notes. The liposomes were mixed with sucrose solution at different lipid-sugar molar
ratios. The samples were hermetically sealed in aluminum pans, and cooled at the rate of
5°C/min to -70°C. After equilibration at -70°C, the samples were heated at the rate of
10°C/min to 25°C. The heating profile is shown in the figure. Heat flow is shown on an
arbitrary scale.
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The pre-lyophilized liposomes were reconstituted for the determination of paclitaxel
retention and PSD. Figure 6-2 shows the effect of sucrose concentration on paclitaxel
retention in the Pac-LCL. Before lyophilization, the amount of free drug was low and the
percent paclitaxel retained in the liposomes was approximately 90%. When the liposomes
were lyophilized without sucrose, leakage of paclitaxel was observed with an increase in
the amount of free drug in the reconstituted dispersion by more than five-fold, and a
sharp decline in percent paclitaxel retained in the liposomes. The formation of ice crystals
during lyophilization might have caused rupture to the bilayer and resulted in loss of
integrity of these liposomes. Secondly, the removal of water molecules which are
necessary for maintaining the structure of the liposomes without replacing them with
lyoprotectants might have altered the arrangement of phospholipids in the bilayer
resulting in loss of integrity. The loss of integrity was restored with increasing
concentrations of sucrose as lyoprotectant in the formulation. The maximum effect of
lyoprotection was observed at 250 mM of sucrose corresponding to a lipid-sugar ratio of
1:5. The free drug content in the reconstituted liposomal dispersion was almost equal to
that observed before lyophilization suggesting the leakage of paclitaxel was completely
prevented at that concentration. Further changes in lipid-sugar ratio did not show any
appreciable effect on paclitaxel retention in the liposomes. These results suggest that
sucrose at the lipid-sugar ratios equal to or below 1:5 efficiently replaced water
molecules hydrogen bonded to the phospholipids of the bilayer and helped to maintain
the integrity of paclitaxel-loaded liposomes during lyophilization.
The gel to liquid crystalline transition temperature also plays a key role in
maintaining the integrity of the liposomes during dehydration and rehydration [217]. The
phospholipids in the rehydrated form remain in liquid crystalline state. If the
phospholipids in the dehydrated state remain in gel phase at room temperature, the
conversion from gel to liquid crystalline state occurs. The liposomes are prone to leak
encapsulated contents during this transition. Lyoprotectants reduce the Tm of the
phospholipids in the bilayer on lyophilization. If such reduction brings the Tm below
room temperature, the dehydrated liposomes stay at liquid crystalline temperature and
rehydration will not result in the transition, and thus leakage of the encapsulated drug can
be avoided. The effect of sucrose on Tm of the phospholipids of the bilayer of Pac-LCL is
shown in Figure 6-3. The DSC thermograms obtained from the lyophilized samples
shows that there is a decrease in the Tm of the phospholipids with an increase in the
concentration of sucrose. But, the Tm of the formulations containing 250 mM sucrose was
above room temperature suggesting that the phospholipids in the bilayer of Pac-LCL at
room temperature will remain in the gel state and a transition during rehydration is
inevitable. It is interesting to note that paclitaxel is a lipophilic drug and for
thermodynamic reasons will stay within the lipophilic bilayers unless forced/precipitated
out of the liposomes. On the other hand, the transition temperature will play a key role on
the retention of hydrophilic drugs in the liposomes because these drugs can easily leak
out of the liposomes if the integrity of the bilayer is compromised during the transition.
Nevertheless, the change in Tm indicates that there is a direct interaction between the
phospholipid head groups and sucrose which is responsible for lyoprotection.
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Figure 6-2. Effect of sucrose concentration on the effect of paclitaxel retention in the
liposomes during lyophilization
Notes. The liposomes were mixed with sucrose solution at different lipid-sugar molar
ratios and then lyophilized. The paclitaxel retained in the liposomes was determined
before and after lyophilization. The lyophilized formulations were reconstituted with
HPLC grade water for the determination of paclitaxel retention. For the determination of
paclitaxel retention, the liposomes were subjected to minicolumn centrifugation in
Sephadex G-25 macro spin columns to separate free paclitaxel from total paclitaxel. The
eluate containing entrapped paclitaxel was digested with ethanol, and quantified by
RPHPLC method. Free paclitaxel was calculated by subtracting entrapped paclitaxel
from the total paclitaxel content quantified from samples before gel filtration. The results
indicate the mean ± standard deviation of three injections (▲ Paclitaxel retained in the
liposomes; ■ Percent paclitaxel retained in the liposomes; ● Free paclitaxel in the
dispersion).
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Notes. The liposomes were mixed with sucrose solution at different lipid-sugar molar
ratios and then lyophilized. About 10 mg of the lyophilized cake was placed in T-zero
aluminum pans. The samples were equilibrated at 25°C and then heated at the rate of
10°C/min to 75°C. The resulting thermograms are shown in the figure. Heat flow is
shown on an arbitrary scale.
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The effect of lyoprotectant sucrose on the PSD of reconstituted liposomal dispersions
compared to their PSD before lyophilization is presented in Figure 6-4. The particle size
increased to almost seven-fold for the liposomes lyophilized without lyoprotectant
sucrose suggesting that fusion and aggregation of liposomes occurred during
lyophilization. The PSD results showed higher variability and a polydispersity index
(PDI) of 0.726 ± 0.275. The addition of sucrose in the formulation for lyophilization
minimized this increase in size with increasing concentrations of sucrose. Similar to the
observations with paclitaxel retention in the reconstituted liposomal dispersion, the
maximum effect of lyoprotectant was observed at sucrose concentration of 250 mM
corresponding to the lipid-sugar ratio of 1:5. The vesicle size after lyophilization was
slightly higher than the liposomes prior to lyophilization. The particle size distribution
was unimodal with a PDI of 0.250 ± 0.011. Further decrease in the lipid to sugar ratio did
not produce any appreciable effect on the PSD. Similar to the effect on integrity of the
liposomes to prevent leakage, sucrose worked as an efficient lyoprotectant to minimize
fusion and aggregation of liposomes and thereby minimized the increase in size after
lyophilization.
The effect of lyoprotectant is maximum when it is present on both internal and
external portions of the bilayer [33]. The sucrose concentration of 350 mM corresponding
to a lipid-sugar ratio of 1:7 was selected for further evaluation of internal to external ratio
of sucrose. When the total 350 mM of sucrose is divided in to 1:6 or 2:5 in the internalexternal part of the bilayer, there would be enough sucrose (at least 250 mM) available in
the external portion of the bilayer of liposomes to provide maximum lyoprotectant effect.
The effect of internal-external ratio of sucrose on the PSD of the reconstituted liposomal
dispersions compared to their PSD before lyophilization is shown in Figure 6-5.
Inclusion of sucrose in the internal portion of the bilayer provided additional protection to
the Pac-LCL during lyophilization as evidenced by the decrease in size of the
reconstituted liposomal dispersions with an increase in internal sucrose. The internal to
external-external sucrose ratio was not decreased further because the minimum required
amount of external sucrose of 250 mM cannot be obtained with a total sucrose
concentration of 350 mM. In addition, literature reports support the use of only a small
fraction of lyoprotectant in the internal portion of the bilayer since the use of higher
amounts of internal lyoprotectant has no effect on apparent stability of the liposomes
[226, 232]. The internal-external sucrose ratio of 2:5 was selected as optimum with a total
sucrose concentration of 350 mM corresponding to a lipid-sugar ratio of 1:7 was selected
as optimum for further development.
6.2.2.

Development of Lyophilized Targeted Liposomes

The optimized composition for lyophilization was used for the preparation of
lyophilized targeted liposomes. The optimum sucrose concentration of 350 mM with an
internal-external ratio of 2:5 provided adequate protection for Pac-RGD-TLCL, and PacTf-TLCL during lyophilization. The presence of either cRGD or transferrin on the
surface of the liposomes did not affect the drug retention or size during lyophilization.
Similar to Pac-LCL, a slight but insignificant increase in vesicle size was observed with
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Figure 6-4. Effect of sucrose concentration on PSD of paclitaxel-loaded liposomes
during lyophilization
Notes. The liposomes were mixed with sucrose solution at different lipid-sugar molar
ratios and then lyophilized. The PSD of the liposomes was determined using dynamic
light scattering. The lyophilized formulations were reconstituted with HPLC grade water
for the determination of PSD. The results indicate mean ± standard deviation of three
independent measurements (■ PSD before lyophilization; ▲ PSD after lyophilization
determined from reconstituted samples).
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Effect of internal-external ratio of sucrose on PSD during lyophilization

Notes. The liposomes were prepared with different internal sucrose concentrations
added at the hydration step and then mixed with sucrose solution to produce different
internal-external sucrose ratios. The PSD of the liposomes was determined using dynamic
light scattering. The lyophilized formulations were reconstituted with HPLC grade water
for the determination of PSD. The results indicate mean ± standard deviation of three
independent measurements (■ PSD before lyophilization; ▲ PSD after lyophilization
determined from reconstituted samples).
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the reconstituted samples of targeted liposomes compared to their size before
lyophilization. The paclitaxel retention was unaffected at the sucrose ratio used in the
preparation of lyophilized Pac-RGD-TLCL and Pac-Tf-TLCL. The moisture content of
the lyophilized cake was less than 1% w/v.
6.2.3.

Stability of Lyophilized Pac-LCL, Pac-RGD-TLCL, and Pac-Tf-TLCL

The stability of the lyophilized formulations of Pac-LCL, Pac-RGD-TLCL, and PacTf-TLCL were evaluated in 2 cc amber vials at 5 ± 3°C for three months and 25°C for 1
month. The stability data for lyophilized Pac-LCL is presented in Figure 6-6. The
moisture content of the lyophilized cake was maintained below 1% w/v through the
testing period. The paclitaxel retained in the liposomes and percent retained were within
acceptable limit of 10% of initial at both the temperature conditions. The particle size and
zeta potential were not affected at 5 ± 3°C, but an appreciable increase in size was
observed at 25ºC suggesting that these liposomes undergo fusion or aggregation at room
temperature. Nevertheless, the Pac-LCL maintained its size, charge, and integrity through
the evaluation period when stored at refrigerated conditions. The stability data for PacRGD-TLCL and Pac-Tf-TLCL is presented in Figure 6-7 and Figure 6-8 respectively.
These targeted liposomes also exhibited a similar behavior in the stability as Pac-LCL.
These targeted liposomes maintained integrity at 5 ± 3ºC as well as 25ºC. An increase in
size of approximately 20 - 40 nm was observed with both the targeted liposomes within
one month of storage at 25ºC but there was no significant change in size or charge at
refrigerated conditions. The stability data suggests that Pac-LCL, Pac-RGD-TLCL, and
Pac-Tf-TLCL lyophilized formulation must be stored at 5 ± 3ºC for a better shelf-life
without any compromise on particle size distribution
6.3. SUMMARY AND CONCLUSIONS
The liposomal formulations containing paclitaxel were lyophilized to improve longterm stability during storage. The Pac-LCL lyophilized without any lyoprotectant showed
a loss of integrity resulting in high concentration of free paclitaxel in the dispersion.
Sucrose was used as a lyoprotectant to stabilize the liposomes during lyophilization. The
optimum concentration of sucrose to minimize paclitaxel leakage was found to be 250
mM corresponding to a lipid-sucrose ratio of 1:5. Further increase in the concentration of
sucrose in the formulation did not produce any appreciable effect on paclitaxel retention.
A similar effect as in paclitaxel retention was observed with particle size distribution of
liposomes lyophilized in presence of different concentrations of sucrose. When the
liposomes were lyophilized without sucrose the particle size increased to above 700 nm.
Increasing concentrations of sucrose minimized this increase in size. A sucrose
concentration of 250 mM provided adequate protection to the liposomes during
lyophilization and minimized fusion and aggregation. To evaluate the internal-external
ratio of sucrose, 350 mM of sucrose was used and internal-external ratios of 0:1, 1:6, and
2:5 were studied. The additional protection to the inner portion of the bilayer further
minimized the particle size increase after lyophilization. Since only a small fraction of
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Stability of lyophilized Pac-LCL formulation

Notes. The Pac-LCL was stored at 5 ± 3ºC (solid symbols) and 25°C (open symbols)
in 2 cc amber vials. Samples were withdrawn at specific intervals, reconstituted with
HPLC water, and analyzed for paclitaxel retention, PSD, and zeta potential. A. For the
determination of paclitaxel retention, the samples were subjected to minicolumn
centrifugation in Sephadex G-25 macro spin columns to separate free paclitaxel from
total paclitaxel. The eluate containing entrapped paclitaxel was digested with ethanol, and
quantified by RPHPLC method. The results indicate the mean ± standard deviation for
three injections (▲ Paclitaxel retained in the liposomes; ■ Percent paclitaxel retained in
the liposomes). B. For PSD, and zeta potential, the results indicate mean ± standard
deviation of three independent measurements (● PSD; ♦ Zeta potential).
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Notes. The Pac-RGD-TLCL was stored at 5 ± 3ºC (solid symbols) and 25°C (open
symbols) in 2 cc amber vials. Samples were withdrawn at specific intervals, reconstituted
with HPLC water, and analyzed for paclitaxel retention, PSD, and zeta potential. A. For
the determination of paclitaxel retention, the samples were subjected to minicolumn
centrifugation in Sephadex G-25 macro spin columns to separate free paclitaxel from
total paclitaxel. The eluate containing entrapped paclitaxel was digested with ethanol, and
quantified by RPHPLC method. The results indicate the mean ± standard deviation for
three injections (▲Paclitaxel retained in the liposomes; ■ Percent paclitaxel retained in
the liposomes). B. For PSD, and zeta potential, the results indicate mean ± standard
deviation of three independent measurements (● PSD; ♦ Zeta potential).
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Stability of lyophilized Pac-Tf-TLCL

Notes. The Pac-Tf-TLCL stored at 5 ± 3ºC (solid symbols) and 25°C (open symbols)
in 2 cc amber vials. Samples were withdrawn at specific intervals, reconstituted with
HPLC water, and analyzed for paclitaxel retention, PSD, and zeta potential. A. For the
determination of paclitaxel retention, the samples were subjected to minicolumn
centrifugation in Sephadex G-25 macro spin columns to separate free paclitaxel from
total paclitaxel. The eluate containing entrapped paclitaxel was digested with ethanol, and
quantified by RPHPLC method. The results indicate the mean ± standard deviation for
three injections (▲Paclitaxel retained in the liposomes; ■ Percent paclitaxel retained in
the liposomes). B. For PSD, and zeta potential, the results indicate mean ± standard
deviation of three independent measurements (● PSD; ♦ Zeta potential).
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internal sucrose is necessary for the lyoprotection the internal-external ratio of 2:5 was
selected as optimum. The composition for lyophilization was optimized for Pac-LCL and
the optimum composition was used in the lyophilization of Pac-RGD-TLCL, and Pac-TfTLCL. The presence of targeting ligands on the surface of these targeted liposomes did
not affect the integrity, size, and charge and were similar to Pac-LCL. The stability data
showed that these liposomes were stable in refrigerated condition for three months. The
particle size increased by 20-40 nm in the samples stored at 25ºC suggesting that these
liposomes undergo fusion and aggregation at room temperature. The freeze dried cake
maintained its appearance and the moisture content was within acceptable limits through
the testing period. The paclitaxel retention, particle size, and zeta potential were
maintained within acceptable limits for three months in refrigerated conditions. A stable
lyophilized formulation was developed for paclitaxel-loaded long-circulating liposomes
and targeted long-circulating liposomes.
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CHAPTER 7. SUMMARY AND CONCLUSIONS
Breast cancer is a serious health care concern affecting nearly 200,000 women a year
in the United States. Paclitaxel is one of the most effective drugs used in the treatment of
breast cancer but it has drawbacks of serious adverse effects due to formulation
components or due to exposure of normal tissues to free drug. Therefore, an effective
drug delivery system that can deliver paclitaxel locally at the tumor sites following
intravenous administration without affecting normal tissues was sought. Liposomes are
attractive choice for this purpose because they are biocompatible in nature, and can
accommodate drugs of hydrophilic or lipophilic nature. In addition, the flexibility in
design allows surface modifications to improve in vivo circulation times, and for
targeting. Passive targeting approach with liposomes can take advantage of the leaky
nature of the tumors for selective accumulation. Combination of passive targeting
approach with an active targeting approach with selective targeting ligands to improve
the cellular uptake of the liposomes at the tumor sites can have a significant impact on
overall effectiveness of the therapy. The objective of this dissertation work was to
develop and evaluate paclitaxel-loaded targeted long-circulating liposomal formulations
for drug delivery to breast cancer. In addition to targeted therapy, attempts were made to
develop ultrasound active liposomes that can be visualized by ultrasound and
disintegrated with high intensity ultrasound pulses. Ultrasound destruction mediated
release, and improved vascular permeability is also expected to improve the effectiveness
of the therapy.
A prototype formulation of cRGD conjugated echogenic liposomes was developed to
target αvβ3 integrin receptors over expressed in actively proliferating cells of the tumor
vasculature. Perfluoropropane, a lipophilic gas commonly used in ultrasound contrast
agents was filled into the bilayer of liposomes by freeze drying gas entrapment method in
presence of mannitol. Mannitol undergoes crystallization during the warming phase of
lyophilization and induces rupture of the bilayer through which gas penetrates the bilayer
of liposomes. This process results in an increase in size of the liposomes to ~800 nm
which makes it unsuitable for drug delivery applications. So, attempts were made to
control the size of these liposomes to 150-200 nm by controlling the crystallization of
mannitol. The use of non-crystallizing solute sucrose at a mannitol-sucrose ratio of 4:3
minimized the crystallization of mannitol and thereby minimized the increase in size of
these echogenic liposomes during lyophilization. Although, surfactant poloxamer 188 did
not show any effect on crystallization, its use at concentrations above 0.05% w/v
minimized the increase in size after lyophilization due to monolayer coating and steric
effects on the surface. The echogenic formulations containing mannitol alone showed
more than two-fold higher echogenicity compared the formulations containing mannitol
and sucrose. The attachment of cRGD to the surface of the liposomes through PEG
spacer did not affect size, charge or echogenicity of the formulation. The optimized
formulation with a size of ~ 150 nm, and a zeta potential of ~ -30 mV was used as a
platform for the development of paclitaxel-loaded echogenic liposomes.
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Paclitaxel loading in the bilayer of liposomes and retention of the encapsulated drug
in the bilayer is important to achieve long term stability of the liposomes. The liposomal
formulation used in the preparation of prototype formulation was optimized to increase
paclitaxel loading. Cholesterol content showed a significant negative influence on
paclitaxel loading with highest loading achieved at 5 moles %. Saturated lipid content
also showed a negative effect on paclitaxel loading. A HSPC-EPC ratio of 1:5 was
selected as an optimum ratio. Total lipid concentration showed proportionate increase in
loading with an increasing lipid concentration. A total lipid concentration of 100 mM was
used in the optimized formulation. Drug-lipid ratio also showed a proportionate increase
in loading with an increase in the amount of paclitaxel. But, paclitaxel precipitated out of
formulations with higher amounts of paclitaxel. Short-term stability studies with different
ratios showed that the drug-lipid ratio of 1:60 was optimum for adequate physical
stability of these long-circulating liposomes. The optimized formulation with paclitaxel
loading of ~ 1.2 mg/mL and a size of 100 ± 20 nm maintained its integrity, size and
charge at 5 ± 3ºC for three months.
The optimized paclitaxel-loaded long-circulating liposomes was used for the
preparation of echogenic liposomes. When these liposomes were lyophilized in presence
of mannitol-sucrose ratio of 4:3, and a poloxamer concentration of 0.15% w/v, optimized
composition from the prototype formulation, the size of the liposomes increased by more
than four-fold suggesting further optimization is necessary. So attempts were made to
minimize the increase in size with different lipid-sugar ratios with sucrose alone in
presence of poloxamer. A decrease in lipid-sugar ratio minimized the increase in size up
to the ratio 1:7, and further decrease did not show any influence. The inclusion of sucrose
in the internal portion of the bilayer at an internal-external ratio of 1:6 helped minimizing
the increase in size due to lyoprotection of the internal portion of the bilayer. Number of
cycles used in the preparation of liposomes showed an influence on the PDI of the
liposomes after lyophilization. The change in PDI after lyophilization was lower in
liposomes prepared with one extrusion cycle. Mannitol was introduced in the formulation
at the concentration of 50, 100, and 150 mM to evaluate its influence on size and
echogenicity of these liposomes. As expected, an increase in mannitol concentration
caused an increase in size and PDI. The in vitro echogenicity evaluation showed that all
the formulations containing mannitol showed ~ 50-fold increase in MGSV compared to
background. The formulation that contained sucrose alone also showed ~ 20-fold increase
in MGSV. Although mannitol containing formulations showed higher echogenicity,
mannitol was excluded from the formulations to have better control on size and PDI. The
cRGD peptide was conjugated to the surface of these liposomes through PEG spacers.
These paclitaxel-loaded targeted echogenic liposomes of size 150-200 nm with a
paclitaxel loading of ~ 500 µg/mL was stable at 5 ± 3ºC for three months. The ability to
disintegrate these echogenic liposomes with ultrasound pulses was evaluated by an in
vitro method using mouse tail vein infusion catheter immersed in water filled in a
plexiglass tank. The decrease in contrast mean power at the ROI showed that these
echogenic liposomes can be disintegrated with high intensity ultrasound pulses. These
targeted echogenic liposomes containing paclitaxel has the potential for improving the
outcome of therapy of breast cancer and other solid tumors. Attempts were made to
establish an in vivo animal model for the evaluation of these paclitaxel-loaded echogenic

146

liposomes. Difficulties were experienced in visualizing these echogenic liposomes in the
mouse xenograft model, which require further investigation. So, the gas-filled longcirculating liposomes were not used further for the in vivo experiments.
The biodistribution of cRGD conjugated liposomes was evaluated in mouse
xenografts bearing MDA-MB-231 breast cancer by NIRF imaging with liposomes
containing a fluorescent dye DiR. The results showed that the accumulation of DiRRGD-TLCL was lower than DiR-LCL, and slightly higher but not significantly different
than DiR solution formulation. The total efficiency for the ROI measurements in the
peritoneal cavity of the animals treated with DiR-RGD-TLCL was significantly higher
compared to non targeted liposomes suggesting these targeted liposomes are cleared
rapidly by the RES comprised of Kupffer cells of the liver and fixed macrophages of the
spleen. The higher accumulation in the spleen was due to the expression of αvβ3 integrin
receptors by the mononuclear cells of spleen. Quantification of paclitaxel in the tumor
tissues after 24 hours of intravenous administration showed a comparable accumulation
of Pac-RGD-TLCL and Pac-LCL for a size ~ 160 nm. But, the accumulation was less
than that of the solution formulation. A decrease in size to ~ 80 nm showed a
significantly higher blood levels and tumor accumulation emphasizing the importance of
the size of these liposomes in tumor accumulation of paclitaxel. The antitumor efficacy of
these tumor vasculature targeted liposomes was compared with tumor cell targeted
liposomes using transferrin directed against TfR1 receptors over expressed by the tumor
cells. The results showed that all the paclitaxel containing formulations were effective in
reducing the percent increase in tumor size compared to normal saline control at 39 days
post tumor inoculation. The efficacy was comparable for Pac-RGD-TLCL, Pac-LCL, and
paclitaxel solution formulation with tumor volumes of ~ 60-70% of the control treatment.
In contrast, the tumor cell targeted Pac-Tf-TLCL showed a significantly higher antitumor
activity compared to all other treatments with the tumor volumes of ~ 30% of the control
treatment on 39 days post tumor inoculation. The tumor vasculature targeting did not
produce an appreciable effect compared to non targeted liposomes possibly due to limited
expression of αvβ3 integrin receptors in the vasculature of well established tumors, and
due to higher clearance of these liposomes by binding of cRGD to these receptors
expressed by mononuclear cells of the spleen. Nevertheless, tumor vasculature targeting
has a potential for improving therapeutic efficacy in breast cancer with metastasis, and
primary tumors with fast developing vasculature. In this animal model studied, tumor cell
targeting produced a higher antitumor efficacy than tumor vasculature targeting because
this strategy utilized the active process involved in Fe transport for targeting. Since TfR1
is over expressed by proliferating tumor cells, receptor mediated endocytosis of Pac-TfTLCL by these cells was enhanced, which in turn improved the efficacy of the treatment.
The physical instability of the liposomal dispersions during storage is a major concern
in liposomal formulation development. Removal of water from the dispersion by
lyophilization can improve the long term stability, and thereby instabilities caused by
hydrolysis or oxidation can be prevented. But, removal of water which is responsible for
maintaining the structure of the liposomes presents more challenges and requires careful
optimization of the formulation and process. The liposomes lyophilized without
lyoprotectant showed more than five-fold increase in free drug, and more than seven-fold

147

increase in size. So, the Pac-LCL was lyophilized using a non-crystallizing solute sucrose
as a lyoprotectant. The leakage of paclitaxel in the lyophilized samples was minimized
with increasing concentrations of sucrose and the minimum concentration required was
found to be 250 mM corresponding to a lipid-sugar ratio of 1:5. Similarly, the increase in
size during lyophilization was minimized by sucrose at lipid-sugar ratios of 1:5 or lower.
Inclusion of sucrose at an intravesicular-extravesicular ratio of 2:5 provided better
protection to the internal portion of the bilayer and minimized the increase in particle
size. The reconstituted pre-lyophilized Pac-LCL was 100 ± 20 nm in diameter with ~
90% paclitaxel retention. The optimized composition was used for the preparation of
lyophilized Pac-RGD-TLCL, and Pac-Tf-TLCL. The lyophilized targeted liposomal
formulations possessed similar characteristics as that of Pac-LCL. The stability
evaluation showed that all these formulations were stable for three months at 5 ± 3ºC.
In conclusion, targeted drug delivery with paclitaxel-loaded long-circulating
liposomes improved the antitumor efficacy of breast cancer in a mouse xenograft model.
Tumor cell targeted transferrin conjugated liposomes were more effective compared to
tumor vasculature targeted cRGD conjugated liposomes. Although the effect of tumor
vasculature targeted liposomes was comparable to non-targeted liposomes and paclitaxel
solution, these cRGD conjugated liposomes have the potential for improving the
therapeutic efficacy in tumor metastasis and primary tumors with fast developing
vasculature. The stability of the paclitaxel-loaded liposomes in dispersion was improved
by selecting an optimum composition. To further improve the long-term stability, these
liposomes were lyophilized in presence of a non-crystallizing solute sucrose. The size,
charge, and integrity of these liposomes were preserved for three months at refrigerated
storage conditions.
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